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PHYSICAL AND MOLECULAR CHARACTERISTICS OF DAY 75 NUCLEAR TRANSFER 
CLONED BOVINE CONCEPTUSES  
 
This study was designed to measure fetal and placental characteristics in bovine day 75 
nuclear transfer and control pregnancies.  Responses included mRNA concentration of the 
insulin-like growth factor (IGF) system [IGF-1, IGF-2, IGF1R, IGF2R, IGFBBP-1, -2, -3] and 
the vascular endothelial growth factor (VEGF) system [VEGF, PlGF, VEGF1R, and VEGF2R].  
Fetal attrition of the cloned pregnancies up to day 75 was high (89%, 63 out of 71 frozen 
embryos transferred; 8 of 16 cloned conceptuses present on day 30 survived to day 75, as did 5 
of 5 controls).  No significant differences in mean weights of large and medium placentomes 
were observed between 8 clones and 5 controls.  However, the variance of mean weight of large 
placentomes was greater in clones than in controls; one gestation had placentomes six standard 
deviations larger than controls.  Interestingly, the mean umbilical cord weight/length ratio was 
significantly greater for clones (P < 0.05).  Mean fetal length, fetal weight, fetal weight/length 
index and mean weights for heart, brain, liver, kidneys and the mean brain/liver index did not 
differ between cloned and control day 75 conceptuses, but numbers per group were limited.   
Northern blot analysis, revealed the presence of three transcripts of 3.7kb, 2.2kb and 1.7kb for 
VEGF and one 1.7 kb transcript for PlGF mRNA in the cotyledons and allantochorion of day 45 
cloned and control gestations.  All three VEGF bands were present in both cloned and control 
day 75 cotyledons and caruncles, but the PlGF transcript was barely detectable, except for the 
cotyledons of one clone.   
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mRNA for all of genes studied could be detected with real time PCR in day 75 
cotyledons and caruncles, and fetal livers contained mRNA for all IGF’s and IGFBP’s evaluated. 
In all placentomal tissues, PlGF mRNA concentration was 100-fold less than VEGF mRNA, 
which seems to be the driving force for placentomal vascularization at day 75.  There was a trend 
for a reduction by half of the PlGF mRNA concentration in caruncle of clones vs. controls (P = 
0.06).  VEGF2R (KDR) mRNA was abundant, but VEGF1R (Flt-1), was only present in very 
low concentrations; our primer set did not distinguish between soluble versus membrane bound 
receptor mRNA for VEGF1R.    
Four of the cloned conceptuses contained substantially less cotyledonary IGF1R mRNA 
than the other clones and controls.  IGFBP-3 mRNA concentrations were very high in 
placentomes; IGFBP-1 and -2 mRNA concentration on the other hand was very low for clones 
and controls.  mRNA for IGFBP-1, -2, -3, however, was abundant in day 75 fetal livers, while 
IGF-1 mRNA was scarce in this tissue.  Fetal livers from cloned pregnancies contained 4-fold 
more IGF-2 mRNA than controls (P<0.01).  We observed that liver IGF-2 mRNA concentration 
and liver weight increased with weight of the largest placentome; in clones these increases were 
associated with a decrease in cotyledonary IGF-2 mRNA, while the opposite occurred with 
controls. Interestingly, there was a trend to lower IGF2R mRNA concentrations (P = 0.09), and 
IGF-1 mRNA was twofold higher in cotyledons of clones (P= 0.03) compared to controls.   
For many measurements, means were not significantly different (P > 0.1) between clones and 
controls.  However, unequal variances were common, and data points with statistical outlier 
behavior were observed for clones, which highlights the heterogeneity of the cloned population.  
This variation in gene expression may exacerbate abnormal placentation later in gestation, and 
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might explain some of the increased morbidity and mortality seen in calves resulting from 
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In this era of biotechnology, mankind reached a major milestone in history with the 
successful cloning of Dolly, a sheep generated by nuclear transfer from a differentiated, adult 
mammary cell.  When first announced, the public was shocked and in disbelief.  Fifteen years 
later, cloning is still a controversial issue.  Cloning ethics, especially in the context of human 
applications, are debated on an almost daily basis.  As with any new technology, there are flaws 
and pitfalls, and success rates are low.  Many reports of gestational and neonatal abnormalities 
following in vitro embryo culture and asynchronous embryo transfer have been published.  
Because of the numerous applications this technology holds, we are driven to not only improve 
the technique, but also to understand the fundamental physiology behind it.   
The basic hypothesis that is tested in this thesis is that gestational aberrancies found in 
pregnancies originating from cloned embryos are due to an abnormal placenta. Gene knockout 
studies have revealed the fundamental importance of the insulin-like growth factor (IGF) system 
in the control of fetal and placental development and growth.  Since placental vascularization 
mediates the exchange of nutrients between mother and fetus, and since we are faced with the 
intriguing question on how the placenta in certain cloned pregnancies can support overgrowth of 
the fetus, we also evaluated the vascular endothelial growth factor (VEGF) system. 
Biometric measurements and evaluation of mRNA expression for the insulin-like growth 
factor and vascular endothelial growth factor systems were made in placentomes and fetal livers 
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of day 75 nuclear transfer cloned and control pregnancies.  During the first trimester, pregnancy 
attrition in cloned gestations is very high (Seidel et al., 1997). At day 75 of gestation, 
placentomal development is well underway, with the largest placentomes centered around the 
umbilical cord; these tissues have sufficient tcRNA for valid use of a variety of molecular 
techniques.     
We believe that basic information in this area can be applied to reducing the huge amount 
of pregnancy attrition that occurs with cloning and in vitro fertilization in a number of species, as 




NUCLEAR TRANSFER CLONING 
 
Definition 
Cloning can be defined as generating an animal or a set of genetically identical animals 
descending from the same parent by asexual reproduction.  Etymologically, cloning is derived 
from the Greek word klon or twig which reminds us of asexual reproduction of certain plants e.g. 
willow trees, potatoes, etc.  Monozygous (identical) twins are naturally occurring clones; they 
are genetically identical, both in nuclear and mitochondrial DNA.  In the 1890’s H. Driesch 
experimented with sea urchin embryos.  If he obliterated one of the cells of a two-cell stage 
embryo, a small but complete sea-urchin developed.  Conversely, fusion of two early sea-urchin 
embryos resulted into one giant sea-urchin (Driesch, 1893).  The earliest attempt to induce 
twinning in vitro was done during the 1920’s, by splitting a newt embryo using a baby’s hair 
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(Spemann, 1938).  With blastomere separation (Willadsen, 1979), cloned sets were limited to 
two to four identical animals, depending on the species.   
In 1986 a major advance in creating larger cloned sets of mammals was achieved: 
blastomere cloning via nuclear transplantation (Willadsen, 1986).  Initially, this involved fusion 
of a cleavage-stage blastomere containing the donor nucleus with an enucleated oocyte or 
zygote.  Later, pluripotent blastomeres from up to a 16-cell embryo were used as donors, and 
clutches of cloned embryos could be serially enlarged when the blastomeres of the first round of 
cloning were separated again and each fused with an enucleated oocyte (Willadsen et al., 1991; 
Westhusin et al., 1992; Wilson et al., 1995).  At that point however, cloning research came to a 
plateau: the number of totipotent cells in a preimplantation embryo is limited to those in the inner 
cell mass, and most cells from more advanced embryos or fetuses are differentiated and lose 
totipotency; at least this was thought to be the case before Dolly. Progressively, nuclear donation 
from older embryos was possible.  However, to expand the potential of cloning, the limitation in 
cells available had to be overcome.   
Embryonic stem (ES) cells are derived from inner cell mass of the early embryo, are 
relatively undifferentiated, and divide indefinitely in culture, although female cells tend to 
become aneuploid.  Murine ES cell lines were established for certain inbred strains; however, in 
other species this is still not a straightforward task.  Could one redirect the nucleus of a 
completely differentiated cell to support the development of a new embryo?  Ultimately, one 
decade later this next milestone in cloning was reached.  In 1995, personnel at the Roslin 
Institute, Scotland, created Megan and Morag by nuclear transfer from nuclei from cell lines 
derived from fetuses and maintained in long-term culture; the cell lines appeared to have 
differentiated to fibroblasts (Campbell et al., 1996b).  Only one year later, the same institute 
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announced the birth of a live lamb “Dolly” produced by nuclear transfer of a donor nucleus 
obtained from a mammary gland cell of an adult sheep (Wilmut et al., 1997).  Although 




Despite the fact that animals can be cloned by nuclear transfer (NT) from differentiated 
cells, success rates are low, rarely more than 2% live offspring per successful NT.  Much effort 
has been invested into improvement of all aspects involved of the cloning procedure. The 
development of embryos reconstructed by NT is dependent upon the stage of the cell cycle and 
the interactions between the donor nucleus and the recipient cytoplasm.   
The steps to clone an animal are depicted in the following flow chart from Infigen: 
 




Understanding these interactions led to two main strategies for cloning.  First, when non-
activated, enucleated oocytes at metaphase II are used as recipients, the nuclear envelope of the 
donor nucleus is broken down (NEBD) and the chromatin is prematurely condensed into 
chromosomes (PCC) due to the high activity of maturation promoting factor (MPF).  After 
parthenogenetic activation, the nuclear membrane reforms, DNA replication begins, and mitosis 
follows. This technique is only feasible for G0 or G1 donor nuclei (2n) since nuclei in G2 (4n) or 
M (4n) phases will result in daughter nuclei with 8n DNA content; nuclei in S (2-4n) phase 
induced to undergo PCC will result in disorganized chromatin.  Premature chromosome 
condensation can cause chromosomal damage or loss and aneuploidy.  However, (Cibelli et al., 
1998) found that donor cells in G1 (2n) condense normally in MII oocytes.  Metaphase II oocytes 
have nuclear reprogramming factors present in the cytoplasm; rapid and drastic structural 
changes including chromosome condensation, spindle formation and protein removal from the 
DNA helix occur at this time, and allow greater access of these factors.  Therefore, sufficient 
exposure time to the high MPF might be beneficial for nuclear reprogramming (Renard, 1998; 
Wilmut, 1998).  
The second method creates a universal recipient by transferring nuclei into activated 
ovum cytoplasm, after MPF declines.  This oocyte cytoplasm is able to reprogram donor nuclei 
in any stage of cell cycle.  No NEBD and PCC of donor nuclei occur because of the low activity 
of MPF, and DNA synthesis occurs in relationship to the cell cycle stage (2n or 4n) of the 
nucleus.  This indicates that reprogramming of donor nuclei might occur without NEBD and 
PCC (Tani et al., 2001). Enucleation of telophase II oocytes is technically easier, removes fewer 
cytoplasmic factors and organelles, provides a synchronous population of activated recipient 
cytoplasts, and results in a higher rate of embryonic development (Baguisi et al., 1999). 
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Cell cycle stage of the donor nucleus and its level of differentiation may facilitate nuclear 
reprogramming.  Quiescent, G0 donor nuclei have reduced transcriptional activity, and chromatin 
modifications associated with G0 may facilitate nuclear reprogramming (Wells et al., 1999).  G0 
donor nuclei are compatible with pre-, post or concomitant fusion (Stice et al., 1998).  However, 
Cibelli et al., (1998), suggest that cells should not have ceased dividing (G0) but be actively 
dividing, indicating relative undifferentiation.  They recommend choosing a cell line that is 
rapidly dividing but has a long G1 phase e.g. fetal fibroblasts or artificially arresting cells in G1.  
Non-passaged fibroblasts have never successfully generated progeny because: 1) they are 
nonconfluent; thus fewer cells are in G0/G1 phase; 2) the cell population is less homogenous, and 
cell type affects cloning competence (Dinnyés et al., 2001). 
Another major factor in the low efficiency of cloning is incomplete activation of the 
recipient oocyte.  During fertilization, sperm-induced periodic increases in intracellular free Ca
2+
 
concentrations activate the oocyte (White & Yue, 1996).  Artificial activation methods fail to 
mimic completely the transient Ca
2+
 oscillations, and usually result in a single intracellular Ca
2+
 
rise.  A sequential treatment of an intracellular Ca
2+
 transient and a temporary inhibition of 
protein phosphorylation by 6-dimethylaminopurine (DMAP) effectively activates bovine 
oocytes.  This combination treatment results in a rapid and sustained inactivation of maturation-
promoting factor and hence, the activation of the oocyte (Dinnyés et al., 2001). 
Developmental potential of reconstituted embryos depends upon reprogramming gene 
expression by the action of cytoplasmic factors, and this might be enhanced by a prolonged 
period of exposure (Campbell et al., 1996a).  According to (King et al., 1996), nuclear 
reprogramming does not occur immediately following NT, but occurs gradually over the first 2 
or 3 cycles.  Lavoir et al., (1997) found reprogramming of the transferred nucleus is absent or 
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incomplete, and aberrant cytokinesis and nucleokinesis, and multinucleated, anucleate and 
polyploid cells were common.  There are different approaches to evaluate nuclear 
reprogramming, e.g. by examining nuclear lamin epitopes, nucleolar morphology and protein 
synthesis.   
In conclusion: there are two methods to obtain viable cloned offspring by nuclear 




The controversy of cloning from adult cells raised questions and criticism.  Was Dolly 
indeed genetically identical to her mother; and why are clones not identical? 
One issue is mitochondrial mosaicism or heteroplasmy.  Mitochondrial DNA (mtDNA) encodes 
genes essential for oxidative phosphorylation and electron transfer, and is inherited maternally 
(Kaneda et al., 1995).  Thus, embryos originating from fusion of a donor cell (containing some 
cytoplasm) and cytoplasm of an oocyte contain mitochondria from two sources if donor and 
recipient cells are from different maternal lines.  Hiendleder et al., (1999) found that mtDNA 
haplotype heteroplasmy in adult bovine clones can vary from 21-79%.  This suggests that the 
mtDNA type of donor and recipient cells must be controlled if clones are to have identical 
nuclear and cytoplasmic genomes.  Reports on cytoplasmic genetic effects on phenotypic traits in 
cattle have been linked to mtDNA polymorphisms (Schutz et al., 1993).  Moreover, it has been 
reported that the in vitro developmental ability of mouse embryos was impaired by heterogenous 
mtDNA, introduced by nuclear transfer (Mereilles & Smith, 1998; Nagao et al., 1998).   
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Chromosomal abnormalities, such as mixoploidy and polyploidy, are frequently observed 
in in vitro produced embryos (Viuff et al., 2001).  Pre- and postnatal environment highly affect 
phenotype.  For example, a thoroughbred horse embryo transferred into a cold blood mare will 
look much more bulky at birth than if born from a thoroughbred mare.  Oocyte donor 
cytoplasmic effects can also play part in the nuclear transfer cloned offspring. 
Another question is whether cloning is a “fountain of youth”?  Can cloning reverse 
cellular aging or will nuclear cloned offspring undergo premature senescence?  Normal somatic 
cells of some species display limited division potential.  However, germline cells, 
"immortalized" tissue culture cell lines, and cancer cells have overcome the limitations of 
cellular replication and aging.  For example, aged parents always give birth to offspring 
containing young cells.  
Telomeres are specialized structures at the ends of chromosomes of nearly all eukaryotes, 
composed of repetitive short DNA sequences and associated telomeric binding proteins, which 
serve as buffer zones against telomeric attrition and prevent DNA ends from combining with 
each other and producing aneuploidy.  With each round of cell replication, incomplete 
duplication by DNA polymerase of the 5´ ends of linear DNA molecules occurs; this loss of 
terminal DNA sequences results in the shortening of chromosomes.  The shortening of telomeres 
may be one of the limiting factors that blocks continued cell division.  A common characteristic 
of cells such as germline cells is enzymatic activity of the ribonucleoprotein complex telomerase 
that maintains telomeres at full length (review Meeker & Coffey, 1997).  Controversy exists 
whether nuclear transfer to oocytes with non-telomerase expressing donor cells reconstitutes 
telomeric length.   Could the epigenetic change of telomere shortening limit donor success of 
adult cells (Shiels et al., 1999).  The findings of Lanza et al., (2000) suggest that nuclear transfer 
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extended the replicative life span of senescent cells and telomere length in animals cloned from 
senescent somatic cells were extended beyond age-matched controls.  This ability of cell 
regeneration has important impact on aging studies and cloning for in vitro tissue and tissue or 
organ replacement.  In this context, it is important to note that nuclear transfer cloning is more 
efficient with embryonic and fetal cells than with adult cells; this might be due to decreased and 
variable telomere length.  Random selection of nuclei may yield those with sufficiently long 
telomeres only rarely, which may explain why few adult cells are successful donors (Anderson & 
Seidel, 1998).  
 
Imprinting 
It has been suggested that the success of cloning depends on proper epigenetic 
reprogramming of transferred nuclei (Santos et al., 2003).  Imprinting is an epigenetic 
mechanism by which the expression of on the order of 100 genes is dependent on whether they 
are inherited from the mother or father (sex of parent allele-specific expression) (Feil et al., 
1998).  Evolution of imprinting is most likely linked to intrauterine fetal development since only 
eutherian mammals distinguish certain genes by imprinting (Killian et al., 2000).   Imprinting 
makes both parental genomes essential for normal embryonic growth. This is proven by many 
studies with parthenotes and androgenotes.  Parthenogenotic embryos have poor trophoblastic 
tissues, while andrenogenotic conceptuses have underdeveloped embryos and prolific 
trophoblasts (Kono, 1998).    The current theory holds that imprinting has evolved to control a 
“parental conflict of interest” (Moore & Reik, 1996).  When the fetus develops, nutrients are 
supplied by the mother.  It is imperative for the fetus that the mother’s well being is not impaired 
by its growth and it is important for the mother that this pregnancy does not compromise future 
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gestations.  On the other hand, especially in non-monogamous species, the paternally derived 
alleles in the fetus will demand more resources from the mother since subsequent pregnancies 
might be from a different father.  Therefore, many genes important in fetal and placental growth 
and development are imprinted.  Paternally imprinted genes tend to favor fetal growth while 
maternally expressed genes will act restrictive (Young et al., 2001).  Thus paternally and 
maternally imprinted genes oppose each others’ effects on fetal growth, for example IGF-2 is 
imprinted paternally, while IGF2R is imprinted maternally. 
All epigenetic modifications are erased in primordial germ cells, and new sex specific 
imprints are established during gametogenesis in the male and female germ-line (Surani, 1998).  
During oocyte growth, maternal modifications will affect primary imprinting with crucial 
downstream effects on regulation of expression of maternal alleles during embryogenesis.  This 
was observed in a study with parthenotes from either neonatally derived non-growing oocytes or 
fully grown oocytes (Obata et al., 1998).   
In the zygote, shortly after fertilization and before DNA replication, the paternal genome 
undergoes genome-wide demethylation.  The maternal genome, on the other hand, undergoes a 
stepwise demethylation during the first mitotic divisions (Dean et al., 2001) that is less radical.  
De novo methylation of non-imprinted genes occurs in bovine embryos at the 8-16 cell stage 
(Dean et al., 2001), coinciding with the major wave of transcriptional activation of the 
embryonic genome (Memili & First, 2000) and the first differentiation event (trophectoderm vs. 
intracellular mass (ICM) cells).  In contrast, with the mouse where de novo methylation is 
limited to the ICM, bovine extraembryonic tissues are highly methylated (Dean et al., 2001).  It 
is important to keep in mind that primary imprinted genes are not demethylated or de novo 
remethylated during preimplantation development.  This provides a basis for the differential 
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susceptibility of imprinted and non-imprinted genes to environmental influences in the 
preimplantation period (Moore & Reik, 1996).  Since imprinted genes are expressed mono-
allelically, they may be more vulnerable to mutations or epimutations (Young, 2001).   
 Tucker et al., (1996) have shown that ES cells can reestablish normal methylation and 
expression patterns of non-imprinted genes, but germ line passage seems to be required to restore 
those of imprinted genes. It is important to note that imprinting is not entirely uniform.  
Functionally active epigenetic imprints are under spatiotemporal plasticity, and cell-type specific 
modification allows for tissue-specific imprinting patterns (Franklin et al., 1996).   
Severity of consequences of disruption of imprinting depends on the time point in 
development and the number and location of cells affected.  To determine if early embryonic 
epigenetic alterations in imprinted genes persist in later development, and are associated with 
aberrant phenotypes, Dean et al., (1998) established a model based on embryonic stem (ES)-cell 
derived murine fetuses.  ES cell lines were evaluated for altered methylation patterns in four 
genes (IGF2R, H19, IGF-2 and U2af1-rs1) known to be imprinted.  All changes in methylation 
that occurred during ES cell culture, persisted in the derived ES fetuses, and 2 of the 4 ES-lines 
resulted in compromised fetal development e.g. polyhydramnios, poor mandibule development 
and interstitial bleeding.  In chimeric fetuses, the degree of chimerism correlated with increased 
body weight (Dean et al., 1998).   
Are the nuclei from some differentiated cells able to regain totipotency?  Is the tissue 
specific imprinting erased when exposed to the cytoplasm of the recipient oocyte?  The genomic 
imprints are not reset as in the germ-line.  Does the artificial environment of in vitro culture and 
manipulation affect the remodeling of the chromosomes?  Doherty et al., (2000) found that 
culture conditions can selectively affect the expression of genomically imprinted genes in 
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preimplantation mouse embryos.  Specifically, the normally hypermethylated and repressed 
paternal H19 allele lost its methylation and was aberrantly expressed in Whitten’s medium, but 
not so in KSOM medium.    
Dean and colleagues (2001) found the global epigenetic reprogramming of bovine 
somatic nuclei to be aberrant in most preimplantation embryos.  In their study, they observed the 
donor nuclei to be considerably demethylated in the recipient oocyte within hours of introduction 
and activation.  Whether the differential methylation in imprinted genes is protected at that point 
is unknown.  No further passive demethylation during the first mitotic divisions was observed, 
and many cloned embryos underwent precocious de novo methylation and transcriptional 
activation at the 4-8 cell stages (Dean et al., 1998, 2001).  These observations might be related to 
improper silencing or non nuclear exclusion of methyltransferase (Dnmt) genes (Dean et al., 
2001).  A more recent study from the same laboratory showed that fewer blastomeres had a 
normal methylation pattern in NT embryos from relatively more differentiated fibroblasts 
compared to those from less differentiated granulosa cells; and this observation correlates with 
the proportion of NT embryos developing into blastocysts (Santos et al., 2003).  
 Not only are epigenetic changes with deteriorating developmental consequences detected 
in the embryonic stage, but also, Young et al., (2001) found that the reduction in expression of 
IGF2R in day 125 sheep fetuses derived from in vitro culture with an overgrowth phenotype 
corresponded with an epigenetic change in the gene. 
In conclusion, reprogramming by ooplasmic gene modifiers during fertilization and early 
embryogenesis is quite labile, and its interruption is likely to affect the developmental program 
(Kono, 1998).  Moreover, epigenetic variation in donor cells along with partial reprogramming 
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results in heterogeneity of epigenetic marking, which is responsible for the developmental 
potential of cloned embryos (Santos et al., 2003). 
 
Cloning applications and commercial opportunities 
The unexpected incidence of abnormal calves from embryos by in vitro manipulation 
resulted in the swift collapse of agricultural application of cloning.  Wide application of IVF in 
cattle also has stalled in part due to calf abnormalities.  The European Community is considering 
banning IVF and cloning applications with farm animals on the basis of animal welfare 
considerations (Sinclair, 1998).  These events clearly demonstrate that problems with abnormal 
calves must be solved if these, and related biotechnologies, are to be used in production 
agriculture.  As important as research on this problem is in the context of applying new 
biotechnologies, obtaining basic physiological understanding from this model may be even more 
important.  Moreover, the gestational abnormalities described in gestations from clones, also 
occur with natural breeding and artificial insemination, albeit at low incidence, on the order of 
1% of calves.  However, this equals half a million calves in the US and Canada annually, a 
severe economic loss.  In addition, annual calf death loss approximates 6-10%.  Half of the 
neonatal calf deaths occur during the first two days of life, of which the majority cannot be 
attributed to infectious disease but rather physiological disturbance (Garry, 1999). 
In the cattle industry, artificial insemination (AI) is a multibillion dollar business.  With 
the introduction of this technique, milk production has been genetically increased by 30% over 
30 years (Lewis et al., 1998).  With cloning, a major change is to come in the artificial 
reproduction industry (Lewis et al., 1998).  The goal in agriculture is to produce clonal lines of 
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genetic identical animals for increasing genetic gains (Lewis et al., 1998), and therefore 
improving efficiency of food production. 
One envisions that if cloned embryos would be available at $30.00 each with a 50 % 
calving rate per embryo, it would be economically feasible for farmers to switch to embryo 
transfer instead of routine AI (McClintock, 1998).  Current laboratory costs to produce a large 
number of genetically identical cloned embryos are $15.00 per blastocyst, but the calving rate is 
only 17% (Lewis et al., 1998).  Therefore, at this point in time, cloning technology in agriculture 
is only economically feasible for elite, performance tested animals used for cattle shows and AI 
service.  Thus cloning for agricultural purpose will become more attractive when efficiencies 
increase and costs come down.    
Potential limitations to agricultural applications of cloning include: 1) the source of 
ooplasm and its labor cost to collect oocytes.  To generate 100,000 live cloned offspring, one 
needs ovaries from 650,000 cows (Lewis et al., 1998)!  Endeavors to automate oocyte collection 
are underway (Lewis et al., 1998); 2) Public perception:  confusion with transgenics, e.g. public 
adversity to genetically modified crops in Europe (McClintock, 1998); 3) one needs to eliminate 
abnormal calves obtain conception rate as with normal breeding without an increase in perinatal 
mortality (Wilmut, 1998).  The use of large scale agricultural cloning implies the risk of 
inbreeding in future generations.  However, McClintock (1998) argues that if done correctly, this 
large scale control over breeding can actually increase the heterozygosity of the current dairy 
herd.  Only a certain percentage of the herd would carry replacement offspring, while others can 
be used to produce crossbreds.  Furthermore McClintock insists that it is the responsibility of the 
country to establish gene banks to prevent loss of genetic variation; the farmer should not be 
expected to be the curator of a museum! 
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In combination with transgenic procedures, nuclear transfer cloning can more easily 
generate transgenic farm animals with defined and commercially useful genotypes (Schnieke et 
al., 1997; Anderson & Seidel, 1998).  Cloned transgenic founder animals (nuclear transfer 
transgenics) can be generated as follows: bovine cell lines derived from embryonic or fetal origin 
(fibroblasts) would be isolated and propagated, and a gene of interest inserted along with a 
positive selection gene.  Bovine cells expressing the construct would then be selected and 
propagated.  Transgenic cell lines serve as donor nuclei, resulting in cloned transgenic embryos, 
fetuses and offspring (Stice et al., 1998).  This technique can be used to express pharmaceutical 
proteins in milk; for pharmaceutical protein production, the inefficiency of the process is offset 
by the high value of pharmaceuticals that can be made from relatively small numbers of animals 
(McClintock, 1998).  Another highly touted commodity is nuclear transfer transgenic pigs for 
xenotransplantation.  Demand greatly exceeds supply for human replacement organs such as 
heart valves, pancreas, etc.  Because of their size, porcine organs are the best fit for humans.  A 
big issue in organ xenotransplantation is tissue rejection because of histocompatibility complex 
issues.  Therefore nuclear transfer knockout pigs for the alpha 1,3-galactosyltransferase epitope, 
foreign to humans may prevent hyperacute rejection in xenotransplantation (Wilmut et al., 
1998).   
Other benefits for the pharmaceutical industry from nuclear transfer (transgenic) (farm) 
animals include models for human genetic disease (e.g. cystic fibrosis in sheep, transgenic mice 
for the evaluation of gene therapy or novel small molecule based therapy) (Wilmut et al., 1998).  
Furthermore, if drugs can be tested in batches of cloned animals, one greatly reduces the genetic 
variability between individual animals, therefore increasing the power of the study and 
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decreasing the number of subjects needed.  The utility of this approach is clear from use of 
inbred lines and their crosses in a few species. 
Cloning can also benefit human medicine.  For gene therapy and organ transplantation we 
ideally need recipient-specific multipotential cells in order to prevent immunological rejection.  
Therefore, if one can produce embryonic stem cells from cloning a patient’s somatic cell, these 
cells might be ideal candidates for these new therapeutics (Trounson, 1997).  For example, 
human fetal neural tissue is highly sought after for transplantation therapy for Parkinson’s 
disease (Stice et al., 1998). 
One last application of cloning involves reproduction of species threatened by extinction 
as well as reproduction of precious pets.  One just needs to keep in mind that genetic identity by 





The placenta has a pivotal role in transfer of essential substrates from the mother to the 
fetus and removal of waste products; it also is responsible for mediating and/or modulating the 
maternal environment (Owens, 1991; Bauer et al., 1998).  Birth weight depends primarily on the 
rate of fetal growth, and is highly correlated with placental weight (Alexander, 1964).  
Phylogenetically, placental membranes (amnion, chorion, allantois, yolk sac) are relatively 
young structures; appearing with development on land instead of in water.  Early in 
development, certain cells are assigned to the development of these tissues for embryonic 
nutrition and protection in both oviparous birds and viviparous mammals.   Eutherian species 
develop a placenta in which the maternal and fetal circulations are brought in close juxtaposition 
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for purposes of exchange (Zumkeller, 2000).  Etymologically the word placenta is Latin in 
origin, and means “flat cake” in reference to the discoidal placenta of humans.  However, 
placental morphology varies greatly between species, and multiple classifications of placental 
types are described.  With deciduata (primates, rodentia, carnivores), interdigitation of fetal and 
maternal tissues is intense.  Upon trophoblastic invasion, the endometrium responds with the 
formation of large polygonal cells named decidual cells.  Outgrowth of fetal tissue (the placenta 
vera) into maternal tissue allows for an intense exchange in a relative small surface area.  At the 
time of afterbirth expulsion, a great part of maternal endometrium (the decidua) is also expelled.  
In contrast, in other species, adeciduata appose the chorion to the endometrial tissue without 
damaging the endometrial epithelium greatly.  Therefore, they are named placenta apposita (e.g. 
placenta diffusa, placenta cotyledonaria).  At birth, the pars fetalis separates from the pars 
maternalis without much loss of maternal tissue with expulsion of the afterbirth.   Depending on 
the intensity of fetal and maternal tissue intergrowth, placentae usually are classified 
anatomically as follows (Grosser, 1909, 1927): 
- Epitheliochorial placenta (e.g. horse, pig): fetal and maternal epithelium remains intact.  
Nutrients from the maternal circulation are transferred through six layers in order to reach the 
fetal circulation: maternal capillary endothelium, maternal endometrial connective tissue 
(stroma) and maternal endometrial epithelium, fetal epithelium (trophoblast), chorionic 
connective tissue or mesenchyme and endothelium of the fetal capillaries.   
- Syndesmochorial placenta (e.g. sheep, goat): in this case there is a disappearance of the 
endometrial endothelium. 
- Endotheliochorial placenta (e.g. carnivores): the fetal villi penetrate to reach the maternal 
capillaries, endometrial epithelium and stroma are strongly reduced. 
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- Hemochorial placenta (e.g. humans, rabbits, rats, mice, guinea pig): The trophoblast (of the 
chorion) is in direct contact with the maternal blood.  The trophoblast consists of at least one 
layer of syntrophoblast.   
When based upon size and shape of the contact interface, five types of placentae are described: 
- Complete diffuse placenta: the entire chorionic surface covers the total endometrial surface 
and the chorial villi are diffusely dispersed (e.g. horse). 
- Incomplete diffuse placenta: idem supra, except the ends of the gestational sacs are villus 
free (e.g. pig). 
- Cotyledonary placenta: placentation only occurs in specific areas of the chorion at the level 
of the caruncles in the endometrium.  Chorial villi of the cotyledons interdigitate and branch into 
the caruncular crypts and form placentomes.  Depending on the  number of placentomes, 
placentas are termed polycotyledonary (e.g. cow, ewe, goat, respectively 75-120; 80-100; up to 
160) or placenta oligocotyledonary (e.g. deer: 10-12 placentomes).  
- Zonary placenta: the chorio-endometrial interface forms a girth (e.g. carnivores). 
- Discoid placenta:  placentation is limited to a disc shaped zone, relatively small compared to 
the entire chorionic surface (e.g. rodents, primates). 
Furthermore placental types can be distinguished based upon the organization of the 
interdigitation of maternal and fetal blood vessels (folded, lamellar, villous, trabecular, 
labyrinth), and the relation of blood flow within maternal and fetal capillaries (concurrent, 






Bovine placentation and embryonic development 
The bovine placenta is apposita, epitheliochorial and polycotyledonaria, and therefore 
belongs to the adeciduata. In an excellent review, Schlafer et al., (2000) describe bovine 
placental development.  Blastulation occurs, and the outer ectodermic layer of the expanded 
blastocyst consists of trophoblast cells and is referred to as “trophoblast” or more specifically, 
trophectoderm.  The endodermic cells lining the inner side of the blastocoele will become the 
yolk sac and the embryonic disc will develop into the embryo.  In sheep and cattle, the yolk sac 
consists of an enlarged sac-like structure below the embryo and two tubal ends that elongate with 
the trophoblast.  At first an open connection between the yolk sac and intestines exists that later 
closes.  The wall of the yolk sac is well vascularized, and primary erythropoeisis occurs within 
these capillaries (Russe et al., 1992).  The vascularized yolk sac supports fetal development until 
day 35 of gestation ((Thompson & Peterson, 2000).  After gastrulation, the outer trophoblast 
layer combines with the somatic/parietal mesoderm (derived from the embryonic disc) to form 
the chorion.  The amnion is formed by folding of the chorion around the embryo.  Upon fusion 
(by day 16), the embryo is enclosed in a membrane lined by amniotic cells.  Part of the amnion 
dorsal to the developing fetus will gradually fuse with the chorion and form the amniochorion.  
The allantois develops from a diverticulum of the embryo’s hindgut by day 20 and fills the entire 
exocoelome during the 4
th
 week.  Eventually, the chorion and the vascularized allantois appose 
and become allantochorion or chorioallantois.  This apposition will provide vascularization to the 
chorion which originates from the mesodermal component of the allantois (Green & Winters, 
1945; De Sousa et al., 2001).   
At about 10 days after fertilization, the embryo starts to elongate rapidly; at 13-14 days it 
will reach 1-4 cm and by 16 days will be 15-20 cm or more in length.  By day 20-22, the 
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elongating embryo will reach the tip of the non-gravid horn.  This elongation is important for 
communicating pregnancy signals to the mother to prevent luteolysis. On days 17-18 the embryo 
will become tightly apposed to the uterine endothelium. Raised areas of non-glandular, well 
vascularized endometrium, termed caruncles, are always present in the uterus of the cow (Orbus, 
1999).  Between day 22 and 30 (Melton et al., 1951), the chorioallantois will begin to become 
irregular over the caruncular endometrial zones, and villi will form and protrude and eventually 
colonize the recesses in the caruncular surface (Schlafer et al., 2000).  The caruncle will develop 
crypts, and the apposing chorioallantoic villi will interdigitate and branch within, thus increasing 
surface contact area and forming placentomes.  Villi in the intercaruncular zones are rudimentary 
in development but soon disappear (Lauwers, 1991).  By 60 days, cotyledons and caruncles are 
firmly attached (Eley et al., 1978), but will keep developing and become stalk-like halfway 
through gestation.  The placentomes appear in an organized pattern: four rows lengthwise along 
both horns (Schlafer et al., 2000).  At term, the placentomes have a domed-ovoid shape about 
10-12 cm in length and 2-3 cm in thickness (Schlafer et al., 2000). The largest and most 
advanced developed placentomes are found in close proximity to the umbilical cord; smaller 
placentomes are found in the non-gravid horn and closer to the tip of the uterine horn. Total 
placentome numbers vary from 70-120.  The total contact surface area, taking into account 
interdigitation, is estimated to be 130 m
2
 (Russe & Sinowatz, 1991; Schlafer et al., 2000).   
Histologically, the caruncle consists of capillaries and connective tissue surrounding 
branching crypts.  Groups of crypts are separated by thin septa.  The crypts are covered with a 
monolayer of a low cylindrical epithelium and open up to the convex side of the caruncle. The 
crypt epithelium carries microvilli that interdigitate with the microvilli of the trophoblast 
(Lauwers, 1991).  The cotyledon covers the convex side of the caruncle and carries branched 
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chorial villi grouped in small clusters on its concave side (Lauwers, 1991).  The axis of the 
chorial villi consists of connective tissue and capillaries covered with a continuous monolayer of 
trophoblast cells.  The trophoblast cells carry microvilli and perform pinocytosis.  When 
maternal erythrocytes accumulate between the endometrium and chorioallantois, they are 
phagocytosed by trophoblast cells as a significant source of iron (Schlafer et al., 2000).  In the 
ruminant placenta, the vast majority of trophoblastic giant cells are binucleate, and they 
compromise approximately one fifth of the bovine trophoblast cells (Wooding et al., 1997; 
Klisch et al., 1999; Schlafer et al., 2000).  They are formed in the chorion and are derived from 
mononuclear trophoblast cells by a single, acytokinetic mitosis (Wooding & Wathes, 1980; 
Klisch et al., 1999).  The binucleate cells are larger than the surrounding cells, carry two nuclei, 
no microvilli, do not have junctions with surrounding cells, and synthesize numerous granules.  
Even though undistinguishable microscopically, many subpopulations have been identified by 
lectin cytochemistry (Munson et al., 1989; Jones, 1994; Schlafer et al., 2000).  Binucleate cells 
produce steroid and protein hormones e.g. progesterone (Reimers et al., 1985); bovine placental 
lactogen (bPL) (Duello et al., 1986), pregnancy associated glycoproteins (bPAG-1, bPAG-2, 
bPAG-3) (Roberts et al., 1995), and transforming growth factor beta (Munson et al., 1996).  The 
large granulated binucleate cells appear at first in the chorionic epithelium when the embryo is 
16-17 days old ((Greenstein et al., 1958; Bjorkman, 1968; Wooding & Wathes, 1980); at about 
20 days, migration of the binucleate cells into the maternal epithelium begins (Wooding & 
Wathes, 1980).  They translocate from the chorionic layer on the fetal side, cross the tight 
junctions, and penetrate the epithelial monolayer lining the caruncular crypts to reach the 
basement membrane where they produce transient trinucleate cells and release their granules by 
exocytosis (Wooding & Wathes, 1980; Wooding, 1992).  Subsequently, the cell condenses to a 
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remnant that is phagocytosed by the chorionic epithelium (Lee et al., 1986). This is in contrast 
with the sheep where binucleate cells fuse to form a syncitial layer (Lee et al., 1986). 
Granule transfer and delivery seems to be the primary function of binucleate cell 
migration (Wooding & Wathes, 1980; Wooding, 1992), and this mechanism might be required to 
transfer large and non-diffusible molecules across the placental barrier (Wooding & Wathes, 
1980).  With the description of fetal binucleate cell migration and fusion and the persistence of a 
uterine epithelium, the new terminology of “synepitheliochorial” placenta is suggested 
(Wooding, 1992). 
The intercaruncular region of the endometrium is glandular with little vascularization 
(Amoroso, 1952; Orbus, 1999).  The endometrial glands secrete a protein/lipid rich uterine milk 
which is phagocytosed by trophoblast cells.  This histotrophic nutrition is present throughout 
gestation, but especially significant during the first 40 days of gestation (Melton et al.,1951); 
thereafter, placentomes have established efficient hemotrophic nutrient and waste product 
exchange.  
The umbilical cord in the cow is relatively short and consists only of amniotic tissue.  As 
described by Robinson & Abuhamad (2000), the umbilical cord is established with the formation 
of the amniotic cavity and the curling of the embryonic disc around the regressing yolk sac.  The 
ectoderm-amnion border becomes the primitive umbilical ring on the ventral surface of the 
embryo.  The umbilical ring contains the allantois, umbilical vessels, extraembryonic coelom, the 
vitelline duct and the vitelline vessels.  As the amniotic cavity enlarges, the contents of the ring 
are compressed and elongate to form the umbilical cord.  Remnants of the yolk sac are 
incorporated into the umbilical cord and disappear halfway through gestation.  Similarly, the 
allantois, vitelline duct and vitelline vessels become obliterated.  Thereafter, the umbilical cord 
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remains, consisting of 2 umbilical veins and 2 umbilical arteries and the urachus canal covered 
by amnion and surrounded by Wharton’s jelly (a mucopolysaccharide gel).  Before entering the 
navel of the fetus, the 2 umbilical veins become one.  At parturition, the umbilical arteries retract 
to the top of the bladder and close by contraction of the tunica media.  The umbilical vein 
remains in the umbilical remnant and will dry up and fall off (Lauwers, 1991). 
 
Placental vascularization 
 Uterine vascularization is supplied by the small ovarian arteries and the large middle 
artery (Hansel & Asdell, 1951).  The middle uterine artery ramifies into numerous primary 
branches in the broad ligament which give rise to a number of arcuate arteries that encircle the 
uterine horn. “T”-shaped arterioles branched from the arcuate arteries vascularize the outer 
muscular layer.  The endometrium is supplied by complex branches and sub branches of the 
arcuate arteries.  Caruncular arterioles are more tightly coiled and possess unusually thick walls 
containing many elastic fibrils (Hansel & Asdell, 1951).  These same arterioles will be 
responsible for the maternal vascular system of the placenta (Carter, 1975).   
 The fetal placental vascularization is derived from the umbilical cord.  Two branches, 
each containing an umbilical artery and vein, extend into respective horns (Steven, 1968) and 
branches from the umbilical arteries and veins vascularize each placentome (Carter, 1975).  The 
microvascular architecture of the bovine placenta is of the villous type. The placentome of the 
cow is mushroom shaped, and fetal villi are located within crypts, surrounded by maternal septa. 
The fetal villous trees are conical in form (wide base, thinning out to the top), creating a 
relatively short distance of vessels from the chorionic plate to the capillary complex.  The 
maternal blood vessels are enclosed in septa and disperse into capillaries on the surface of the 
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crypts and caruncle (Tsutsumi & Hafez, 1966).  The fetal villous tree is subdivided into segments 
of stem villi, intermediate villi, and terminal villi (Kaufmann et al., 1979; Kaufmann, 1982; 
Leiser et al., 1997).  In accordance with the villar organization, vessels are described as stem 
arteries and veins, intermediate arterioles and venules, and terminal capillaries (Leiser, 1987; 
Leiser et al., 1997). The caruncular stalk consists of narrow arteries and veins spiraling (Leiser et 
al., 1997) towards the caruncular basal plate where they are interwoven into a dense connecting 
vasculature.  From this basal plate, stem vessels radiate to form septae, which end in peripherally 
located capillary complexes.   
 The course of fetal as well as the maternal arteries and arterioles brings the two capillary 
systems into close apposition. Stem villi consist of one centrally located artery accompanied 
peripherally by several veins; this pattern is similar for the intermediate villus.  In the neck of the 
terminal villi, capillary loops are arranged asymmetrically.  One shorter arterial limb situated 
centrally of the terminal capillary system meets with a few longer, more convoluted venous 
capillary limbs in the periphery.  Maternal capillaries surround the fetal capillary in a basket-like 
fashion (Leiser et al., 1997).  Within each cryptal/villous unit, blood flow conditions are cross-
current, but the overall arrangement is more of a countercurrent flow because maternal as well as 
fetal stem arteries reach out to the fetal and maternal sides of the placentome, thus orienting both 
capillaries in opposite ways (Leiser et al., 1997).   
 Maternofetal exchange occurs in the capillary complexes (Kaufmann et al., 1979; 
Benirschke & Kaufmann, 1995), and the more voluminous the capillary complex, the more 
efficient the process.  However, the shorter the venules and veins are, the faster oxygenated, 
nutrient rich blood can be transported to the fetus.  Therefore, smaller villous trees are more 
efficient.  And, as Leiser et al. (1997) concluded, the larger the term ruminant placentome, the 
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smaller the effect for substantial exchange.   However, the bovine mushroom shaped placentome 
with conical villous units favors short routes of supply for voluminous capillary beds over the 
cup-like placentome of goat and sheep (Tsutsumi, 1962).  This is also reflected by a weight ratio 
of neonate to placenta of 13:1 in the cow vs. 10:1 in sheep or goat (Dantzer et al., 1988; 
Kaufmann, 1990).  One interesting phenomenon is that in the intermediate villi, one arteriole is 
surrounded by up to eight very thin-walled venules in a countercurrent setting.  This extensive 
venular system conspicuously slows down the blood return to the fetus, but allows for 
reabsorption of substances.  This might be of functional importance for distribution of hormones 
produced by the placenta (Leiser et al., 1997). 
Initially, placental growth exceeds that of the fetus.  The instantaneous growth rate of the 
placenta and cotyledons reaches a maximum at 207 and 202.5 days of gestation respectively, 
while peak growth rate of the bovine fetus occurs at 230 days (Prior & Laster, 1979).  The 
increase in placental weight during gestation is attributed to both the steady rise of uterine tissue 
weight as well as the rapid expansion of the fetal villi into maternal stroma (Barcroft & Barron, 
1946; Davies & Wimsatt, 1966; Stegeman, 1974; Ehrhardt & Bell, 1995; Orbus, 1999).  The 
initial rise and decline in placental wet weight has been attributed to Wharton’s jelly (a 
mucopolysaccharide), which contributes to the dramatic initial expansion of connective tissue in 
the villi.  Throughout gestation, this connective tissue will be replaced by continuous remodeling 
of vascular architecture of the placentome (Barcroft & Barron, 1946; Wimsatt, 1950; Stegeman, 
1974; Ehrhardt & Bell, 1995; Orbus, 1999).  Both maternal and fetal genotype (breed, e.g. 
Charolais vs. Brahman) affect placentomal and caruncular weight, but cotyledonary weight is 






The availability of nutrients to the fetus is mediated by the placenta and greatly affects 
fetal growth (Bauer et al., 1998).  Birth weight depends primarily on the rate of fetal growth, and 
is highly correlated with placental weight (Alexander, 1964).  Ferrell (1991b) suggests that fetal 
growth may be limited by uterine blood flow and by function of the uteroplacenta, especially 
approaching term.  Birth weight of twin fetuses is reduced in comparison with singletons, partly 
due to the reduced blood flow per fetus perfusing the placenta (Ferrell & Reynolds, 1992).  Both 
maternal and fetal genotype influence fetal growth (Ferrell, 1991a).  The maximal rate of 
increase in bovine fetal weight occurs around 230 days of gestation (200g/day) (Eley et al., 
1978; Prior & Laster, 1979).  In late gestation, a decrease in bovine fetal growth rate is observed 
(Ferrell et al., 1976; Eley et al., 1978); either the placenta cannot sustain the absolute growth rate 
or, alternatively, hormonal signals from the fetus and/or the placenta may decrease fetal growth 
rate (Eley et al., 1978).  After elongation, growth is due initially to an increase in cell numbers 
(hyperplasia) with a constant individual cell size.  As development continues, growth is due to 
both hyperplasia and hypertrophy, but later primarily to hypertrophy (Winnick & Noble, 1965; 
Prior & Laster, 1979).  In the bovine fetus, hyperplasia occurs throughout gestation based upon 
increasing total DNA per fetus, protein/DNA and RNA/DNA ratios, near term (Prior & Laster, 
1979).  Growth by hypertrophy as indicated by protein/DNA and RNA/DNA ratios continue to 
increase with increasing fetal age (Prior & Laster, 1979).  Growth due to hyperplasia is lower 
than growth due to hypertrophy; as fetal age increases, retardation of fetal growth later in 




GESTATIONAL ABNORMALITIES OBSERVED WITH CLONING 
 
What causes pregnancy attrition? 
Manipulation of gametes and preimplantation embryos through in vitro culture, in vitro 
fertilization, nuclear transfer, etc. can influence differentiation and growth at later stages of 
development and may cause fetal and neonatal abnormalities (Dean et al., 1998). Culture of 
cloned embryos may cause an imbalance in the distribution of cells to the trophoblast relative to 
the inner cell mass (Rieger, 1998).  The presence and concentration of serum, glucose, 
ammonium ion and growth factors in the culture medium all may affect one or more factors in 
embryonic growth: mitosis, apoptosis, mRNA stability, imprinting, transcription, gene 
expression and protease activity.  For example, high levels of glucose or accumulation of 
ammonium from amino acid breakdown in cell culture medium result in fetal retardation (De 
Hertogh et al., 1992; Lane & Gardner, 1994).  Often, in vitro manipulations result in abnormal 
embryogenesis, overgrowth, lengthened gestation, increased abortion, and increased perinatal 
and postnatal mortality (Kono, 1998).  However, one can obliterate the gestational abnormalities 
seen with in vitro produced, but not cloned bovine embryos, if the embryos are first transferred 
to the oviduct of sheep and then transferred at the blastocyst stage into heifers (Behboodi et al., 
1995).  On the other hand, when in vivo matured and fertilized ovine eggs were cultured in vitro 
for 6 days, an increase in mean birth weight was observed, depending on the culture system used 
(Sinclair, 1998). 
In the past decade, several reports of gestational and neonatal abnormalities following in 
vitro embryo culture, asynchronous embryo transfer, nuclear transfer, early maternal exposure to 
excessively high progesterone (Kleemann et al., 2001) and changes in protein content of 
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maternal diet (Perry et al., 1999; Wallace et al., 1999), have been published.  The “large 
offspring syndrome” (LOS) in cattle and sheep, was first identified by Willadsen et al., (1991) 
who reported that some calves from nuclear transplantation were exceptionally large, up to 80 % 
of the cloned calves have a pathological metabolism that leads to high neonatal mortality, but if 
given intensive care at birth, calves become essentially normal (Garry et al., 1996).  These data 
infer a genetically or epigenetically abnormal placenta. The placenta is directly responsible for 
mediating and/or modulating the maternal environment and has a pivotal role in transfer of 
essential substrates from the mother to the fetus.   
 
Abnormal placentation 
High pregnancy attrition rates during the first trimester in gestations from cloned and in 
vitro produced bovine and ovine embryos are very likely caused by inadequate placental 
development.  Stice et al. (1996) were first to indicate abnormal placentomal development in 
gestations of clones derived from embryonic stem cells. All pregnancies were lost prior to 60 
days of gestation.  Most remarkable was the absence of cotyledons but the presence of a 
hemorrhagic response in the caruncles at 38 days.  Fetal organogenesis, completed by day 42, 
was apparently normal.  Until around day 40, the bovine conceptus can survive on histotrophic 
and yolk sac nutrition; after this point, hemotrophic (placentome) nutrition becomes essential 
(Melton et al., 1951; Thompson & Peterson, 2000; De Sousa et al., 2001).  Pregnancy loss in the 
study of Stice et al. (1996) coincided with timing at which placentomal functioning becomes 
essential.  The hemorrhaging in the caruncles indicates a maternal response.  Therefore, aberrant 
fetal placental development is most likely to blame for the high loss of early pregnancies.  In 
agreement with these findings, Peterson & McMillan (1998) observed allantoic malformation 
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characterized by retarded or non-existent growth and by complete lack of vascularization in in 
vitro derived bovine embryos during the first month of gestation.  Since the allantois is 
responsible for chorionic vascularization, maldevelopment of the cotyledon may be due to a 
deficient allantois (Wells et al., 1999).  In ruminants much of the placenta is derived from 
trophoblast; however the amnion and allantois are derived primarily from the inner cell mass, so 
any of these structures might be involved in the etiology of abnormal placental function.  
Histologically, a reduction in chorio-allantoic epithelial height, cellularity and capillary numbers 
in placentas from first semester, bovine cloned fetuses, was observed by Hill et al., (1999, 2000).  
In pregnancies from cloned sheep, De Sousa et al., (2001) observed a high incidence of 
developmental retardation and chorionic hypoplasia and deficiencies in chorioallantoic 
vascularization in day 35 sheep gestations.  De Sousa et al. were unable to determine if the lack 
of vascularization was due to a lack of allantoic outgrowth or an absence of vasculogenesis.  
Stice et al. (1996) and Kato et al. (1999) tried rescuing their NT clones by creating chimeras, this 
did not improve development to term, suggesting that the placental deficiencies may not depend 
on the individual cell (i.e. karyotype anomaly) but rather on interaction between cell types (De 
Sousa et al., 2001).   Hill et al. (2000) noted a reduction in chorio-allantoic epithelial height, 
cellularity and capillary numbers in H&E sections of day 90 placentomes from cloned placentae.  
Later in gestation, Farin et al. (2000) evaluated placental morphology in gestations derived from 
bovine in vitro produced embryos at day 222.  They found the percent total superficial caruncular 
surface, villous volume density and fetal binucleate cell volume density all to be significantly 
less in IVF than control pregnancies.   
In the third trimester, pregnancy loss is often a consequence of hydroallantois.  A high 
incidence of hydrops amnion and hydroallantois has been reported by multiple groups and is 
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accompanied by a very high rate of mortality of recipient cows (Hasler et al., 1995; Cibelli et al., 
1998; van Wagtendonk-de Leeuw et al., 1998; Wells et al., 1999; Zakhartchenko et al., 1999).  
The incidence of hydroallantois is about 1% for pregnancies from IVF (1,376 pregnancies) 
(Hasler, 1998).  It is suggested that this excessive fluid accumulation might be a consequence of 
a low number in placentomes, causing placental dysfunction (Wells et al., 1999).  Fewer and 
enlarged placentomes, enlarged umbilical vessels and edematous placental membranes (Hasler et 
al., 1995; Garry et al., 1996; Kruip & den Daas, 1997; Cibelli et al., 1998; Wells et al., 1999; 
Van Wagtendonck-de Leeuw et al., 2000) and intercotyledonary areas that are thickened with a 
gelatinous-like material at parturition (Garry et al., unpublished) are also frequently observed.   
Parturitions are frequently lengthy, lacking normal signs of impending birth or pronounced 
uterine contractions (Avery & Greve, 1995).   
Ultimately, parturition does not seem to progress, and the mammary gland is 
underdeveloped.  Again this may reflect placental dysfunction, since placental hormones affect 
mammogenesis during pregnancy (Wells et al., 1999).  The rising levels of fetal cortisol will also 
induce changes in steroidogenic enzyme activity of the placenta, converting progesterone to 
estradiol 17β, initiating a cascade of events leading to parturition (Nathanielsz, 1996; Wells et 
al., 1999).  Finally, it is important to note that placental abnormalities in clones are not limited to 
the ruminants, but are also found in cloned mice; e.g. placental weights of twice the normal value 
(Wakayama et al., 1999), severe placental hypertrophy with a histologically disrupted 
architecture (Ono et al., 2001) and, midgestational failure with deficiencies in embryo derived 
placental vasculature (Kato et al., 1999). 





The incidence of oversize calves from cloning by nuclear transplantation has been 
documented in a study involving thousands of calves by Wilson et al. (1995).  Overgrowth is the 
most obvious characteristic of cloned calves for the laymen’s eye, and likely is caused by an 
imbalance in contributions of growth promoting genes versus growth inhibitory genes in certain 
tissues at specific stages of development (Li et al., 1998a).  It is important, however, to note that 
most abnormal pregnancies do not in fact result in oversized calves, but are still very abnormal in 
that up to 80 % of the cloned calves have a pathological metabolism that leads to high neonatal 
mortality (Garry et al., 1996).  Calves derived from IVF or nuclear transplantation seem to 
require extra, intensive care due to metabolic pathologies.  
The Barker hypothesis suggests that certain diseases such as coronary heart disease, 
stroke, hypertension and non-insulin dependent diabetes originate through impaired growth and 
development due to nutritional constraints at critical phases of key fetal development; other adult 
disease states such as cancer may also be related to nutrition during pregnancy (Barker & Clark, 
1997).  Therefore, the fetus would adapt to a lack of nutrients or oxygen by slowing its rate of 
cell division and/or changing the proportion of cell types, hormonal feedback, metabolic activity 
and organ structure.  Consequently, this differential constitution results in permanent changes in 
physiology and metabolism (Young, 2001).  Even the peri-conception nutritional status of the 
mother can affect preimplantational embryonic development, as seen in high yield producing 
dairy cattle that have a difficult time conceiving (Young, 2001).  More extreme effects of 
preimplantation insults are seen with in vitro manipulation of the early embryo. A high 
percentage of these pregnancies are lost throughout gestation.  In the first trimester, abortion 
rates are high, later in gestation hydroallantois is lethal to the fetus and usually also the dam.  
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Ultimately at birth, up to 80% of cloned calves show metabolic disorders and perinatal morbidity 
is high, unless intensive care is provided.  The most striking observation at birth is the Large 
Offspring Syndrome (LOS).  Dystocia associated with increased birth weight often requires 
delivery by caesarian section (Kruip & den Daas, 1997).  LOS has been linked to serum exposure 
during in vitro culture.  However, full sibling embryos, cultured in the same drop result in both 
developmentally normal and abnormal offspring (Sinclair et al., 2000).  Of course a later 
synergistic effect by the maternal environment has to be taken into consideration.  Also Hardy et 
al. (2001) suggested predisposition of the oocyte before embryo manipulation; by means of a 
mathematical model, they found that the rate of apoptosis might be predetermined by an oocyte 
factor.  Calves with fetal overgrowth, also can have an enlarged heart, changes in liver and 
kidneys and increased musculature (Young, 2001).  Other neonatal problems observed with 
cloned offspring that are not necessarily related with birth weight, are breathing difficulties, 
unresponsive calves that are slow to stand and nurse and sudden perinatal death (Garry et al., 
1996; Walker et al., 1996 and others).   
Garry et al. (1996) reported that calves independent of size were hypoxic, hypoglycemic, 
and hypothermic, suffered from metabolic acidosis and had abnormalities in metabolic hormones 
including low thyroxin and T3, and insulin concentrations four times higher than the reference 
population shortly after birth.  They suggested, in line with the Barker hypothesis, that in utero 
energy supply and utilization might be different in cloned gestations, promoting growth, but 
predisposing difficulty with adaptation to extrauterine life.  One could compare this with human 
gestational diabetes, except that in that case, the origin of the problem is maternal.  Increased 
muscle mass, changes in muscle fiber composition (Maxfield et al., 1997), cerebral dysplasia 
(Schmidt et al., 1996) and skeletal and facial malformations (Walker et al., 1996) all have been 
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reported.  Enlarged organs and greater organ allometric growth coefficients for organs (Farin & 
Farin, 1995; Sinclair et al., 1997, 1998) have been measured, suggesting a disturbed growth rate 
and development of organs (Young et al., 1998).  Interestingly, increased fetal weight is not 
associated with larger placentae (Sinclair et al., 1997, 1998).  This might indicate that 
overgrowth is driven by the fetus and not the placenta; still placental function might be altered 
independent of size (Young et al., 1998).   
Large offspring syndrome affects both female and male offspring (Wilson et al., 1995; 
Goodhand et al., 1997; Yazawa et al., 1997) and occurs in a variety breeds (Kruip & den Daas, 
1997).  Even though large at birth, offspring size evens out with control populations by 1 year of 
age (Wilson et al., 1995), and apparently normal offspring are produced in the next generation.  
It has been suggested that the observed fetal hypoxia might be correlated with the observed 
edematous placenta (Garry et al., 1996; Hill et al., 1999) impairing O2 exchange between mother 
and fetus.  Hill et al., (1999) suggested that the placental edema may result from elevated 
systemic pressures, linked to a dysfunctional right heart and congenital pulmonary hypertension.  
Certain calves also suffer from pulmonary distress due to lack of surfactant, which is common.  
Two potential causes suggested by Hill et al. (1999) are poor production of surfactant by Type II 
alveolar cells and/or a reduced surfactant concentration due to dilution by excess amniotic fluids.  
One cloned calf from the Hill study manifested itself with diabetes mellitus, a disease very rare 
to the bovine species (Mostaghini & Ivoghli, 1977); the underlying cause was attributed to 
hyperplasia of insulin-producing pancreatic β-cells (Hill et al., 2000).  Renard et al. (1999), 
reported the death of a cloned calf with severe anemia, lymphoid hypoplasia (hypoplastic lymph 
nodes, thymus and spleen) and deficiency in CD45, a common leucocyte antigen.  This condition 
may impair immune response and render individuals more susceptible to infection.  Thompson 
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and Peterson (2000) indicated a link of this phenotype of depressed haematopoiesis with 
allantoic malformation since both the yolk sac and allantois have been suggested as potential 
contributors of haematopoiesis (Al Salami et al., 1985). 
Oversized umbilical cords develop inexplicably during most cloned pregnancies, 
sometimes two to three times the normal size (Cibelli et al., 1998).  At Cyagra, a company that 
produces cloned calves commercially, these cords are surgically ligated at birth, to prevent 
exsanguination (B Henderson, personal communication 2003). 
The tremendous variability in anecdotal abnormalities observed in cloned offspring, 
highlights the complexity of the syndrome.  This again shows our lack of understanding of 
normal fetal development and the need for research in this field. 
 
 
THE INSULIN-LIKE GROWTH FACTOR SYSTEM 
 
Introduction  
Growth hormone (GH), released by the anterior pituitary, is the major regulator of 
postnatal growth (Spagnoli & Rosenfeld, 1996).  In contradiction with the original 
“somatomedin hypothesis”, its biological actions are either mediated by somatomedins, or result 
from direct action on target cells (Maharajan & Maharajan, 1993). The two somatomedins, 
insulin-like growth factor 1 and 2 (IGF-1 and –2) are single chain polypeptides of approximately 
7 kDa, with structural homology to proinsulin (Adams et al., 1983; Keller, 1996).  Most tissue 
types synthesize IGF’s at low levels; however, the liver is their major source (90 %) of secretion, 
and is responsible for systemic distribution at relatively high levels in serum (1 μg/ml, 1000 fold 
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higher than that of insulin) (Froesch et al., 1985).  Only small quantities of IGF are stored in 
liver cells; both synthesis and secretion are rapid and relatively constant (Froesch et al., 1985; 
Keller, 1996).  Therefore, IGF concentrations in blood do not fluctuate dramatically.  
 
Figure 1.2 The IGFs, their receptors and their binding proteins (Reik et al., 2001). 
 
Although the IGF’s exert insulin-like activity, there is a different consequence: cellular 
hypertrophy.  They maintain the basal metabolic rate; promote (but do not control) cell survival, 
proliferation, differentiation, migration and aggregation; and inhibit apoptosis in a variety of cell 
types (McCusker, 1998).   It is important to keep in mind that IGF’s do not direct the cell’s fate, 
but they facilitate and enhance the rate towards this fate, determined by other regulatory factors 
(Ewton, Falen, & Florini, 1987; McCusker, 1998).  For example, IGF-1 seems to function as a 
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mediator of the mitotic actions of estradiol on the endometrium during the menstrual cycle in 
women (Giudice et al., 1998; Han & Carter, 2000).  Because of the need for cell hypertrophy 
prior to mitosis, IGF’s will stimulate nutrient transport, and DNA, mRNA and protein synthesis 
(McCusker, 1998).  Through these biological effects, IGF-1 and –2 match growth and 
development to the animals nutritional status (Wathes et al., 1998), and because of the very 
complex regulation, maximal IGF activity occurs only when the conditions are optimal for 
growth (McCusker, 1998).  Insulin also enhances cell hypertrophy, but does so primarily as a 
means to increase nutrient stores, and it targets different cell populations (McCusker, 1998).  
Whether cells respond to insulin or IGF’s, is mediated by the presence of the respective receptors 
i.e. the IR or IGF1R.  IR’s are abundant on cells with energy storage as their main function (e.g. 
adipocytes), while the IGF1R will be represented on cells undergoing hyperplasia or 
differentiation (McCusker, 1998). Expression of receptors can change, e.g. terminal 
differentiation, and quiescence of cells will decrease the IGF1R’s (LeRoith et al., 1995; 
McCusker, 1998).  Insulin secretion varies rapidly, and spikes following nutritional intake.  IGF-
1 concentrations on the other hand are very steady, and its increased secretion is modulated very  
slowly to ensure availability of a continued  source of energy and protein and stimulation of the 
IGF1R (McCusker, 1998).  This is important since it can take up to several days to complete the 
cell cycle and differentiation process (Yang & Pardee, 1986; McCusker, 1998).   
In the adult, four primary factors control IGF-1 secretion and action in coordinance with 
nutrient availability and the environment: GH, insulin, glucocorticoids, and thyroid hormone 
(McCusker, 1998). Growth hormone is released by the anterior pituitary and mediates the 
secretion of somatomedins by the liver and other organs.  Only steady elevation in GH levels 
will increase IGF-1 secretion.  Low insulin results in lowered IGF-1 secretion, but elevated 
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insulin will not enhance IGF-1 secretion (Thissen et al., 1994; Thrailkill et al., 1997; McCusker, 
1998).  Normal glucocorticoid concentrations guarantee optimal IGF-1 secretion, and elevated 
glucocorticoid levels (under stress) will depress IGF-1 secretion (Park et al., 1994b; McCusker, 
1998).  In accordance with temperature, low amounts of thyroid hormone suppress IGF-1 
secretion, while high amounts of thyroid hormone enhance IGF-1 secretion (Rodriguez-Arnao et 
al., 1993; McCusker, 1998).   
The growth promoting effects of the IGF’s in vivo have been indicated in patients with 
acromegaly, who have serum levels of IGF-1 elevated three times that of normal patients (Jones 
& Clemmons, 1995). However these patients also have greater than normal concentrations of 
growth hormone.  African pygmies have low serum concentrations of IGF-1 and do not respond 
to exogenous administration of growth hormone (Merimee et al., 1981).  Another informative 
example is the dog breeds (e.g. poodles) which have multiple size categories with different levels 
of IGF-1 but normal concentrations of growth hormone (Eigenmann et al., 1984).  
Intra-uterine growth and fetal development seem to be largely growth hormone 
independent and under direct regulation of the complex insulin/insulin-like growth factor (IGF) 
system (Young et al., 2001).  A positive correlation of IGF-1 and –2 with fetal weight and fetal 
liver weight in sheep was demonstrated by (Owens et al., 1994).  More sophisticated gene 
deletion studies in mice confirmed the overall control of the IGF system over placental and fetal 
growth.  Genetically engineered mice heterozygous for a disrupted paternal IGF-2 allele or with 
a homozygous knockout of the IGF-1 gene showed a 40% growth deficiency at birth (DeChiara 
et al., 1990). Fetal overabundance of IGF-2, by null mutation of the IGF-2/M6PR, causes fetal 
overgrowth and perinatal lethality in mice (Filson et al., 1993; Lau et al., 1994).  In these 
mutants, the placenta, which normally ceases to grow at day 17, continues to grow until term 
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(Lau et al., 1994).  Placental growth was impaired in the IGF-2(p-) mutation, but neither IGF-1(-
/-) nor IGF-1R(-/-) mutations affected placental weight (Baker et al., 1993).  These observations 
suggest that IGF-2 has a relatively greater role in placental development. 
IGF action is controlled by a complex system of altered secretion, multiple receptors, and 
insulin-like growth factor binding proteins (IGFBP).  IGF’s mediate their effects by binding to 
specific type 1 and 2 IGF receptors on target cell surfaces.  Even though serum levels of IGF’s 
are high, very little free IGF is present since most IGF in circulation is bound to a family of 
IGFBP’s.  IGFBP’s transport and increase the half-life of IGF’s, modulate ligand-receptor 
interaction and exert IGF-independent actions (Lackey et al., 2000).  They are ubiquitous, and 
their expression is cell and tissue specific (Lackey et al., 2000).  They provide a labile pool of 
IGF’s that can temporarily maintain IGF delivery to target cells when IGF secretion is 
compromised (Hossner et al., 1997; McCusker, 1998).  The pool of IGFBP’s is large, and growth 
rate is proportional to flux of IGF’s through the pool, not the pool size (Hossner et al., 1997; 
McCusker, 1998).  Trace elements, specifically zinc, have been ascribed a role in targeting 
IGFBP’s to the cell surface, may change the affinity of IGF1R, and optimize IGF activity of cell 
associated IGFBP’s (McCusker, 1998).  
 
IGF-1 and IGF-2 structure  
IGF-1 and –2 are members of a gene family that includes insulin and relaxin.  They are 
60% identical with each other in amino acid sequence, and show 40% sequence homology with 
insulin.  Their structure resembles the pre-pro-insulin pattern but the C-chain is not cleaved off 
before secretion since the Arg-Arg coding is missing; this makes the IGF’s about 50 % longer 
than insulin.  A terminal extension, the D + E-domain, is also attached.  The secondary structure 
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as in the proinsulin protein is preserved by the intrachain disulfide bridges of the cystein groups.  
The A-domain of IGF-1 is involved with receptor binding, and in some instances, both the A and 
B domain bind the IGFBP’s (Foyt & Roberts, 1991; Keller, 1996).  Both IGF-1 and 2 are highly 
conserved genes; sequence homology across species from xenopus to human is 88% within the A 
and B domains (Foyt & Roberts, 1991; Keller, 1996).  Several upstream regulatory regions exist 
for both IGF genes, and an array of transcript sizes is produced due to differential splicing, and 
alternative transcription start sites and polyadenylation sites (Foyt & Roberts, 1991; Keller, 
1996).   
 
Insulin-like growth factor 1 
The IGF-1 gene spans more than 45 kilobases and consists of 6 exons and 5 introns, 
while the IGF-2 gene has 9 exons (Foyt & Roberts, 1991).  Two predominant transcripts of IGF-
1 mRNA, which encode the same IGF-I protein, are approximately 7 and 1 kilobases long and 
differ in the length of 3’untranslated sequence.  The half-lives of these two transcripts are 
remarkably different; the 1.0 kb transcript has a much shorter decay rate than the longer 
transcript (Hepler et al., 1990).  In addition to multiple transcripts, several protein variants of 
different lengths have been described.  A truncated form of IGF-1, des (1-3)-IGF-I, that lacks the 
first three N-terminal residues, has been located in fetal and adult human brain (Carlsson-Skwirut 
et al., 1986; Sara et al., 1986) and bovine colostrum (Francis et al., 1988).  This form of IGF-1 
has 1.4-10 times higher biological potency than full length IGF-1 (Francis et al., 1988), which 
may reflect the lack of affinity of this form for IGFBP’s.   Numerous transcription initiation sites, 
multiple transcripts of varying stability, and variable post-translational modifications of these 
genes are responsible for only part of the seemingly overwhelming and complex regulation of 
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IGF’s.  IGF-1 regulation is under influence of many factors.  Estradiol will upregulate IGF-1 
mRNA in the oviduct and uterus at estrus (Murphy & Ghahary, 1990; Wathes et al., 1998).  
Prolonged environmental changes like stress, nutritional availabilities and temperature will 
change IGF concentrations (McCusker, 1998).  Thissen et al., (1994) thoroughly reviewed the 
nutritional control of IGF-1 and concluded that in general, a restriction in diet will reduce serum 
IGF-1 and raise circulation levels of GH.  Maternal starvation and hypoglycemia during 
pregnancy will decrease fetal plasma IGF-1 concentrations (Gallaher et al., 1994), and Fowden 
(1995) suggested that insulin may affect IGF-1 gene transcription.  
 
Insulin-like growth factor 2   
IGF-2 concentrations rarely fluctuate in parallel with changes in IGF-1 concentrations, so 
they are clearly regulated differently (McCusker, 1998).  The concentration of IGF-2 is high in 
the fetus (Hossner et al., 1997) and has a major role in the control of fetal growth (Jones & 
Clemmons, 1995).  After birth, IGF-2 levels decline and its role at that point remains unclear.  
Interestingly, IGF-2 expression is tightly regulated by imprinting, which causes IGF-2 to be only 
expressed from the paternal allele in most tissues in the mouse, human and sheep (Ranier et al., 
1993; Feil et al., 1998; Hagemann et al., 1998; McLaren & Montgomery, 1999).  In humans and 
sheep, IGF-2 exhibits a developmental switch from imprinted expression in most fetal tissues to 
a general silencing in the adult, except for biallelic expression in the liver (McLaren & 
Montgomery, 1999).  IGF-2 is not expressed at all after birth in the mouse.  At present genomic 
imprinting of IGF-2 and IGF2R have not yet been demonstrated in cattle.  However, paternal 
imprinting of IGF-2 has been shown in sheep (Feil et al., 1998). 
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 The delicate control of allele silencing is prone to error and can easily be disrupted with 
consequent doubling of active copies of the IGF-2 gene (biallelic expression).  In humans, 
relaxation of IGF-2 imprinting, causes pathological phenomena like the Beckwith-Wiedemann 
overgrowth syndrome, Wilm’s tumor and other cancers (O’Dell & Day, 1998).  In the liver of 
the human and sheep, but not the mouse, a physiological switch from imprinted to biallelic IGF-
2 expression occurs with development from fetus to adult (McLaren & Montgomery, 1999).  
Transcription of the IGF-2 gene is under control of four promotors and its imprinting status, 
which is highly dependent on the methylation of the cluster of genes surrounding the IGF-2 gene 
(Reik et al., 2000).  Because of imprinting, expression from promotor P1 is biallelic, and from 
P2-P4 is monoallelic (Yun et al., 1998).  Methylation patterns of these promotors and multiple 
regions of the IGF-2 and H19 gene are developmentally regulated, and, therefore, the promotors 
can also be classified as fetal, fetal-neonatal and adult promotors (de Pagter-Holthuizen et al., 
1987).  This may well explain the dynamic regulation of the IGF-2 gene in the liver (Li et al., 
1998b).  Just recently, Constância et al., (2002) described a trophoblast-specific transcript P0 of 
IGF-2 in the mouse.  This P0 promotor leads to paternal transcription of the exons 4-6.   
IGF-2 expression is possibly regulated by placental lactogen (PL) in the ovine fetal 
placenta since IGF-2 concentrations correspond to those of PL during gestation (Gluckman et al., 
1987).  On the other hand, it is the cortisol rise at term that induces the fetus to switch from IGF-
2 to IGF-1 production, which is in its turn partly responsible for the switch from proliferation to 






The insulin-like growth factor receptors 
Thus far, besides the low affinity insulin receptor, two major types of receptors specific 
for IGF binding have been described.  IGF-2 is known to interact with both the IGF1R and 
IGF2R.  However, it is believed to recognize an additional unknown receptor (XR) because 
growth retardation of embryos lacking both the IGF1R and IGF-2 (30% of normal birth weight) 
is more severe than in either individual mutation (45% vs. 60%, respectively) (Louvi et al., 
1997).  XR is probably not the M6P/IGF2R, since IGF2R mutants are not smaller in size at birth 
(135%), but suffer high neonatal mortality (Lau et al., 1994; Ludwig et al., 1996), due to their 
inability to clear IGF-2.  In a study by Louvi and others (1997), nullizygous offspring for both 
IGF1R and the insulin receptor (IR) also results in 30% growth deficiency, indistinguishable 
from the IGF1R/IGF-2 double mutant phenotype.  This finding indicates that the growth 
promoting function of IGF-2 during fetal life must be partially mediated through IR signaling in 
the mouse (Louvi et al., 1997).   
 
Insulin-like growth factor 1 receptor 
The IGF-1R and the insulin receptor are similar in structure and their intracellular signal 
transduction is similar. Type 1 IGF receptors are usually expressed on cells in proliferation or 
differentiation, while insulin receptors will reside on non-mitogenic cells responsible for nutrient 
storage (McCusker, 1998).   Hybrid IGF1R and Insulin receptors do occur in the placenta and 
bind IGF-1 with preference over insulin (Jones & Clemmons, 1995).   
The type 1 IGF receptor (IGF1R) belongs to the family of transmembrane tyrosine 
kinases.  The IGF1R exists as a disulfide linked (-) hetero-heteromer on the cell surface.  
The -subunits have binding capacity and the intracellular -subunits have tyrosine kinase 
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activity (LeRoith et al., 1995). Monomeric pro-receptor molecules are biosynthesized 
intracellularly, and are protected by lectin chaperones until correct folding.  When the lectin 
chaperones release the monomers, receptor dimerization occurs, followed by export from the 
endoplasmic reticulum. The IGF1R mediates most of the biological effects of IGF-1 and IGF-2 
(O’Dell & Day, 1998) and preferentially binds IGF-1, has an intermediate affinity for IGF-2 and 
has low affinity for insulin.  IGF1R expression seems to be controlled by IGF-1 and –2 
concentrations, but other unidentified tissue specific mechanisms might be involved (Wathes et 
al., 1998).  Interestingly, IGF1R 
+/-
 tg mice are long lived and display greater resistance to 
oxidative stress.  Their energy metabolism is normal and their nutrient uptake, physical activity, 
fertility and reproduction are unaffected.  This finding suggests a role for the IGF1R as a central 
regulator of mammalian lifespan (Holzenberger et al., 2003). 
In an excellent review, Adams (2000) states, “given the diverse physiological functions 
regulated by IGF-1, a diverse (and expanding) repertoire of intracellular proteins has been 
identified as substrates/effectors of ligand activated IGF-1R signaling”.  Ligand binding induces 
auto-phosphorylation of the kinase regulatory domain.  Subsequently other tyrosines in the 
cytoplasmic domain are phosphorylated and become functional docking sites for the recruitment 
of other proteins, initiating the signaling cascade.  Two major pathways have been characterized, 
involving two distinct adaptor proteins Shc and IRS (insulin receptor substrate).  In the first 
pathway, IGF-1 activates the serine-threonine mitogen-activated protein (MAP) kinases, and the 
extracellular signal-related kinases ERK1 and ERK2.  These in turn phosphorylate a variety of 
cytoplasmic and nuclear proteins such as growth factor receptors, transcription factors, kinases 
and other enzymes which mediate a metabolic, mitogenic or differentiative cellular response 
(Adams, 2000).  IGF-1 can also effectively utilize the PI 3-kinase signaling pathway with a 
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major role in protection of cells and tissues from programmed cell death.  Substrates of the IGF-
1 / PI 3-kinase cascade are the Akt/PKB serine/threonine kinases.  Upon activation, Akt/PKB, a 
common denominator of antiapoptotic signaling, mediates metabolic responses, proliferation and 
inhibition of apoptosis (Adams, 2000). 
 
The insulin like growth factor 2 receptor 
The type 2 IGF receptor is a monomeric 300 kDa transmembrane protein with no tyrosine 
kinase activity (Kornfeld, 1992).  It is the same molecule as the cation-independent mannose-6-
phosphate receptor (Kiess et al., 1988) that binds most lysosomal enzymes and other mannose 6 
phosphate containing ligands for delivery to the lysosome (Osipo et al., 2001); but in mammals, 
it also interacts with IGF-2 (Ludwig et al., 1996).  No clear cut downstream pathway has been 
identified for this receptor, and it is more likely believed to function as a clearance molecule to 
remove IGF-2 from circulation by internalization and targeting of bound ligand for lysosomal 
degradation (Kornfeld, 1992; Baker et al., 1993).  IGF2R is also thought to exert growth 
inhibitory effects by participating in the activation of latent transforming growth factor β (TGF-
β) (Dennis & Rifkin, 1991).  Active TGF-β regulates the synthesis and degradation of 
extracellular matrix and is a potent growth inhibitor of most normal and transformed cells 
(Massagué, 1990).  Loss of IGF2R in tumor cells supports increased growth and vascularization 
of tumors by allowing higher local levels of IGF-2 and/or by decreasing the focal activation of 
latent TGF-β (Osipo et al., 2001).  Interestingly, Volpert et al. (1996) have shown in vitro that 
proliferin, a peptide that stimulates endothelial cell migration and neovascularization in vivo, 
binds to the IGF2R.  Apparently, IGF2R plays an essential role in proliferin-induced 
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angiogenesis; and IGF-2 binding with IGF2R was also shown to have the same angiogenic 
effects.   
In some cell types, IGF2R in the trans Golgi reticulum is essential for transport of newly 
made lysosomal enzymes to the lysosome (Sahagian et al., 1987).  IGF2R in the plasma 
membrane modulates levels or activities of a variety of ligands that regulate cell growth 
including TGF-β, IGF-2, retinoic acid, and LIF (Osipo et al., 2001). 
The affinity of the type 2 receptor is very selective for IGF-2, 500-fold higher than for 
IGF-1, and does not bind insulin (Kornfeld, 1992; Wathes et al., 1998).  The IGF2R locus is 
imprinted in a polymorphic fashion in humans and, only a minority of people show monoallelic, 
maternal expression.  Often times, this locus is also found to be inactivated in a variety of human 
tumors (Murphy & Jirtle, 2000).  In mice (Barlow et al., 1991) and sheep (Young et al., 2001), 
the IGF2R is imprinted and normally only the maternal allele is expressed.  When this allele is 
disrupted, mutant mice have an increase in serum and tissue IGF-2 levels.  At birth they exhibit 
overgrowth (135%), organomegaly, a kinky tail, postaxial polydactyly, heart pathology, and 
edema.  Perinatal death is frequent, which indicates the importance to survival of the 
M6P/IGF2R lysosomal enzyme trafficking (Lau et al., 1994; Ludwig et al., 1996).  
A circulating form of the extracellular domain of the IGF-2R protein exists freely in the 
plasma and is produced by proteolytic deletion of the transmembrane and intracellular domains 
of the cellular form (Zaina & Squire, 1998).  The soluble form of the IGF2R is believed to down 
regulate growth.  In ovine fetal plasma, high concentrations of this soluble IGF2R are present 
that can contribute up to 40% of total IGF binding in the blood (Gelato et al., 1989; Gallaher 
BW, Breier BH, Blum WF, McCutcheon SN, 1995). Transgenic mice with the transmembrane 
domain sequence of IGF2R deleted, show a reduction in organ size.  When this mutation is 
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crossed with mice overexpressing IGF-2, the decrease in organ growth appears to be exclusively 
mediated by reducing IGF-2 action in some organs, but must involve other interactions in other 
tissues (Zaina & Squire, 1998).  Loss of IGF2R promotes growth in cancer by sustaining IGF-2 




Frasca et al. (1999) identified a new insulin receptor isoform A with high affinity for 
IGF-2.  The insulin receptor (IR) occurs in two isoforms (IR-A and IR-B) resulting from 
alternative splicing of exon 11 of the gene (Sciacca et al., 1999).  The IR-A isoform is 
predominantly expressed in fetal tissue and malignant cells and binds IGF-2 with high affinity 
(Frasca et al., 1999).  Both Ins and IGF-2 activate IR-A, they activate different intracellular 
signaling pathways and elicit different biological effects.  Activation of IR-A by insulin leads 
primarily to metabolic effects, whereas activation by IGF-2 leads primarily to mitogenic effects 
(Frasca et al., 1999).  The Ins – PI3-K/Akt pathway, protects cells from apoptosis and the  IGF-
2- Shc/ERK pathway, stimulates cell migration (Sciacca et al., 2002). Scalia et al. (2001) suggest 
that the coordinated activation or deactivation of Akt, glycogen synthase kinase 3-β (Gsk3β) and 
Erk may account for the IGF-2 mitogenic effects and support an active role for IR(A) in IGF-2 
action.  The IR and the IGF1R have a highly homologous structure, but different biological 
effects.  Insulin and IGF-1 half receptors can heterodimerize, leading to the formation of 
insulin/IGF-1 hybrid receptors that bind IGF-1 with high affinity (Jones & Clemmons, 1995).  
Hybrid receptors containing IR-A bind to and are activated by IGF-1,-2 and Insulin.  Hybrid-Rs 
containing IR-B bind to and are activated with high affinity by IGF1, with low affinity by IGF-2 
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and insignificantly by Insulin.  Cell proliferation and migration is more effectively stimulated in 
hybrid-R(A) containing cells (Pandini et al., 2002). 
 
Insulin-like growth factor binding proteins 
Unlike insulin, the IGF’s are bound in serum and other biological fluids to a family of six 
structurally and evolutionary related binding proteins, termed IGF-binding proteins (IGFBP-1 to 
IGFBP-6) (Schneider et al., 2000).  Their characteristics in common are: 1) a conservation of 
gene organization, 2) three structural domains in the mature proteins, with conserved, cysteine 
rich amino- and carboxy-terminal domains, and 3) high binding affinity for both IGF-1 and –2 
(Baxter, 2000).  Other proteins e.g. mac25 (sometimes named IGFBP-7 (Oh et al., 1996) that 
share a structural homology with one domain of the IGFBP’s, have been assigned as IGFBP-
related proteins and are members of the IGFBP-superfamily because of structural homologies in 
the amino-terminal end, and low-affinity IGF-binding activity (Hwa et al., 1999).   Thus far, 10 
IGFBP related proteins have been identified, some of which may exert IGF-independent actions 
(Hwa et al., 1999).  They maintain a labile pool of IGF in circulation and can temporarily 
maintain IGF delivery to target cells when IGF secretion is compromised (Hossner et al., 1997).  
All IGFBP’s bind the two IGF’s with relatively similar affinities, except IGFBP-6 that has a 
markedly higher affinity for IGF-2 (Baxter, 2000). IGFBP’s fail to bind insulin (Jones & 
Clemmons, 1995).  IGFBP’s compete with IGF receptors for IGF binding and have a 
considerably greater affinity than the receptor when they are in solution. Besides the prevention 
of insulin-like side effects due to the large concentrations of IGF’s in circulation, they can 
modulate IGF action.  In general, interaction of an IGFBP with IGF-1 or –2 will block receptor 
activation (Baxter, 2000).  All six IGFBP’s have been shown to inhibit IGF action, but 
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stimulatory effects have also been established for IGFBP-1, -3, and -5 (De Mellow & Baxter, 
1988; Clemmons, 1991; Baxter, 2000).  The concentration of circulating IGFBP’s has been 
shown to be nutritionally regulated.   
An average of 75-80% of the IGF’s in circulation are present in a 150 kDa complex, 
composed of an IGF-1 or IGF-2 molecule, an 85 kDa acid-labile subunit (ALS), and IGFBP-3.  
This ternary complex has a half life of 6 to 24 times  (12h) longer than the binary complexes of 
IGF with IGFBP-1 or –2 (Jones & Clemmons, 1995).  The remaining 20-25% IGF fraction is 
associated with other IGFBP’s, forming a 50 kDa complex.  Only less than 1% of the IGF’s 
circulate “free” (7.5 kDa) (Rajaram et al., 1997; Schneider et al., 2000).  As a consequence of 
metabolic stress, the ratio of the IGFBP-3-ALS unit vs. IGFBP-1 plus –2 slowly decreases in 
serum (McCusker, 1998).   
The IGFBP affinity for the IGF’s can be modulated by post-translational glycosylation, 
phosphorylation, proteolysis or by cell or matrix association.  IGFBP-1, -3, -5 are also found as 
phosphoproteins, however this phosphorylation only seems to affect IGFBP-1, increasing its 
affinity for IGF-1 six-fold (Jones et al., 1991).  The state of phosphorylation of IGFBP-1 may be 
important in the metabolic regulation of the bioavailability of free IGF’s and seems to be 
hormonally regulated (Westwood et al., 1995).   
Several proteases can cleave IGFBP’s, reducing their ability to bind IGF-1 and -2. 
Proteolysis occurs mainly at the central domain, leaving the amino- and carboxy-terminals intact 
(Baxter, 2000).  The release of endoproteases for IGFBP degradation is a mechanism by which 
cells can regulate local IGF activity, freeing IGF’s for rapid clearance from the circulation to 
target cells (McCusker, 1998).  This has been observed in cellular differentiation in which the 
release of IGFBP’s and their proteases seems to be temporally regulated.  For example, during 
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follicular atresia in the human, IGFBP-4 will block IGF action, but this will be restored under 
influence of an IGFBP-4 protease during follicular development (Iwashita et al., 1996; Baxter, 
2000).  
When IGFBP’s attach to a cell membrane or extracellular matrix, their binding affinity 
for IGF’s is reduced.  This mechanism could actually allow bound IGF’s to be released so they 
can act upon the cells (Baxter, 2000).  Therefore, the presence of bound IGFBP’s can actually 
enhance IGF action by creating a local depot, and therefore increased local availability of IGF’s 
for receptor binding (Han & Carter, 2000).  This has been observed in cell culture systems in 
which IGFBP-3 seems to potentiate IGF activity by this mechanism.  All IGF binding proteins 
except IGFBP-3 can leave the circulation when chelated with IGF’s, this may allow for tissue 
specific targeting (Bar et al., 1990; Wathes et al., 1998). 
Interestingly, IGFBP-1, -3, and -5 possess actions independent of the IGF1R.  IGFBP-1 
stimulates cell migration independently from IGF, through interaction with 51-integrin, a 
fibronectin receptor (Jones et al., 1993), and IGFBP-3 and -5 may have specific cell-surface 
receptors with serine kinase activity. 
Even though all IGFBP’s interact with IGF’s, their expression seems to be strictly 
regulated in time and tissue-specific ways.  To evaluate specific actions of the individual 
IGFBP’s in vivo, researchers have investigated transgenic mouse models.  An excellent review 
by Schneider et al. (2000) summarizes these findings.  When the knockout approach was applied 
to the IGF’s and their receptors, very specific phenotypes were induced.  In contrast, IGFBP 
knockouts did not manifest extreme phenotypes, probably due to functional compensation by 
other members of the IGFBP- superfamily (Schneider et al., 2000).  Alternatively, transgenic 
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overexpression of IGFBP’s has successfully induced informative phenotypes (Schneider et al., 
2000).   
 
IGFBP-1 was originally isolated from human amniotic fluid and has a molecular weight 
of 30 kDa.  It contains an amino-acid Arg-Gly-Asp integrin recognition sequence for cell surface 
binding (Wathes et al., 1998).  Transcripts for IGFBP-1 are present in the fetal and adult liver.  
In vitro studies indicate that this BP mainly inhibits IGF-dependent cellular growth and 
differentiation.  Its biological actions are associated with carbohydrate metabolism, female 
reproductive functions, and fetal growth.  IGFBP-1 overexpression reduced brain weight and 
caused brain growth retardation, and in 50 % of cases, hydrocephalus.  In vitro, IGF’s stimulate 
proliferation and survival of neural cells, and in vivo they are essential for normal development 
of the nervous system (Stewart & Rotwein, 1996; Schneider et al., 2000).  Insulin knockout 
murine fetuses as well as hypoxia will upregulate IGFBP-1 expression (Tazuke et al., 1998).  
This may support the idea that IGFBP-1 is an important regulator of fetal growth, probably by 
limiting the availability of IGF’s to their target tissues under hypoxia or nutrient deprivation 
(Schneider et al., 2000).   IGFBP-1 overexpression induces hyperglycemia; this may be due to 
alterations observed in the pancreas, or simply IGFBP-1 inhibiting the hypoglycemic effect of 
free IGF’s.  In IGFBP-1 overexpression models, litter size reduction was observed and linked to 
reduced ovulation and blastocyst implantation (Huang et al., 1997; Schneider et al., 2000).  
Proteinuria and glomerular lesions were seen; this finding might relate to aberrant expression of 
the IGF system observed in diabetic renal disease (Schneider et al., 2000). 
IGFBP-2 is the second most abundant IGFBP in circulation and preferentially binds IGF-
2.  The liver and kidney are the major source in adults, but it is expressed in most tissues except 
muscle.  Its protein size is 32 kDa.  Just like IGFBP-1, IGFBP-2 has an integrin recognition 
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sequence to bind cell surfaces (Wathes et al., 1998).  Often IGFBP-2 mRNA is found in rapidly 
proliferating tissues in association with IGF-2 mRNA (Delhanty & Han, 1993; Wathes et al., 
1998).  Since transgenic mice overexpressing IGF-2 have increased IGFBP-2 serum levels, 
IGFBP-2 expression seems to be ligand regulated.  The inverse phenotype of IGFBP-2 
overexpression vis-à-vis IGF-1 overexpression suggests the role of IGFBP-2 is an inhibitor of 
IGF actions.  Some findings indicate the potential involvement of IGFBP-2 with glucose 
homeostasis and enhanced glucose transport in microvascular endothelial cells (Jones & 
Clemmons, 1995). 
IGFBP-3 is expressed in the fetal liver and widely expressed in the adult, most 
abundantly in the kidney (Jones & Clemmons, 1995; Baxter, 2000; Schneider et al., 2000).  Its 
molecular weight tends to vary considerably from 16-30 kDa, due to different N-glycosylation.  
IGFBP-3 cell association involves cell surface glycosaminoglycan interaction (Wathes et al., 
1998).  Serum concentrations are several fold higher than other IGFBP’s with a very high 
affinity for the IGF’s.  Therefore, it is a major carrier of IGF’s in circulation. IGFBP-3 has both 
enhancing and inhibitory effects on IGF action and has growth regulatory effects, independently 
of IGF’s (Schneider et al., 2000).  The transgenic overexpression models developed a significant 
organomegaly (Murphy et al., 1995).  Involution of the mammary gland after lactation was 
retarded, and may be due to a decrease in apoptosis, either a direct consequence of IGFBP-3 or 
mediated by IGF-1, known for its antiapoptotic properties (Neuenschwander et al., 1996). 
IGFBP-4 exists as a 24 kDa non-glycosylated or 28 kDa N-glycosylated protein 
(Schneider et al., 2000).  It is again widely expressed in both fetal and adult tissues.  During 
embryonic development it is expressed in the polarizing zone of the limb bud, and the fact that it 
is present in the interdigital zone might indicate a counteractive role towards the antiapoptotic 
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effect of IGF-1.  IGFBP-4 also plays a major role in bone formation and resorption.  
Interestingly, the pregnancy associated plasma protein-A (PAPP-A) secreted at high levels by the 
human placenta, is identical to an IGFBP-4 protease (Lawrence et al., 1999; Han & Carter, 
2000).  In vitro experiments indicate IGFBP-4 to be consistently inhibitory to IGF actions.  
However, the IGFBP-4 knockout models are smaller than wild types.  This finding might suggest 
that IGFBP-4 is necessary for optimal IGF-2 action in vivo, instead of being an inhibitor. 
IGFBP-5 is very abundant in bone extracts, has a strong affinity for hydroxyapatite and 
functions as a storage for IGF’s, especially IGF-2 in this tissue.  IGFBP-5 binds to the 
extracellular matrix (Wathes et al., 1998).  It is universally expressed and involved in ovarian 
and kidney physiological processes.  In circulation it is also found as a ternary complex with 
IGF-1 or –2 and ALS, and therefore might also have a systemic impact on the regulation of IGF 
action. 
IGFBP-6 has been studied the least.  It remarkably prefers to bind IGF-2 over IGF-1 and 
is widely expressed in adult tissues as a 32 kDa protein.  In vitro as well as in vivo IGFBP-6 
expression inhibits tumor cell growth, most likely preventing IGF-2 action, an autocrine tumor 
growth factor (Schneider et al., 2000). 
 
 
THE IGF SYSTEM IN THE PREGNANT UTERUS 
 
IGF-1 and -2 both participate in the endocrinological regulation of fetal growth 
(Gluckman, 1995).  However, IGF-1 acts exclusively in the fetus (and postnatally), while the 
IGF-2 system acts both in the fetus and in the placenta (Reik et al., 2001).  In Reik’s opinion, 
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IGF-2 seems to act predominantly in an endocrine fashion, coordinating organ growth with the 
growth of the organism.  However in overgrowth and growth deficiency syndromes, imprinted 
growth factors can act by more local mechanisms, resulting in disproportionate growth (Reik et 
al., 2001).  In contradiction with Reik (cfr. supra), Han et al. (1987) believe that IGF’s and 
IGFBP’s mainly act in an autocrine/paracrine fashion.  Therefore, the identification of their 
location of synthesis can indicate the potential site of their biological function.  In the discussion 
below, I will repeatably refer to a study by Reynolds et al. (1997) with findings on in situ 
expression of IGF mRNA components in the uterus of the ewe.  It is important to keep in mind 
that these observations were only verified during the first third of gestation, and may differ for 
other ruminants.   
IGF-1, -2, IGF1R and IGF2R mRNA’s have been identified to be present from zygote to 
blastocyst stage in bovine embryos (Watson et al., 1992).  IGF-1 and -2 are important regulators 
of preimplantation and placental development (Wathes et al., 1998).  Both stimulate the 
development of blastocysts (Kaye et al., 1992), while only IGF-2 increases both cleavage rate 
and yield of in vitro cultured bovine blastocysts (Carolan et al., 1995).  Schultz et al. (1996) 
found an upregulation of IGF-2 and IGF-1R mRNA and downregulation of IGF-1 mRNA in 
bovine nuclear transfer blastocysts.  Byrne et al. (2002) described how IGF-1 and -2 but not 
insulin increased the proportion of embryos which form blastocysts.  Insulin decreased the 
incidence of apoptosis without affecting blastocyst cell number, IGF-1 decreased apoptosis and 
increased total cell number and IGF-2 increased cell number alone.  They suggested that IGF-2 
might not act directly as a survival factor but rather to advance embryonic development and cell 
proliferation to a point where apoptosis is downregulated.  And Petrik et al. (1999) found that 
mice overexpressing IGF-2 showed decreased apoptosis in islet cells of the pancreas. 
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Oviductal cells also transcribe IGF-1 and IGF-2 (Watson et al., 1994; Stevenson & 
Wathes, 1996), but local oviductal production of IGF-1 seems more influential to early 
embryonic development than IGF-2 in sheep (Wathes et al., 1998).  Oviductal IGF-1 may 
stimulate embryo growth directly or indirectly by stimulation of the secretory activity of the 
ampulla (Wathes et al., 1998).  Similar findings in the mouse and human confirm this theory.  In 
human oocytes and preimplantation embryos, transcripts for IGF-2, IGF1R, IGF2R and IR are 
present, but not for IGF-1.  IGF-2 has been shown to have an autocrine effect on preimplantation 
development (Lighten et al., 1997).  IGF-1 and insulin, on the other hand, are secreted by the 
maternal reproductive tract in the mouse and act in a paracrine fashion (Lighten et al., 1997).   
At days 15 and 18 of the estrous cycle in cattle, IGF-2 expression by the endometrium is higher 
in pregnant vs. control cows.  Therefore, Geisert et al., (1991), suggest that the presence of a 
conceptus must have a stimulatory effect on this expression.  In the ewe, uterine IGF-1 mRNA 
levels were low following implantation, highest in the maternal stroma surrounding the uterine 
glands although this declines during early pregnancy, and undetectable in the caruncles after fetal 
villi invasion (Reynolds et al., 1997).  Fetal placental tissue did not appear to contain IGF-1 
mRNA (Reynolds et al., 1997).  In analogy with murine IGF-1 deletion studies (Baker et al., 
1993), these findings suggest that local IGF-1 production might not be important in placental 
development (Reynolds et al., 1997).  Also, in IGF-1 knockout mice, placental growth is normal 
(Baker et al., 1993). 
 
Insulin-like growth factor 1 
Bovine fetal serum IGF-I concentration increases during gestation (Holland et al., 1989), 
and in the ewe, there is a positive correlation between fetal and maternal IGF-1 concentrations in 
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late gestation and placental weight.  In humans and sheep, cord blood IGF-I concentration 
positively correlates with fetal size and birth weight and placental weight (Carr et al., 1995; 
Ostlund et al., 1997).  In sheep, both plasma IGF-1 and -2 levels correlate with fetal weight and 
fetal liver weight (Owens et al., 1994).  These findings suggest that maternal nutrition may 
influence placental growth via an alteration in circulating concentrations of IGF-1 (Carr et al., 
1995). However, Putney et al. (1990) thought the fetus regulates placental IGF-1 secretion via 
secretion of estrogen precursors in the baboon. Both IGF-1 and IGFBP-1 stimulate trophoblast 
proliferation in early human pregnancy (Hills et al., 1999).  Infusion of 50 g/h/kg of IGF-1 
increases sheep fetoplacental amino acid uptake, whereas placental lactate production decreased 
significantly; therefore, IGF-1 has anabolic effects on fetoplacental protein and carbohydrate 
metabolism (Harding et al., 1994).  Concentrations of IGF-1 and IGF-2 are significantly lower in 
arterial blood of late-term cloned pregnancies than controls (Garry et al., 1998).  Immediately 
after birth, (Matsuzaki & Shiga, 2002) found the plasma concentrations of cortisol and IGF-1 to 
be lower in somatic cell cloned cattle.  They suggest that due to an insufficient prepartum rise in 
plasma cortisol, the cloned calves failed to initiate the switch to an adult mode of the IGF system 
during late gestation.  Therefore, inappropriate developmental changes in endocrine system may 
be partly responsible for the fetal overgrowth and perinatal complications associated with 
cloning. 
 
Insulin-like growth factor 2 
IGF-2 is secreted in large quantities in the fetus (Holm et al., 1996) and serves as a 
constant signal for growth in fetal circulation (Kruip & den Daas, 1997); there is also 
considerable expression of IGF-2 in the placenta throughout gestation (Wakayama et al., 1998).  
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 IGF-2 has a major effect on tissue composition and cell biomass; it also has effects on 
fluid dynamics and might control fluid uptake by direct action on maternal capillaries (Gallaher 
et al., 1994).  IGF-2 mRNA was found abundantly throughout gestation in ovine fetal 
mesodermal allantochorion (Reynolds et al., 1997).  In early gestation, IGF-2 is most abundantly 
expressed at the invading front of intermediate trophoblast in the anchoring villi, stimulating 
migration (Han et al., 1996; Hamilton et al., 1998).  In late pregnancy in humans, IGF-2 binds 
mainly at the syncytiotrophoblast, but IGF-2 mRNA is only expressed in trophoblasts and 
chorionic mesoderm, suggesting the syncytiotrophoblast as the target of IGF-2 action (Han et al., 
1996).  Lower levels were present in the caruncles, placentome capsules and endometrial stroma 
(Reynolds et al., 1997).  The day 114 (gestational age) ovine placentome shows IGF m-RNA is 
present in the endothelium of fetal vessels, the mesoderm of the fetal villi and is abundant below 
the trophoblast, which does not express IGF-2 mRNA (Han & Carter, 2000).  Surgical reduction 
of placental size in sheep causes intrauterine growth retardation and is accompanied by an 
increase of serum IGF-2 (Jones et al., 1988). IGF-2 stimulates extravillous trophoblast migration 
and invasion through the IGF2R and MAPK pathway (McKinnon et al., 1999), indicating a 
crucial role of IGF-2 in trophoblast migration and invasion.  In preeclampsia, increased IGF-2 
mRNA is found in intermediate trophoblasts of peri-infarct regions, suggesting a role for IGF-2 
in placental repair or remodeling (Gratton et al., 2002).  In diabetic pregnancies fetuses receive a 
large influx of glucose; this may stimulate the expression of IGF-2 in the placenta, resulting in 
higher utilization of glucose and overgrowth of the placenta (Shen et al., 1986). 
Genetically engineered mice heterozygous for a disrupted IGF-2 allele showed a 40% 
growth deficiency at birth (DeChiara et al., 1990).  From the same laboratory: placental growth 
was impaired in the IGF-2(p-) mutation, but neither IGF-1(-/-) nor IGF-1R(-/-) mutations 
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affected placental weight (Baker et al., 1993). Fetal overabundance of IGF-2, by disruption of the 
IGF-2/M6PR, causes fetal overgrowth and perinatal lethality in mice (Filson et al., 1993; Lau et 
al., 1994).  IGF-2 has been shown to possess local growth promoting effects in fetal tissues, as 
demonstrated in H19 null mice (Eggenschwiler et al., 1997) in which pups were 30% overgrown 
at birth, and IGF-2 was only elevated in tissues, not in circulation.   
When Constancia et al. (2002) abolished the P0 promotor transcript, a marked reduction 
in IGF-2 signal was observed specifically in the labyrinth trophoblast of the mutant placentae.  
The absence of the P0 transcript of the IGF-2 gene resulted in 30% reduction of placental and 
fetal weights near term.  Therefore, eliminating this IGF-2 transcript exclusively from the 
placenta has a profound growth retarding effect.  Levels of IGF-2 peptide in the fetal circulation 
were not affected, and IGF-2 transcripts from other promoters were expressed at wild-type 
levels. The restriction in growth was as great as with complete lack of placental IGF-2 even 
though P0 constitutes only 10% of total IGF-2 transcripts in the placenta (but maybe differential 
translatability of IGF-2 transcripts), suggesting that the P0 transcript is the principal determinant 
of action of this growth factor in the placenta.  Mutant placentae had the same morphological 
organization as wild type, and volume fraction determinations were proportionally smaller for all 
areas.  Reduction of organ size - with exception of the brain – was largely proportionate.  
Therefore, the IGF seems to coordinate growth effects (demand and supply) on organ systems, 
suggesting that brain growth is apparently independent of nutritional demand and supply (Reik et 
al., 2001), or that a preferential distribution of nutrients towards the brain exists. 
Because of the observed growth restriction later in gestation in this knockout, a likely 
hypothesis is that lack of IGF-2 mRNA affects placental function in the supply of nutrients.  
Either placental size became limiting for fetal growth only at later stages of gestation, or at 
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earlier stages of gestation, the smaller placenta compensated by an increased efficiency of 
nutrient transfer.  In order to evaluate placental transport, Constancia et al. (2002), tested the P0 
knockout model by placental function assays.  The system A transporter has been shown to be a 
determinant of fetal growth (Cramer et al., 2002).  Unidirectional maternal-fetal transfer was 
measured with 
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C-MeAIB), which is specifically transported by the system A amino acid 
transporter in the placenta (Johnson & Smith, 1988), secondary active transport capacity was 
evaluated.  Passive permeability to the hydrophilic solute decreased with increasing length of 
gestation.  At earlier stages of gestation, the efficiency of the active transfer was increased and 
seemed to compensate for reduced placental size and passive permeability. The decrease in 
passive permeability may involve changes in placental exchange barrier paracellular pore 
dimensions. At the later stage the increase in efficiency became insufficient to meet 
requirements, resulting in fetal growth restriction.  However, depressed placental system A 
transporter activity is observed in human FGR in vitro in placental vesicle studies.  This may be 
an attempt to upregulate total placental system A activity (Regnault et al., 2002b).  It was 
concluded by Constancia et al. (2002) that reduced fetal size can be the outcome of reduced 
supply or reduced demand, and that the mouse IGF-2 gene is remarkable in combining the 
control of both supply and genetic demand for maternal nutrients in a single gene!   
In humans and mice, fetal overgrowth results from altered expression of several 
imprinted genes (H19, IGF-2, IGF2R).  For example, in the Beckwidth Wiedemann Syndrome 
(in humans), the mechanism of overgrowth is induced by the loss of imprinting and 
overexpression of IGF-2. In sheep on the other hand, from in vivo fertilized eggs that were 
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cultured in vitro for 5 days with co-cultured granulosa cells and/or serum before transfer into 
ewes, 25% of the fetuses that were recovered at d125 of gestation (term =d147) were defined as 
large offspring (LO).  RT-PCR showed no difference in steady state transcription levels of IGF-2 
mRNA in liver, kidney, muscle and heart.  By contrast, IGF2R expression was reduced by 30-
60% in these LO fetuses. (Young et al., 2001).  Then again, in cattle at Day 70 of gestation, 
Blondin et al., found that fetuses originating from in vitro production systems possessed higher 
levels of IGF-2 mRNA in the liver and a trend to lower levels in skeletal muscle (Blondin et al., 
2000).  Schrader et al. (2003) compared differential gene expression of two day 45 cloned 
bovine fetal livers to the original nuclear transfer cell donor day 45 fetus fetal liver by DDRT-
PCR.  cDNA’s of 39 genes/Expressed Sequence Tags were found to be differentially abundant.  
When corresponding mRNA’s were verified by semi-quantitative RT-PCR, no significant 
differences were detected.  Moreover, IGF-2 specific primers used in the RT-PCR reaction did 
not reveal differential expression in the liver.   
 
Insulin-like growth factor 1 receptor 
The IGF1R and IGF2R are both present in bovine embryos (Watson et al., 1992).  Bovine 
placental membranes are rich in both type 1 and type 2 IGF receptors, while there is a 
preponderance of type 1 in humans and type 2 in sheep (Van Buul-Offers et al., 1988). Term 
placentas from pregnancies complicated with intrauterine growth restriction have significantly 
higher levels of IGF-2 and IGF1R expression; this may represent a counter regulatory 
mechanism in response to the growth restriction (Abu-Amero et al., 1998). In the ewe expression 
of the IGF1R was high in deep intrauterine glands. This high concentration of IGF-1R on uterine 
endothelial glands suggests a role for IGF-1 and –2 in regulating their secretory activity (Wathes 
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et al., 1998).  Secretion of uterine histotroph by endometrial glands in the intercotyledonary 
regions is thought to continue to provide an important source of nutrients to the developing fetus 
throughout gestation in the ewe (Moffat et al., 1987; Roberts & Bazer, 1988). Before 
implantation, moderate IGF1R levels were present in the caruncular stroma.  However, after day 
30 of gestation when fetal-maternal interdigitation is established, no more IGF1R could be 
detected in either the fetal or maternal parts of the sheep placentome (Reynolds et al., 1997).  
Local IGF-2 expression present at villi interdigitation raises questions about which receptor the 
local IGF-2 binds.  Based upon these data, any putative actions of the high IGF-2 concentrations 
within the placentomes cannot be mediated via the IGF-1R (Wathes et al., 1998); this and other 
strong evidence from murine knockout studies again raises the question of the existence of an 
unknown XR.  IGF-1 or IGF1R murine knockouts do not affect placental weight, while IGF-2 
knockout of the paternal allele in mice severely diminishes placental development (Baker et al., 
1993).  The placentas of murine IGF-2/IGF1R double mutants were equally affected by growth 
retardation as seen in the IGF-2 single mutants.  In vitro studies with human placental tissues 
have indicated the presence of an unknown high affinity IGF receptor with equal affinity for 
IGF-1 and –2, and only slightly less affinity for insulin (Hintz et al., 1984).  LeRoith and others 
(1995) detected IGF1R discrepancies in molecular mass and antibody neutralizing binding 
activity, and therefore suggested the existence of another receptor; however, this also might have 
represented IR-IGF1R heterodimers (Jones & Clemmons, 1995).  Lacroix et al. (1995), however, 






Insulin-like growth factor receptor 2 
IGF-2/M6P receptor content is differentially regulated during bovine fetal development 
(Pfuender et al., 1995). In ovine fetal plasma, the circulating form of the IGF-2/M6PR is 
extremely high (Gelato et al., 1989; Gallaher et al., 1994), but placental IGF-2/M6PR decreases 
in ewes during pregnancy (Lacroix et al., 1995).  IGF2R mRNA in the ewe was localized to the 
caruncular-like stroma lining the luminal epithelium (Reynolds et al., 1997).  Lacroix and his 
group (1995) immunohistochemically located IGF2R protein in the fetal placental mesoderm.   
The IGF2R gene is imprinted, and normally only the maternal allele is expressed.  When this 
allele is disrupted, mutant mice have an increase in serum and tissue IGF-2 levels.  At birth they 
exhibit overgrowth (135%), organomegaly, a kinky tail, postaxial polydactyly, heart pathology, 
and edema.  Perinatal death is frequent, which indicates the importance to survival of the 
M6P/IGF2R lysosomal enzyme trafficking (Lau et al., 1994; Ludwig et al., 1996).  Disruption of 
IGF2R has also been shown to indirectly affect placental neovascularization (Young & Fairburn, 
2000).  Large sheep fetuses born after in vitro culture of in vivo fertilized eggs to the blastocyst 
stage, showed a decrease in IGF2R transcript and circulating IGF2R protein in late gestation, but 
no corresponding increase in circulating IGF-2 or tissue IGF-2 expression (Young et al., 2001).  
Therefore, IGF2R may also affect fetal growth in IGF-2-independent mechanisms, and 
epigenetic change in the imprinted IGF2R locus might explain a genetic component of the 
“Large Offspring Syndrome” (Young et al., 2001). 
 
Insulin-like growth factor binding proteins 
All IGFBP’s studied so far are synthesized either in the uterine luminal epithelium or in 
underlying subepithelial stromal cells.  This suggests that the IGFBP’s are important for 
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regulating the transfer of IGF-1 and –2 between fetal and maternal compartments (Wathes et al., 
1998).   
IGF binding protein -1 is a secretory product of decidualized endometrium and a major 
constituent of amniotic fluid (Crossey et al., 2002).  Phosphorylated IGFBP-1 has been shown to 
inhibit metabolic actions of IGF-1 on trophoblast cells in vitro.  Conversely, non-phosphorylated 
BP-1 had the opposite effect, enhancing IGF activity (Yu et al., 1998).  In vivo, an inverse 
correlation between fetal growth and BP-1 levels in fetal circulation exists.  Small for gestational 
age babies have elevated BP-1 levels in fetal cord serum (Langford, 1994). 
IGFBP-1 stimulates trophoblast proliferation in early human pregnancy (Hills et al., 1999).  The 
BP-1 gene has putative progesterone response elements that mediate endometrial stromal cell 
BP-1 gene expression early in gestation (Crossey et al., 2002).  Therefore, the migration of first 
trimester invasive trophoblast in vitro is stimulated by IGFBP-1, likely by interaction with the 
RGD-binding site of the 51-integrin (Irving & Lala, 1995).  Gleeson et al. (1999), furthermore, 
indicated that IGFBP-1 seems to stimulate extravillous trophoblast migration and invasion by 
signaling through 51-integrin, leading to signal transduction via FAK and MAPK.  IGFBP-1 
also increases the activity of gelatinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in 
first trimester cytotrophoblastic cells independently from IGF-1 (Bischof et al., 1998). Even 
though IGFBP-1 is abundant in baboon uteri during implantation, this is not the case in 
ruminants (Tarantino et al., 1992; Han et al., 1996).  This might be explained by the fact that 
IGFBP-1 appears to facilitate trophoblast penetration of the maternal interface, a much more 
invasive process in primate vs. ruminant placental development (Tarantino et al., 1992; Wathes 
et al., 1998).  At birth, fetal weight and IGFBP-1 concentration was inversely correlated in 
humans (Ostlund et al., 1997), and there is a slight negative correlation between serum IGFBP-1 
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levels and placental weight (Rutanen et al., 1984).  High IGFBP-1 levels in amniotic fluid are 
associated with lower placental weight (Verhaeghe et al., 1999).  
In primates, during implantation, the cell-cell communication between fetal trophoblasts 
and maternal decidual cells at the maternal-fetal interface is mediated by interactions between 
IGF-2 and IGFBP-1 (Hamilton et al., 1998).  BP-1 is expressed abundantly in the maternal  
decidua basalis throughout pregnancy (Han et al., 1996; Giudice, 1997), and BP-1 facilitates 
normal invasion into the maternal decidua (Han et al., 1996; Hamilton et al., 1998) since BP-1 
may modulate the action of IGF-2 on villous trophoblast proliferation, syncitial differentiation or 
apoptosis (Gratton et al., 2002).  In preeclampsia, trophoblast invasion into the maternal decidua 
and the spiral arteries at the maternal-fetal interface are impaired (Bronsens et al., 1973; Zhou et 
al., 1993, 1997).  This results in shallow placental invasion and reduced perfusion, which may 
reduce oxygen tension in the placenta, and alter trophoblast differentiation and function 
(Redman, 1991; Zhou et al., 1993; Genbacev et al., 1996), suggesting cell specific altered 
growth processes in the placenta.   In preeclampsia, IGF-2 and IGFBP-1 expression is altered at 
the maternal-fetal interface (Gratton et al., 2002).  Low levels of circulating BP-1 in the second 
trimester predict onset and are a marker of pre-eclampsia (De Groot et al., 1996; Giudice et al., 
1997; Hietala et al., 2000).  At term, maternal circulating levels of BP-1 are elevated, but basal 
plate decidua has significantly decreased BP-1 mRNA in preeclampsia (Gratton et al., 2002).  
Therefore, the increased level of BP-1 in circulation in women with preeclampsia is most likely 
not from decidual origin, and the conflict in levels is most likely because of sources of BP-1: 
maternal liver, decidua, or fetal BP-1 transported into maternal circulation (Gratton et al., 2002).  
In women with severe late second and early third trimester preeclampsia, the elevated BP-1 is 
most likely due to increased hepatic production, which is consistent with the correlation with 
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hepatic transaminases (Giudice, 1997; Gratton et al., 2002).  Even though increase in circulating 
BP-1 is seen in women with preeclampsia, there is no change in IGF-2 levels (Giudice, 1997).  
The decrease in circulating BP-1 is the biochemical proof/evidence of impaired trophoblast 
invasion and decidual dysfunction, and decreased BP-1 at materno-fetal interface may contribute 
to abnormal trophoblast invasion in preeclampsia (Gratton et al., 2002).  Crossey et al. (2002), 
modeled the effects of excess IGFBP-1 on fetoplacetal growth in transgenic mice overexpressing 
human IGFBP-1.  As explained in a recent comment by de Vrijer et al. (2002), we will mention 
their findings with caution, since it is important to keep in mind that in wild-type rodents, no 
IGFBP-1 is expressed in the decidua, only in the myometrium.  In mice, however, BP-1 like 
actions may be ascribed to decidual alpha 2 macroglobulin which can bind IGF's (Han & Carter, 
2000).  In the BP-1 overexpression model Crossey et al. (2002) found marked effects early in 
pregnancy such as early placental failure.   Effects on later placental development seemed rather 
minimal since normal term placental and fetal weights were obtained; suggesting other factors 
may overcome the initial BP-1 related deficiencies (Regnault et al., 2002c).   
In conclusion, Crossey et al. (2002) found that: decidual BP-1 excess was associated with 
increased placental mass (mainly in the labyrinth zone).  Placental IGF-2 expression was 
unchanged, but IGF-2 bioavailability at the fetomaternal interface might be altered.  In this study 
phosphorylated BP-1 predominated, which would suggest reduced IGF bioavailability.  In the 
placentomegaly of the transgenic dams, trophoblast invasion of the decidualized endometrium 
was less pronounced.  BP-1 was only present in amniotic fluid of transgenic mothers, 
independent of fetal genotype, indicating that IGFBP-1 would be mainly derived from maternal 
deciduas.  Crossey et al. (2002) suggested the following potential explanatory mechanisms: BP-1 
excess might attenuate trophoblast invasion and proliferation as a consequence of reduced local 
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IGF bioavailability.  Alternatively, reduced IGF might influence trophoblast differentiation, 
perhaps favoring the growth of noninvasive over invasive trophoblast lineages.  On the other 
hand, BP-1 may have direct IGF-independent effects on trophoblast invasion.   Irwin & Giudice  
(1998) reported that BP-1 inhibited trophoblast invasion of endometrial stromal cells in vitro.  In 
contrast, Gleeson et al. (2001) showed increased trophoblast invasion in response to BP-1.  Both 
studies show that these effects are mediated through binding of BP-1 to the α5β1 integrin.  In 
comparison with IGF-2 deficient mice, in both cases, spongiotrophoblast cells account for a 
greater proportion of the junctional zone.  However, in the IGF-2 null mice, placental mass is 
reduced, whereas there is a large increase in labyrinthine zone and therefore increased placental 
mass in IGFBP-1 mutants.  The exchange functions of the rodent placenta are largely confined to 
the labyrinthine zone.  Thus, compensatory changes in fetal vascularization could result in an 
increase in labyrinthine tissue volume. 
 Regnault et al. (2002c) studied fetal gene expression in a placental insufficiency - 
intrauterine growth retardation (PI-IUGR) model. With ribonuclease protection assays, they 
found fetal liver IGFBP-1 to be upregulated in the model, but no significant differences were 
seen for IGF-1, IGF-2 and IGFBP-3 prior to maximal growth. 
Endometrial expression of IGFBP-2 occurs in early pregnancy, and in the control non-
gravid estrous cycle in the cow but not the sheep; this may be mediated by the rise in 
progesterone (Geisert et al., 1991).  From day 29 on in ovine gestation, IGFBP-2 is exclusively 
detected in the dense caruncular-like stroma underlying the luminal epithelium (Reynolds et al., 
1997).  This finding agrees with a previous study by Delhanty & Han, (1992), which showed 
IGFBP-2 was present in close proximity to IGF-2 in rapidly proliferating tissues.  Plasma 
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concentrations of BP-2 were higher in somatic cell cloned cattle, immediately after birth 
(Matsuzaki & Shiga, 2002). 
In pregnant ewes, IGFBP-3 is present in the caruncles, endometrial stroma, placentome 
capsule and some allantochorion (Reynolds et al., 1997).  IGFBP-3 was not detected in fetal 
tissue by in situ hybridization (Reynolds et al., 1997).  Remarkably high levels of IGFBP-3 
mRNA were localized to maternal blood vessel walls of the caruncles in the region of fetal villi 
penetration (Reynolds et al., 1997).  This might be important in regulation of placental blood 
flow and in the rate of transfer of IGF-1 and –2 from the maternal circulation to the uterus 
(Wathes et al., 1998).  It is important to remember that both IGF-1 and –2 when complexed to 
IGFBP-3 cannot cross the placental epithelium (Bar et al., 1990).  There is a strong correlation of 
IGF-1 and IGFBP-3 serum levels and birth weight as well as placental weight (Osorio et al., 
1996).  Serum from pregnant women and rats contains a placental protease that cleaves IGFBP-
3, reducing its affinity for IGF’s (Davenport et al., 1992; Han & Carter, 2000).  In cases of utero-
placental insufficiency, IGFBP-3 protease activity was increased (Langford et al., 1995; 
Zumkeller, 2000).  Zumkeller (2000) suggests that decidual IGFBP protease activity may be 
modulated by IGF-1 and progesterone.  
During pregnancy in the ewe, IGFBP-4 mRNA expression is co-localized with IGFBP-2 
in the caruncular stroma lining the luminal space, and is also abundant in the placentome capsule 
and somewhat less in the caruncular stroma (Reynolds et al., 1997).  This localization creates a 
barrier of IGFBP-4 surrounding the placentome and might help concentrate IGF-2 within the 
placentome (Wathes et al., 1998).  In the ovine fetus, levels of IGFBP-1 and -2 are higher than in 
the adult, while IGFBP-3 concentrations are lower (Wathes et al., 1998).   
67 
 
Starvation of the ewe will cause a fall in insulin, while IGFBP-1 and -2 levels will go up, 
fetal glucose will drop, and IGFBP-3 and -4 concentrations will decrease (Gallaher BW, Breier 
BH, Blum WF, McCutcheon SN, 1995).  This rise in fetal plasma IGFBP-1 was linked to a fetal 
hepatic, but not placental origin (Osborn et al., 1992).  Ligation of the uterine artery in the rat 
(Unterman et al., 1990; Price et al., 1992) and reduction of uterine blood flow in sheep 
(McLellan et al., 1992) induced IGFBP-1 upregulation in the fetal liver.  In newborn cloned vs. 
control calves, there was no difference in GH concentrations, while IGF-1 levels were lower, 
IGFBP-1 and -2 were higher, and IGFBP-3 and -4 seemed to be lower (Chavatte-Palmer et al., 
2000).  At 3 weeks of age, patterns for these factors balanced out between both groups.  
Interestingly, in human intrauterine growth restriction (IUGR), IGFBP-1 is also elevated; this 
may reflect fetal suffering due to placental insufficiency (Popovici et al., 2001), even though one 
pathology represents undergrowth and the other overgrowth (Chavatte-Palmer et al., 2000).  In 
accordance with these data, Garry et al. (1998), reported that concentrations of IGF-1 and IGF-2 
were significantly lower in arterial blood of late-term cloned pregnancies.  Also preimplantation 
blastocysts cloned by nuclear transfer indicated an upregulation of IGF-2 and IGF-1R mRNA, 
and downregulation of IGF-1 mRNA (Schultz et al., 1996). 
Exogenous administration of bGH to pregnant ewes stimulates fetal growth in the last 
third of gestation, but has little effect on placental size.  This suggests a role for growth hormone 
in regulation of fetal growth due to changes in maternal nutrient partitioning or placental 
function (Jenkinson et al., 1999). 
There are other imprinted genes that influence fetal growth, however; their mechanistic 
effect on the insulin/IGF system is unknown: 
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1) Meg1/Grb10 (growth factor receptor bound protein 10) is maternally expressed and may 
inhibit signal transduction of the IGF’s as well as insulin to direct fetal growth (Murphy & Jirtle, 
2000; Reik & Walter, 2001).  In both mice and man, 2) the insulin gene is imprinted and can 
have fetal growth consequences.  It is chromosomally adjacent to the IGF-2 gene and is also 
paternally expressed in the placenta, but not normally in the pancreas (Giddings et al., 1994).   
3) Peg3 (paternally expressed gene 3) null mice exhibit fetal growth retardation, suggesting a 
role of this gene in fetal growth.  4) Peg1/Mest (paternally expressed gene 1/mesoderm specific 
transcript) has a growth-promoting role.  5) Deletion of Snrpn (small nuclear ribonucleoprotein 
polypeptide N) and its flanking sequence yields smaller progeny (Vrana et al., 1998; Tilghman, 
1999).  6) Gpc3 (glypican 3) may bind and affect IGF-2.  It is not imprinted, but because of its 
location on the X-chromosome it is probably subjected to haploid dosage control.   7) Tsix, is the 
antisense gene reciprocally imprinted to the X-inactivation gene, Xist (Lee, 2000).  Mice with a 
Tsix deletion feature IUGR.  8) Mash2 is an essential regulator of trophoblast giant cell 
differentiation and is embryologically lethal (Guillemot, 1995). 9) Other gene mutations 
associated with placental development that are not lethal but result in fetal growth retardation 
are, for example: Esx1, PdgfB, Wnt2 (Efstratiadis, 1998; Ihle, 2000). 
From the preceding review, it is obvious that IGF regulation is exceedingly complex.  
During pregnancy this complexity is even more difficult to unravel due to interaction among 
fetal, maternal, and placental compartments.  Nonetheless these complexities must be dealt with 






THE VASCULAR ENDOTHELIAL GROWTH FACTOR SYSTEM 
 
Development of an adequate placental blood supply is imperative for normal fetal growth 
and developmental rates (Barcroft & Barron, 1946; Rosenfeld et al., 1974; Reynolds, 1986; 
Reynolds et al., 1987).  About 40 days after conception in cattle, placental functioning becomes 
a sine qua non since hemotrophic exchange of substrates from the mother to the fetus is mediated 
by the placenta, an organ in which the fetal and maternal circulation are brought in close 
apposition.   
During placentation, fetal chorionic villi invade the maternal crypts.  New blood vessels 
sprout and branch abundantly, forming a complex architecture.  This process is induced and 
controlled by complex interactions of numerous angiogenic factors.  Moreover, growth and 
remodeling of the placental vascular beds takes place throughout gestation in concert with 
increasing rates of uterine and umbilical blood flow rate as well as fetal oxygen and nutrient 
uptake (Rosenfeld et al., 1974; Reynolds, 1986; Reynolds et al., 1987).  The underlying 
mechanism of control of this vascular architecture is delicately balanced, and can easily be 
disrupted by environmental stressors (e.g. hypoxia) which induce structural adaptations in an 
attempt to enhance the capacity for exchange (Penninga & Longo, 1998).  In this chapter, the 
complex interactions of the most important factors influencing vasculogenesis and angiogenesis 
will be discussed.  
 
Vasculogenesis versus angiogenesis 
Vasculogenesis occurs solely in the embryo and pertains to the initial differentiation of 
mesenchymal cells into angioblasts, the precursors of endothelial and haematopoietic cells from 
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the mesoderm (Poole & Coffin, 1989; Sherer & Abulafia, 2001), and the subsequent 
establishment of a primitive vascular network.  Angiogenesis, on the other hand, is defined as 
development of new capillaries from pre-existing vessels (Folkman, 1985).  Physiologically 
angiogenesis is observed during the ovulatory cycle in the follicle, placentation, and embryonic 
and fetal development.  Pathologically, it is induced by inflammation, wound healing, immune 
reactions and neoplasia (Sherer & Abulafia, 2001).       
Vascularization of the placental villi is the result of de novo formation of capillaries 
rather than protrusions of embryonic vessels (Ahmed et al., 2000).  Villi are made up of a solid 
trophoblast with a loose mesenchymal center derived from the extra-embryonic coelomic cavity 
(Benirschke & Kaufmann, 1995; Ahmed et al., 2000).  Before actual formation of blood vessels, 
macrophages (Hofbauer cells) (Demir et al., 1989) migrate into the mesenchyme of the villi, and 
present angiogenic growth factors.  These growth factors will stimulate the haemangioblastic cell 
cords, which are precursors for fetal endothelium, to form capillary lumens (Ahmed et al., 2000; 
Breier, 2000). 
Angiogenesis on the other hand, begins with a focal degradation of the basement 
membrane of a pre-existing capillary.  This defect allows endothelial cells to migrate, proliferate 
and assemble into new tubes.  Subsequently, peri-endothelial support cells are recruited to 
support further vessel maturation (Klagsbrun & D’Amato, 1991; Hanahan, 1997; Koblizek et al., 






Figure 1.3 The endothelial signaling system.  TM: is transmembrane domain, FN: fibronectin-
like domain, Ig: immunoglobulin-like domain, Kinase: intracellular tyrosine kinase domain, Tie 
receptors express epidermal growth factor-like repeats (EGF).  (Breier, 2000) 
 
Based upon  these  excellent reviews (Hanahan, 1997; Ahmed et al., 2000; Breier, 2000; 
Sherer & Abulafia, 2001), I will discuss the current consensus on vascular morphogenic 
signaling and placental angiogenesis.  Regulation of angiogenesis depends on a fine balance of 
numerous promoting and inhibiting paracrine signals, modulating the activity of certain receptor 
kinases.  Promotors of angiogenesis include vascular endothelial growth factor (VEGF), 
placental growth factor (PlGF), angiopoietins (Ang-1, Ang-2, Ang-3 and Ang-4), acidic and 
basic fibroblast growth factors (FGF); platelet-derived growth factors (PDGF), transforming 
growth factor  (TGF-), transforming growth factor  (TGF-), tumor necrosis factor  (TNF-
), folliculostellate-derived growth factor, angiotropin, and angiogenin. Non-specific 
angiogenesis inhibitors include interferons and platelet factor 4.  Specific anti-angiogenic factors 




Vascular endothelial growth factor 
Endothelial cell motility is promoted by binding of extracellular matrix proteins such as 
vitronectin and fibronectin to integrins expressed on the plasma membrane of endothelial cells 
(Eatock et al., 2000).  VEGF, also VEGF-A, is a potent-endothelium specific mitogen with a key 
role in the induction of angiogenesis in the placenta (Cheung, 1997); it also is important in 
development and maintenance of placental vascular function during gestation.  Initially the 
molecule was identified as a potent permeability factor (VPF) (Senger et al., 1983; Connolly et 
al., 1989), and therefore VEGF might be involved in the regulation of amniotic fluid volume and 
composition (Cheung, 1997).   
The active form of VEGF is a 40-45 kDa disulphide-linked homodimeric glycoprotein 
that is structurally related to the platelet-derived growth factor family.  This growth factor is 
highly conserved across species.  Thus far five isoforms derived from a single gene by 
alternative splicing of the 8 exons, have been found, resulting in proteins of 121,145,165,189 and 
206 amino acids in length, respectively (Tischer et al., 1991; Ferrara et al., 1992; Dvorak et al., 
1995).  The larger forms (VEGF189 and 206) contain a unique heparin binding domain which 
affects their diffusibility because of cell membrane/matrix association (Torry & Torry, 1997).  
VEGF165 is the most abundant isoform, including in the sheep placenta (Cheung & Brace, 1998); 
it is both diffusible and heparin binding. VEGF145 is specific to the human endometrium 
(Charnock-Jones et al., 1994). VEGF 189 and 206 maintain full biological activity and can be 
released from the extracellular matrix by proteolysis.   
 
 Cheung et al. (1995) have demonstrated expression and localization of VEGF mRNA in 
ovine placenta and fetal membranes and defined its possible role in fetal development and 
placental function (Cheung, 1997). In the pig, the VEGF system distribution is spatio-temporally 
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regulated throughout gestation. VEGF-KDR interaction is the main signal during initial placental 
angiogenesis, whereas the VEGF-Flt-1 interaction is more important in regulation and 
maintaining vessel integrity during late pregnancy (Dantzer et al., 2000). 
 Athanassiades et al. (1998) have shown that VEGF will stimulate proliferation but not 
migration or invasiveness, in human extravillous trophoblast isolated from 1
st
 trimester 
placentae.  Ablation of VEGF alleles in mice results in abnormal blood vessel development and 
is lethal by mid-gestation (Carmeliet et al., 1996).  With VEGF deficiency, in situ differentiation 
of blood islands (vasculogenesis), sprouting from pre-existing vessels (angiogenesis), lumen 
formation, formation of large vessels, establishment of interconnections, and the spatial 
organization of intra- and extra-embryonic vessels are impaired (Carmeliet et al., 1996).  VEGF 
and VEGF receptors are expressed in all developing organs, and the high affinity VEGF 
receptors are localized primarily in the developing vessels, whereas VEGF is secreted from cells 
in the vicinity.  In sheep, expression of VEGF by trophoblast cells probably allows for paracrine 
effects on both maternal and fetal endothelial cells in the vicinity of the fetal villi, causing 
vascular remodeling and controlling permeability to increase the surface area and rate of nutrient 
exchange between mother and fetus (Torry & Torry, 1997; Orbus, 1999). This indicates the 
importance of VEGF in stimulation of growth and survival of blood vessels in a paracrine 
fashion (Breier, 2000). Levels of VEGF are increased in many tumors and are elevated in women 
with pre-eclampsia (Clark et al., 1998b). 
 
VEGF activity is stimulated by hypoxia, cytokines and various other hormones (Neufeld 
et al., 1994). The hypoxia inducibility of VEGF transcription seems to be largely mediated by 
HIF-1 (hypoxia-inducible factor) activity (Semenza et al., 1999) a heterodimeric transcription 
factor tightly regulated by oxygen concentration (Richard et al., 1999).  This transcription factor 
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interacts with the VEGF hypoxia response element (HRE), activating transcription (Ikeda et al., 
1995; Levy et al., 1995; Breier, 2000).  In addition to transcriptional upregulation induced by 
hypoxia, VEGF-A mRNA is stabilized by specific proteins binding to the 3’-untranslated region 
of the transcript (Claffey et al., 1998; Levy et al., 1998).  Apparently, VEGF mRNA contains 
destabilizing elements in its 3’untranslated region (3’UTR), 5’UTR and coding region.  Each 
region can independently promote mRNA degradation under normoxic conditions.  In contrast, 
under hypoxia mRNA stabilization depends on the cooperation of all three elements (Dibbens et 
al., 1999).  Both IGF-1 and -2 are also potent inducers of VEGF expression (Punglia et al., 1997; 
Kim et al., 1998).  In vitro, IGF-1 regulates VEGF expression in endometrial adenocarcinoma 
cells at the post-transcriptional level by enhancing the stabilization of VEGF121 and VEGF165 
(Bermont et al., 2000). And in the eye, elevated IGF-1 levels have been shown to promote 
neovascularization through increased retinal VEGF gene expression (Punglia et al., 1997). On 
the other hand, IGF-2 induced by hypoxia may contribute to the angiogenesis of hepatocellular 
carcinomas (Kim et al., 1998). Steroids induce endometrial expression of various growth and 
angiogenic factors (Eatock et al., 2000), and in fact, VEGF may serve as a local mediator of the 
effects of reproductive hormones on the endometrial vasculature (Jaffe, 2000).  Estrogens 
upregulate VEGF expression in uterine tissue from rats (Cullinan-Bove & Koos, 1993) and 
women (Ahmed et al., 1995).  VEGF is also known to increase endothelial nitric-oxide synthase 
(eNOS) expression via activation of the KDR receptor tyrosine kinase (Shen et al., 1999).     
 
In the past few years, at least six more proteins have been identified as members of the 
VEGF family (Veikkola & Alitalo, 1999) because of sequence similarity and interaction with 
receptors of the VEGF family.  The VEGF-B variant has 45 % amino acid homology to VEGF-A 
and has a mitotic effect on endothelial cells and a regulatory role in regulation of extracellular 
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matrix degradation and cell adhesion (Olofsson et al., 1998).  VEGF-B is particularly abundant 
in heart and skeletal muscle (Olofsson et al., 1996).  Clark et al. (1998) were unable to detect 
mRNA for either VEGF-C or VEGF-B in the human placenta by in situ hybridization, but 
Vuorela et al., (1997), identified large amounts of mRNA for both VEGF-B and –C in human 
placenta by Northern blotting.  VEGF-C functions as a regulator of lymphangiogenesis 
(Olofsson et al., 1999).   
VEGF-D is structurally most closely related to VEGF-C by virtue of the presence of N- 
and C- terminal extensions not found in the other VEGF family members (Farnebo et al., 1999).  
Large amounts of VEGF-D are found in lung tissue, and this gene is strongly upregulated in 
embryonic lung prior to birth.  Therefore VEGF-D may be of importance to lung vascularization 
during the last trimester of gestation (Farnebo et al., 1999).    Thus far, VEGF-D mRNA has not 
been detected in placental tissue (Fairbrother et al., 1998). 
Interestingly, VEGF’s –A, -B and -C appear to be differentially regulated.  Among them, 
only VEGF-A is induced by hypoxia (Enholm, 1997; Yonekura et al., 1999).   Other potent 
inducers of VEGF-A, like Ras oncoprotein and mutant p53 tumor suppressor, also do not 
increase VEGF-B and –C mRNA levels (Enholm, 1997).  Growth factors such as PDGF, 
epidermal growth factor (EGF), TGF-, and the tumor promotor phorbol myristate 12,13-acetate 
(PMA), on the other hand, stimulate VEGF-C but not –B mRNA expression (Enholm, 1997).  
These differential findings in regulation led to the suggestion by Enholm (1997) that the 






Placental Growth Factor 
Placental growth factor (PlGF) is another angiogenic factor expressed in the placenta 
(Maglione et al., 1991; Persico et al., 1999). Structurally, PlGF shares 53% homology (71% 
similarity) with the PDGF-like region of VEGF.  PlGF is a homodimeric glycoprotein of 46-50 
kDa in size. Three isoforms of PlGF have thus far been described and are generated by 
alternative splicing of the mRNA for PlGF (Cao et al., 1997; Ziche et al., 1997).  PlGF-2 has a 
21-amino acid insertion not present in PlGF-1 coding for a highly basic region near the C-
terminus (Hauser & Weich, 1993) that appears to be a heparin-binding domain (Athanassiades et 
al., 1998).  PlGF-3 is 70 amino acids longer than PlGF.  
Ziche et al. (1997) have shown with in vitro studies that PlGF has a comparable effect to 
VEGF on cultured microvascular endothelium, and demonstrated that PlGF-1 can induce 
angiogenesis in vivo and stimulate migration and proliferation of endothelial cells in vitro.  
Despite this finding, PlGF is a very weak stimulator of endothelial cell chemotaxis and 
proliferation (Hauser & Weich, 1993).  (Park et al. (1994), indicated that PlGF has no effect 
alone, but potentates the action of low doses of VEGF on microvascular endothelial cells both in 
vitro, and even more strikingly, in vivo.  Murine Gene knock-outs for PlGF, however, develop 
normally (Carmeliet & Collen, 1999), probably because of compensation by other VEGF family 
members; also, PlGF might act primarily on trophoblast cells (Athanassiades et al., 1998) that 
express Flt-1 (Breier, 2000).  PlGF mRNA has been reported in the sheep fetal placenta 
(Regnault et al., 2003). In that report, pregnant sheep were exposed to heat-stress to induce intra-
uterine growth restriction (IUGR).  They found no effect of tissue or treatment on oPlGF 
expression, but cotyledonary oVEGF mRNA content increased during the active stage of 
placental development, and oVEGF mRNA was elevated following heat exposure during the 
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period of maximal development.  Ahmed et al., (2000) obtained different results: PlGF mRNA 
and protein increased in IUGR placentae. 
In vitro exposure of human trophoblast cell cultures to low oxygen tension downregulates 
PlGF expression, while increasing VEGF expression (Shore et al., 1997).  In human placentae, 
PlGF levels rise during the second trimester and peak at the beginning of the third trimester 
before falling to low levels at delivery (Torry et al., 1998). In vitro, PlGF promotes extravillous 
trophoblast cell proliferation without influencing migratory or invasive behavior (Athanassiades 
et al., 1998).  In conclusion, PlGF appears to function in a paracrine mode on vascular 
endothelial cells in placental angiogenesis, and as an autocrine mediator of trophoblast function 
(Sherer & Abulafia, 2001) 
 
PLGF and VEGF dimers 
Both PlGF and VEGF form homodimers as well as heterodimers with each other 
(DiSalvo et al., 1995; Cao et al., 1996).  Homodimers of PlGF bind to Flt-1 with high affinity, to 
Flt-1 but not to KDR (Park et al., 1994a).  PlGF/VEGF heterodimers on the other hand do bind 
KDR and elicit a mitogenic response in vitro, but with a 20- to 50-fold decrease in activity 
compared to homodimers (Cao et al., 1996).  These PlGF/VEGF heterodimers stimulate a strong 
chemotaxis in endothelial cells similar to that elicited by VEGF homodimers; PlGF homodimers, 
however do not influence chemotaxis by these cells.  Two possible conclusions are deduced from 
these findings.  PlGF expression may function to down-regulate the mitogenic effects of VEGF 
by formation of heterodimers, while up-regulating the chemotactic effects of VEGF on 
endothelial cells, possibly through various ligand-induced receptor dimerizations (Cao et al., 
1996).  On the other hand DiSalvo et al. (1995), found PlGF/VEGF heterodimers to be equally 
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potent endothelial cell mitogens as VEGF homodimers, and therefore PlGF would only serve to 
enhance the mitogenic activity of VEGF.  As Cao et al. (1996) point out, it is important to keep 
in mind that different levels, or types of receptors expressed by the endothelial cells used in each 
assay may have a large impact on the outcome. 
 
Receptors 
Thus far two major receptors for the VEGF family have been identified; the kinase 
domain containing region (KDR) and the fms-like tyrosine kinase (Flt-1); both are found in 
human placental tissues (Terman et al., 1992; de Vries et al., 1992).  They belong to a family of 
transmembrane receptor tyrosine kinases (RTK’s), and are endothelial cell specific (Terman et 
al., 1992; de Vries et al., 1992), each with distinct signals.   Several other reports, however, have 
also demonstrated functional VEGF receptor expression in non-endothelial cells (Charnock-
Jones et al., 1994; Ahmed et al., 1995).  These receptors are widely expressed in vascular 
endothelial cells, and are also found in placental tissues where VEGF is localized (Cheung, 
1997).  Basic receptor tyrosine kinase (RTK) signaling is mediated through ligand-dependent 
autophosphorylation and activation of Ras pathways (Hanahan, 1997).  Both receptors have an 
extracellular region containing seven immunoglobulin (Ig)-like domains, a single transmembrane 
domain, and a cytoplasmic consensus tyrosine kinase sequence (Banks et al., 1998) (figure 1.3).   
 
The first receptor, KDR (kinase-insert domain-containing receptor) or VEGF-R2 is 
homologous to the murine Flk-1 (fetal liver kinase-1) (Terman et al., 1992).  Mice 
homozygously deficient for Flk-1 show failure of blood-island formation and vasculogenesis, 
and severe reduction in haematoangioblast progenitors and then endothelial cells; they die mid-
gestation (Shalaby et al., 1995).  Heterozygous mutants are essentially normal.  In a study of 
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VEGF binding to its receptors in ovine placenta and fetal membranes, the predominant placental 
site of KDR was the maternal vascular endothelium, but there was a weaker signal in the 
maternal epithelium at 62, 103 and 142 days.  At 103 and 142 days but not at 62 days, KDR was 
abundantly present in villous blood vessel endothelium.  In fetal membranes, at the same days of 
gestation, KDR was expressed in the amniotic epithelium and intramembranous blood vessel 
endothelium; there was no KDR or VEGF binding in the chorionic cytotrophoblast (Bogic et al., 
2001). 
Flt-1 (fms-like tyrosine kinase) or VEGF-R1 is the other major receptor for the VEGF 
family proteins (Quinn et al., 1993).  Homodimers of PlGF bind with high affinity to Flt-1, but 
not to KDR (Park et al., 1994a).  Embryos lacking the Flt-1 gene homozygously, have normal 
hematopoietic progenitors and abundant endothelial cells that migrate and proliferate; however, 
there is a failure to assemble these cells into normal vascular cells (Fong et al., 1995).  Again, 
heterozygous deletions are normal. Flt-1 appears to be the predominant receptor in humans, 
whereas KDR is the major receptor in sheep (Cheung, 1997). 
Bogic et al., (2001) could not detect Flt-1 expression in sheep placentae or fetal 
membranes by Northern-blots at 62, 103 and 142 days of gestation.  However, Regnault et al. 
(2002a), did identify Flt-1 mRNA by ribonuclease protection assay and reverse transcription 
PCR in sheep placentomes.   
A pregnancy-associated soluble variant of the flt-1 receptor (sFlt-1) has also been 
described (Kendall & Thomas, 1993; Kendall et al., 1996; Banks et al., 1998; Clark et al., 
1998a).   The protein has a subunit size of 150 kDa.  Normally it is present as a multimer of 400-
550 kDa, and complexes of 600-700 kDa are formed after binding multiple VEGF molecules 
(Banks et al., 1998).  So far the Flt-1 mRNA’s identified arise by alternative splicing (Kendall & 
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Thomas, 1993).  Flt-1 is secreted by the human placenta and expected to function as a VEGF 
antagonist, suggesting that regulation of VEGF action is essential to successful pregnancy (Clark 
et al., 1998a).  Regnault et al. (2002a) were unable to identify sFlt-1 in ovine placental 
membranes.  
In conclusion, KDR appears to be required for early development of the endothelial cell 
lineage and the mitogenic and chemotactic responses of endothelial cells. Flt-1 may be important 
for regulation of normal endothelial cell adhesion and interaction with the extracellular matrix 
(Bogic et al., 2001), and the maintenance of mature blood vessels (Waltenberger et al., 1994; 
Fong et al., 1995; Orbus, 1999).  In situ binding studies with recombinant VEGF in ovine 
placenta and fetal membranes suggest KDR plays a key role in maintaining vascularity and 
permeability (Bogic et al., 2001).  
More recently two other receptors, neuropilin-1 (NRP-1) and neuropilin-2 (NRP-2), were 
identified.   The ligands VEGF-A165 (Soker et al., 1998), PlGF-2 (Migdal et al., 1998), VEGF-B 
(Makinen et al., 1999) and the virus-encoded VEGF-E (Meyer et al., 1999) bind to NRP-1.  
VEGF165, PLGF-2 and VEGF-C bind to NRP-2.  VEGF121 does not bind to either of these 
receptors (Neufeld et al., 2002).  Originally, neuropilins were identified as receptors for 
semaphorins with a function in axonal guidance (Chen et al., 1997; He & Tessier-Lavigne, 
1997).  The intracellular domains of the neuropilins are short and for signal transduction to 
occur, they complex with other receptors.  Co-expression of KDR and neuropilin-1 on 
endothelial cells causes an increase in binding affinity of KDR for VEGF165 (Soker et al., 1998); 
however, controversy exists whether KDR complexes to NRP-1 (Neufeld et al., 2002).  In 
contrast, it has been shown that Flt-1 can form complexes with the neuropilins (Neufeld et al., 
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2002).  Neuropilin-1 knockout mice die in utero due to abnormal development of the 
cardiovascular system (Kitsukawa et al., 1997). 
Furthermore, VEGFR-3 or Flt-4 has been identified as the receptor for VEGF-C and –D; 
it does not play a role in vasculogenesis, but is important in vascular remodeling and the 
formation of lymphatic vessels (Veikkola & Alitalo, 1999). 
In a model of placental insufficiency and intrauterine growth restriction, both caruncular 
and cotyledonary VEGF and PlGF mRNA concentrations increase with gestational age, but the 
respective protein concentration would only increase in the cotyledon.  Furthermore, VEGF 
mRNA is elevated in hyperthermic ewes at 55 days of gestation.  Later at 90 days, no changes in 
VEGF and PlGF mRNA were observed by hyperthermia.  For the receptors, Flt-1 and KDR, 
levels rose over time in this model.  However, receptor mRNA concentration was significantly 
reduced in the cotyledon of placentas from sheep exposed to hyperthermia (Regnault et al., 
2002a).  
 
Angiopoietins and their receptors 
To make the story on vasculogenesis and angiogenesis more complete, it is important to 
discuss two other major regulators: angiopoietin-1 and –2 (Ang-1 and Ang-2) and their receptor 
Tie-2.  The Ang-1 and Ang-2 proteins are both about 75 kDa in size and are fairly homologous 
in sequence (Hanahan, 1997).  They both contain a coiled-coil and a fibrinogen-like domain and 
bind to Tie-2 with similar affinity; neither binds the Tie-1 receptor.  VEGF stimulates Ang-2 
expression (Oh et al., 1999).  Ang-2 mRNA transcription is increased under reduced oxygen 
pressure, and the stability of Ang-1 mRNA is reduced under this condition (Charnock-Jones, 
2002).  Ang-1, Ang-2 and VEGF may affect the presence of occludin and plakoglobin.  These 
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two proteins modulate tight junction stability, and therefore permeability of the materno-fetal 
endothelial barrier (Leach, 2002).  Ang-1 induces autophosphorylation of Tie-2 in vitro.  Ang-2 
however does not induce receptor phosphorylation upon binding, and seems to competitively 
inhibit Ang-1-induced kinase activation of the Tie-2 receptor (Hanahan, 1997).  Tie-2 is 
expressed on trophoblast, and its activation induces trophoblast proliferation, migration and 
production of nitric oxide (Ahmed & Perkins, 2000).  Tie-2 knockout mice die later in 
embryogenesis; endothelial cells are present and organized into tubes, but the vessels are 
immature, lacking branching and organization into large and small vessels (Dumont et al., 1994; 
Sato et al., 1995).  In these mice, the neurectoderm lacks vascularization, the endocardium and 
myocardium are mal-developed at the cellular level, and defects in vessel architecture are evident 
in multiple other tissues.  Therefore, Tie-2 appears to control recruitment of stromal cells to 
stabilize the structure of endothelial tubes and modulate the function of blood vessels.  Tie-1 has 
a similar structure to Tie-2, and the null phenotype is lethal with edema and hemorrhage as the 
major pathological finding, implicating Tie-1 control in fluid exchange across capillaries and in 
hemodynamic stress resistance (Puri et al., 1995; Sato et al., 1995). 
In conclusion, Hanahan (1997) suggests a model for control of vasculogenesis, vessel 
maturation and maintenance, angiogenesis, and regression, based upon gene-knockout 
phenotypes.  Early in embryogenesis, VEGF binds VEGFR-2, inducing the differentiation and 
proliferation of endothelial cells.  In contrast VEGF binding VEGFR-1 elicits endothelial cell-
cell interactions and capillary tube formation, a process that closely follows proliferation and 
migration of endothelial cells.  Ang-1 binding to the Tie-2 receptor recruits and maintains the 
association of peri-endothelial support cells (pericytes, smooth muscle cells, myocardiocytes), 
thus stabilizing newly formed blood vessels.  Ang-2 does not activate Tie-2, but binds and blocks 
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kinase activation in endothelial cells. This Ang-2 negative signal loosens vessel structure, 
reducing endothelial cell contact with surrounding matrix and support cells.  In presence of 
VEGF and other inducers, this renders the endothelial cells more accessible and responsive 
towards angiogenesis.  In absence of these angiogenic inducer proteins, Ang-2 elicits endothelial 




















CHAPTER II: CHARACTERISTICS OF PLACENTAL AND FETAL TISSUES FROM 





Recent scientific breakthroughs in nuclear transplantation with fetal and adult somatic 
cells highlight the need to investigate associated pregnancy anomalies, such as excessive 
abortion rates, hydroallantois that usually is lethal to the recipient, stillbirths and metabolically 
abnormal neonates.  The incidence of oversize calves from cloning by nuclear transplantation has 
been best documented in a study involving thousands of calves by Wilson et al. (1995).  Most of 
these abnormal pregnancies did not in fact result in oversize fetuses, but were still very 
abnormal, resulting in neonatal death.  Calves derived from IVF or nuclear transplantation 
require extra, intensive care due to metabolic pathologies. This is best documented by Garry et 
al. (1996) who reported that calves independent of size, were hypoxic, hypoglycemic, and 
hypothermic, and had abnormalities in metabolic hormones including low thyroxin and T3, and 
insulin concentrations four times higher than the reference population shortly after birth.  With 
intensive care at birth, calves become essentially normal, and as determined from other studies 
(Wilson et al., 1995), such offspring have normal pregnancies and offspring.   
The placenta has a pivotal role in transfer of essential substrates from the mother to the 
fetus and is responsible for mediating and/or modulating the maternal environment.  Placental 
and parturitional abnormalities have been observed directly with pregnancies from nuclear 
transplantation and IVF (Holm et al., 1996; Kruip & den Daas, 1997). Parturition is frequently 
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lengthy, lacking normal signs of impending birth or pronounced uterine contractions (Avery & 
Greve, 1995).  The incidence of hydroallantois is about 1% for pregnancies from IVF (1,376 
pregnancies) (Hasler, 1998), which is about 10 times the normal incidence and is accompanied 
by a very high rate of mortality among recipient cows. Furthermore, cotyledons from cloned 
pregnancies are edematous, and intercotyledonary areas are thickened with a gelatinous-like 
material at parturition (Garry et al., unpublished).  Enlarged umbilical vessels, edematous 
membranes, and a greater than usual allantoic volume also were observed by Wells et al., (1999).   
Peterson & McMillan (1998) observed impaired allantoic development and vascularization in 
24% of in vitro-derived embryos at day 25.  Allantochorion colonizes the maternal caruncles 
between days 20 to 35 (Melton et al., 1951), so growth restriction during this period can limit 
numbers of placentomes.  Later in pregnancy, size and morphology rather than number of 
placentomes are affected (Melton et al., 1951).  Nuclear transfer pregnancies from pluripotent 
embryonic cell lines were all lost before 60 days of gestation in one study (Stice et al., 1996).   
These fetuses developed through organogenesis (by day 42); however, a deficiency in 
placentome development occurred where cotyledons and villi were absent, and a hemorrhagic 
response was noted in the caruncles void of crypts. Timing of pregnancy loss in this study 
coincided with timing of placentome formation in normal conceptuses. The caruncular 
hemorrhaging of nuclear transfer pregnancies indicated a maternal response; however, proper 
placentome formation did not ensue (Stice et al., 1996). Since the bovine conceptus can survive 
on uterine milk until approximately 40 days of gestation (Melton et al., 1951), fetal-maternal 
exchange via the placenta only becomes necessary thereafter.  These data thus infer a genetically 
or epigenetically abnormal placenta, and we hypothesize that aberrant placental development 
may explain much of the attrition and pathologies of nuclear-cloned pregnancies.   
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Our objective was to characterize and compare fetal and placental tissues from nuclear-
cloned and control day 75 bovine pregnancies.  In a previous study with nuclear transfer embryos 
from the same origin, we showed that most recipient cows pregnant at day 70, would carry 
pregnancies to term (Seidel et al., 1997).  By this time point, gestational losses due to embryonic 
failure or severely underdeveloped placentation are eliminated.  However in such pregnancies 
stillbirth, hydroallantois, dystocia or perinatal morbidity still occur, and many times this seems 
related to placental pathology (Cibelli et al., 1998; Hill et al., 1999).  Basic information in this 
area might be applied to reducing the huge amount of pregnancy attrition in cloning and in vitro 
fertilization experiments, as well as provide information to decrease fetal and neonatal death that 
occurs with conventional reproduction. 
 
 
MATERIALS AND METHODS 
 
Cloned embryos 
Frozen, cloned bovine Brangus embryos produced by nuclear transplantation were kindly 
donated to us by Dr. JM Wilson from Granada Biosciences, Inc.  Embryos were cloned as 
described by Willadsen et al., (1991), Westhusin et al., (1992) and Wilson et al., (1995).  
Oocytes were bisected, and each half was fused with a blastomere from a 16+ -cell embryo 
(Westhusin et al., 1992).  In most cases, cloned clutches were enlarged by serial nuclear 
transplantation; when embryos of the first round of cloning reached the morula stage, 
blastomeres were again separated, and each was individually fused with a bisected oocyte to 
enlarge the clutch of cloned embryos. After fusion, embryos were transferred surgically to 
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ligated sheep oviducts and recovered 6-7 days later.  Those embryos developing normally (late 
morulae and blastocysts) were frozen in 0.25cc French straws using 1.5 M ethylene glycol in 
modified Dulbecco’s phosphate-buffered saline (Voelkel & Hu, 1992).  Straws were seeded at –
7
o




C/min.  Embryos were then held at –35
o
C for 15 min before 
plunging in LN2.  Thawing was in air for 12 sec followed by 12 sec in a 35
o
C water bath.  Even 
though these embryos can be transferred directly, without the need for removal of the ethylene 
glycol, we expelled the thawed embryos in PBS in order to evaluate embryo quality 
(1=excellent…4=poor).  Subsequently, embryos of quality 1 or 2 were loaded pair wise into 
straws, and transferred, one or two per recipient, ipsilateral to the corpus luteum 6 to 8 days post-
estrus.  All gestations of clones in this study were from different cloned sets and of different 
parental origin, except within twin pregnancies. 
 
Procedures with animals 
All heifers were kept at the Animal Reproduction and Biotechnology Laboratory and fed 
10 kg alfalfa hay once daily.  All procedures with animals were approved by the University 
Animal Care and Use Committee.  Estrous cycles of heifers were synchronized by injection of 25 
mg PGF2 i.m. For day 45 tissue sample collections, eight control Angus heifers were 
artificially inseminated with Brangus semen 12 hours after first signs of estrus.  Seven days after 
the first signs of estrus, twenty-nine frozen-thawed nuclear cloned embryos of grade 1 or 2 and 
from different clonal sets were transferred nonsurgically into 15 beef heifers. Recipient heifers 
received caudal epidural anesthesia prior to nonsurgical transcervical transfers (Elsden & Seidel, 
1995); after local clipping and scrubbing the tailhead with betadine soap and 70% isopropyl 
alcohol, 6 ml of 2% lidocaine was injected into the epidural space at the 1
st
 intercoccygeal joint.  
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45 days post-estrus, heifers again received epidural anesthesia and placental membranes were 
collected nonsurgically by transcervical, nonsurgical aspiration (Glover & Seidel, 2003).  A 
stainless steel 30 cm tube fitted around a solid cervical round tip expander of 5mm diameter (Fig. 
2.1) was gently manipulated through the cervix.  Once the expander-tube communicated with the 
uterine lumen, the expander was removed and plastic tubing was hooked up to the stainless steel 
tube.  About 100 ml 0.4% bovine serum albumin fraction V (USB - Amersham Life Science, 
70195 Albumin fraction five CAS 9048-46-8) in phosphate- buffered saline (PBS) (Elsden & 
Seidel, 1995) were infused by gravity into the uterine cavity, and the uterus was gently massaged 
transrectally.   
Once membranes ruptured, the intrauterine content was aspirated under negative pressure 
with a 100 ml syringe.  After aspiration, all heifers received 25 mg ProstaglandinF2 (Lutalyse, 
Upjohn, Michigan) i.m.  
 
 




For the day 75 tissue collections: ten control Angus heifers were bred by artificial 
insemination with Brangus semen, 12 hours after the first signs of estrus.  Seven days after the 
first signs of estrus, Seventy-one frozen-thawed, cloned embryos of grade 1 or 2 and from 
different clonal sets were transferred nonsurgically into 41 beef heifers as described above.  All 
heifers were checked by ultrasound for a fetal heartbeat at 30, 45, 60 and 75 days of gestation. 
 
Tissue Collection 
For the day 45 tissue collections, the aspirated fetal placental membranes were identified 
and separated into intercotyledonary allantochorion, cotyledons and amnion.  The cotyledons 
were dissected from the allantochorion with microsurgical scissors under a stereoscope at 7-10 
X.  All tissues were snap frozen and stored in liquid nitrogen.  
 For day 75 tissue collections, the uterus was removed from the 75  1 day pregnant 
heifers by means of mid-ventral hysterectomy.  Heifers were fasted 24 hours prior to surgery and 
then underwent a midventral laparatomy under general anesthesia.  Anesthesia was induced by 
intravenous injection of sodium thiopental (~5 mg/lb), and heifers were intubated and maintained 
on 2-4 % halothane gas for the duration of surgery.  Analgesia was started intra-operatively (1 
mg/kg i.v. banamine at surgery and daily for 3 days); beginning analgesia pre-operatively could 
have compromised the experiment since pharmacological effects on the tissues being collected 
are unknown.   
  The anesthetized heifers were placed on their backs and tied to the surgical table upside 
down. The surgical area was clipped and prepared using multiple alternate scrubs of betadine 
soap and 70% isopropyl alcohol, and then sprayed with betadine. Plastic booties were placed on 
the hind feet, the area flanking the incision was covered with sterile towels; a sterile surgical 
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drape was placed over the entire cow, except the head.  A 25 cm incision was made between the 
navel and udder, and the reproductive tract was exposed.  The ovarian artery and vein on both 
sides were isolated, clamped and double ligated.  The uterus was removed starting with the apex 
of the horns, and the vessels within the broad ligament were ligated as removal of the horns 
proceeded.   The uterus was amputated through the uterine body by double clamping and a 
double ligation with sterile umbilical tape caudal to the line of transaction.  The clamp cranially 
to the line of transection was to avoid peritoneal spillage of uterine contents.  The stump was 
oversewn with an inverting suture pattern.  The abdominal incision was closed in three layers; 
individual chromic catgut sutures were used for the first layer, continuous sutures with chromic 
catgut for the second layer, and individual Braunamid sutures for the outer layer. The heifers 
were monitored for surgical complications at least twice daily for the week following surgery.  
The braunamid skin sutures were removed 10 days after surgery. 
Once the uterus was collected, it was kept on ice, and weighed after the mesometrium 
was removed.  The intact feto-placental unit was exposed by cutting through the uterus along the 
mesometrial surface from the tubo-uterine junctions to the uterine body.  Gross anatomy was 
observed, and specific attention was paid to development, length and vascularization of amnion, 
allantois and chorion; abnormalities were recorded.  Allantoic and amniotic fluids were aspirated 
by using sterile 20 gauge needles and plastic syringes and aliquots of fluids were stored at -20
o
C.  
The entire amnion was dissected, and the fetus and umbilical cord were removed. The fetus was 
dissected free of membranes, and fetal wet weight and crown-rump length (curved) were 
recorded.  The crown rump length was measured from a point midway between the orbits of the 
eyes following the vertebral ridge to the base of the tail, i.e., approximately the first coccygeal 
vertebra (Hubbert et al., 1972).  The length and weight of the umbilical cord were measured.  
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Two large placentomes in the umbilical area, 2 medium and 2 small placentomes were kept 
intact, dissected, weighed and measured.  The remainder of the placentomes were manually 
separated into fetal cotyledonary and maternal caruncle components, cotyledons were counted, 
and samples of cotyledons and caruncles classified as large, medium or small were measured and 
weighed. The fetus was dissected, and weights of the brain, heart, kidneys and liver were 
documented.  Intercaruncular endometrium and myometrium, and intercotyledonary 
allantochorion were also biopsied.  All tissues were rinsed in physiological saline and respective 
samples were snap frozen in liquid nitrogen for tcRNA or protein isolation, or fixed in 4% 
paraformaldehyde (PFA) in PBS, and embedded in OTC for potential studies of histology, in situ 
hybridization and immunocytochemistry. 
 
Data analysis 
No physical measurement data were obtained from day 45 pregnancies.  For day 75, 
physical measurement values are given as mean ±SEM.  Due to the low sample number and 
heterogenous variance, we opted to analyze data from physical measurements by the non-
parametric Wilcoxon rank sum test of SAS (SAS institute, Cary, NC).  We compared placentome 
weight (of the largest placentome), fetal length, fetal weight, fetal weight/length index, umbilical 
cord weight/length index, heart, brain, liver and kidneys weights and the organ/bodyweight 
indexes and brain/liver index between treatment groups (controls vs. clones), sex and twinning.  
To evaluate twin effects, we also analyzed data including and excluding the measurements from 
twin pregnancies (recipient numbers 61, 82 and 39 – see table 2.2.).  Equality of variances were 
evaluated by the 2-tailed F-statistic (SAS institute, Cary, NC).  Furthermore, Pearson correlation 
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coefficients were determined among all physical measurements, including the weight of the 






Day 45 tissue collections  
Five of eight inseminated control heifers were diagnosed pregnant at 45 days.  Six of 15 
recipient heifers were pregnant with a live cloned pregnancy at day 45 as determined by 
ultrasonography.  The nonsurgical, transvaginal aspiration was effective for obtaining adequate 
amounts of fetal membranes at this stage of gestation.  Placentomes are very primitive in their 
development at this point of gestation, with a range in diameter of 3-10 mm, and we usually 
could dissect about 7-15 cotyledons from the tissues obtained.  In one case (out of eleven) we 
retrieved the fetus.   
 
Day 75 tissue collections  
Five of 10 control heifers inseminated with Brangus semen, remained pregnant through 
day 75.  From the 71 embryos transferred into 41 heifers, 16 day 30 pregnancies were obtained, 
and as determined by ultrasound of a fetal heartbeat, 13, 8, 8 conceptuses remained viable at 45, 
60, 75 days of gestation respectively.  Thus, there was a higher pregnancy attrition between day 




Figure 2.2 Conceptus attrition. 
 
One fetus died between 45 and 60 days, but spontaneous abortion did not occur by day 
75.  At surgical recovery, we found jellied allantoic fluid and a decomposing, brown colored 
fetus in a brownish amniotic fluid.  In one of the three twin pregnancies, one of the fetuses died 
between 30 and 45 days; its regressing gestational sac occupied one uterine horn without 
placentomes, but the counterpart was alive with no obvious abnormality, except for its rather 
small size (45 g) at Day 75 (see table 2.1., 2.2 and Fig 2.3.a.)   
Even though placentomes seemed generally larger in the cloned gestations, no significant 
difference in large medium and small placentomes was found between treatment groups, 
although one cloned gestation had placentomes six standard deviations larger than the mean 
control placentomes (see table 2.1., 2.2 and Fig 2.3.b). However, we should keep in mind that 
sampling and categorization by size was somewhat subjective.  Because of the amputation of the 
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75 of gestation, we were unable to count all placentomes.  Nevertheless, there were clearly fewer 
placentomes when very large ones were present. 
Interestingly, the mean weight to length ratio (g/cm) of the umbilical cord was 
significantly greater for clones (table 2.2, fig 2.3.c).  Mean weights of heart, brain, liver, kidneys 
did not differ between groups (table 2.1).  Neither did organ/bodyweight and the brain/liver 
indexes.  However, numbers per group were limited, and the cloned population is very 
heterogenous (table 2.2, Fig 2.3 a, b, c).   
Also, when removing the three cloned twin gestations from the data set, findings were only 
altered slightly (table 2.1).  When the physical measurements were evaluated by fetal sex, 
ignoring treatment, only the brain weight stood out as different, with males having heavier brains 
than females at this point in gestation (P < 0.08 with twins, P < 0.07 without twins).  When the 
weight of the largest placentome of the gestation was correlated with fetal weight, length and 
liver weight, positive correlations with p-values of r = 0.45 (P = 0.09), r = 0.50 (P = 0.06) and r = 
0.27 (P = 0.34) were found when including twins; excluding twins the following p-values were 
obtained r = 0.82 (P = 0.004), r = 0.77 (P = 0.01) and r = 0.93 (P < 0.0001), respectively.   
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Table 2.1 Physical Measurements of gestational tissues collected on day 75 of gestation 
 Controls (N=5) 
(Mean  SEM) 
Clones (N=10) 
(Mean  SEM) 
P 
variance 
w/o Twins (N=5) 









2.41  0.24 
0.86  0.13 
0.18  0.03 
 
4.25  0.98 
1.23  0.19 






3.25  0.43 
1.08  0.22 








Fetal weight (g) 
 
59.5  2.23 
 









Fetal length (mm) 
 
129  5.63 
 






























2.33  0.07 
 











0.48  0.07 
 











0.34  0.06 
 











2.48  0.09 
 








       






























+ 1 SD (65.3) 
 
Very large placentomes 
 
 
+ 6 SD (9.9) 
 
- 1 SD (0.30) 
39 1 D, 1 S - 2 SD (45.4) 38 placentomes in one horn only  
 
< 1 SD (2.6) + 2SD (0.48) 
49 1 S - 2 SD (50.2) Gravid horn: wart-like placentomes; 
non-gravid horn: regular placentomes 
but poorly vascularized 
 
< 1 SD (2.3) + 1 SD (0.44) 
31 1 L + 2 SD (69.5) Large placentomes 
 
+ 2 SD (4.0) + 1 SD (0.46) 
82 2 N < 1 SD (58.9) Normal placentomes 
 
< 1 SD (1.9) + 2 SD (0.63) 
54 1 S - 2 SD (47.1) Normal placentomes 
 
< 1 SD (2.4) + 1 SD (0.42) 
29 1 N < 1 SD (63.9) Uterus: size of twin pregnancy, lots of 
allantoic fluid, large placentomes, non 
gravid horn, few placentomes 
 
+ 1 SD (3.2) + 2 SD (0.51) 
79 1 L + 2 SD (73.7) Large placentomes + 2 SD (4.4) + 1 SD (0.44) 
 
a
 Number of standard deviations from controls. 
b 
L=large, S=small, D=death, N=normal, for twins,  




































































Figure 2.3 Means, standard errors and range of physical measurements in day 75 placentomes.  
Boxed numbers are recipient numbers (see table 2.2.). 





Our population of cloned embryos has previously been shown to result in gestational 
abnormalities typically observed with cloning.  Field data from the company Granada 
International show that about 10% of these frozen, cloned embryos develop to term.  Embryos 
from the same source were used by Garry et al. (1996) and resulted in 73 cloned calves, many of 
which were severely abnormal metabolically.  In another study in our laboratory, seven 
recipients were flushed nonsurgically 8 days after transfer.  From these, 3 of 14 (21%) embryos 
transferred were recovered and appeared to be developing normally (Seidel et al., 1997).  
Seventy more of these day-7 cloned embryos were thawed and transferred; 13 (19%) appeared 
normal ultrasonographically at 4 weeks of gestation.  However there was a linear attrition up till 
day 70, and only 5 (7%) went to term (Seidel et al., 1997).  In the present study, we also 
demonstrated severe gestational loss.  Initially, more than 75% failed.  And from the cloned 
gestations alive at 30 days (22.5%), we lost another half by day 60 (11.3%).  Around day 35 is 
when placentation becomes imperative for gestational survival in the cow (Thompson & 
Peterson, 2000).  At that point organogenesis is completed, and the embryo is now a fetus; its 
further growth and development can no longer be supported by histotroph or vascularized yolk 
sac nutrition.  Therefore hemotrophic nutrition becomes essential (Melton et al., 1951; 
Thompson & Peterson, 2000; De Sousa et al., 2001).  If the primitive establishment of 
placentomes fails at this time, gestational death will follow.  This has been well documented in 
cloning experiments by Stice et al., 1996; Peterson & McMillan, 1998 and Thompson & 
Peterson, 2000.  Therefore, we suspect that most of the lost gestations seen in this experiment 
between days 30 and 60 were probably caused by severely impaired placentation.  The vital 
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pregnancies that we collected at day 75 all had placentomes established.  However, in one twin 
pregnancy, cotyledons were absent on the gestational sac of the dead fetus, and no caruncles 
were seen in that horn of the uterus; the other horn contained 38 placentomes and a viable, but 
small fetus.  As described in table 2.2., many macroscopic aberrancies such as large 
placentomes, irregularly shaped, wart-like placentomes, and pale, poorly vascularized 
placentomes were observed.   This is an early indication of high variability in cloned gestations.  
If gestation would have continued, some of these placentae would most likely have caused fatal 
pathologies manifesting either later in gestation (e.g. hydroallantois) or perinatally (e.g. 
edematous placenta with impaired oxygen transfer to the fetus).  
  Besides the large variance in fetal weight, only one fetus (#54) seemed to have 
macroscopically abnormal organs in that these seemed jellied even though the fetus was alive.  
To our knowledge, this has not been reported in the literature previously.   
The one gestation with a fetus that died at day 55 did not abort by day 75, but why is 
unknown.  Somehow the allantoic but not the amniotic fluid had jellified.  This prevented 
separation of the placentomes into cotyledons and caruncles and might have prevented uterine 
prostaglandin release, luteolysis and abortion.   
Of extreme interest is the observation of enlarged umbilical cords so early in gestation.  
Anecdotal reports of huge umbilical cords at birth in clones are numerous.  Many times, if not 
taken care of surgically at birth, the umbilical will rupture at birth causing perinatal death due to 
exsanguination.  Thus far, no explanation has been offered for this phenomenon.  Molecular 
research on vascular and other growth factors and the functional role of Wharton’s jelly are 
imperative for elucidation of this problem.   
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None of the mean organ weights or organ/bodyweight ratios differed between controls 
and clones; however, numbers were limited in this study.  Also the brain/liver index did not 
deviate between treatment groups.  When an embryo is nutritionally deprived, organs such as the 
liver will grow relatively smaller in comparison with the brain, which will be normal in size; this 
probably involves a brain saving mechanism. Day 75 might be too early in gestation to see 
energy depriviation effects.   
Fetal sex did not seem to affect our findings.  It has been shown previously that fetal 
gender has no effect on cotyledon weight, cotyledon area, placental weight (Prior & Laster, 
1979).  In a study by Szuba et al. (1988), no statistically significant differences between male 
and female fetuses in weight and length were revealed.  Hubbert et al. (1972) showed that as 
fetal weight increased, the changes in organ weight: fetus weight ratio varied between organs.  
Organ weights did not significantly differ for breed or sex differences at respective fetal ages.  
Certain organs maintained a relative constant relationship with fetal weight throughout the fetal 
period (heart 0.8%, pancreas 0.07%, spleen 0.3%), while other organs changed in relation to fetal 
weight by 50 % or more.  Interestingly, we observed a tendency to heavier brains in males at this 
point in gestation independent of treatment.  When twins were excluded from the data set, a high 
positive correlation between size of the largest placentome and fetal weight, length and liver 
weight was observed, regardless of treatment.  Early data on fetal growth and placental 
development indicated that birth weight depends primarily on fetal growth rate, and is highly 
correlated with placental weight (Alexander, 1964).  Interestingly, (Sinclair et al., 1997, 1998) 
found that overgrowth of cloned fetuses at term was not associated with larger placentae.  
However, at Day 75 of gestation, larger placentomes supported larger fetuses, both in control and 
cloned pregnancies.  It makes sense that twin pregnancies bias this finding since placentomes 
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from these gestations actually have to support 2 fetuses.   Most likely, the larger liver size is a 
consequence of the larger fetal size. 
We conclude that there is marked attrition in cloned pregnancies between day 30 and 75 
of gestation.  Placentation appears necessary to support fetal growth at day 75. Placentomes from 
clones were not enlarged significantly at this point of gestation, but aberrancies in morphology 
and vascularization were observed.  This is the first study identifying enlarged umbilical cords of 
cloned pregnancies as early as Day 75 of gestation; in contrast, cloned fetuses and their organs 
were not enlarged in this study. These observations support the hypothesis that abnormal 

















CHAPTER III: PLACENTAL AND FETAL LIVER EXPRESSION OF INSULIN-LIKE 





Recent scientific breakthroughs in nuclear transplantation with fetal and adult somatic 
cells highlight the need to investigate associated gestational and neonatal anomalies such as 
excessive abortion rates, hydroallantois lethal to the recipient, stillbirth, high birth weights and 
metabolically abnormal neonates (Willadsen et al., 1991; Behboodi et al., 1995; Wilson et al., 
1995; Garry et al., 1996; Walker et al., 1996; Kruip & den Daas, 1997; Garry, 1999; Farin et al., 
2001; Bertolini & Anderson, 2002).  Findings of abnormal placentation in the first trimester 
(Stice et al., 1996; Peterson & McMillan, 1998; Thompson & Peterson, 2000) and morphological 
abnormalities of placentation at birth such as an edematous placenta, few but very large 
placentomes, and pale, poorly perfused placentomes (Farin & Farin, 1995; Garry et al., 1996) all 
infer a genetically or epigenetically abnormal placenta, and may explain much of the attrition 
and pathologies of nuclear-cloned pregnancies. The placenta has a pivotal role in transfer of 
essential substrates between the mother and the fetus and is responsible for mediating and/or 
modulating the maternal environment.  Abnormal expression of one or more genes almost 
certainly is the cause of the abnormal pregnancies described.   
Insulin-like growth factors (IGF's) are amongst the logical candidate genes for aberrant 
expression in cloned pregnancies. IGF-1 and IGF-2 and their receptors and binding proteins are 
involved with transport and metabolism of glucose and other carbohydrates and lipids.   The IGF 
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system has especially profound effects on cell proliferation and differentiation during fetal 
development; its control over placental growth has been confirmed by gene deletion studies in 
mice (Baker et al., 1993).  IGF-2 is secreted in large quantities in the fetus (Hossner et al., 1997) 
and serves as a constant signal for growth in fetal circulation (McCusker, 1998); there is also 
considerable expression of IGF-2 in the placenta throughout gestation (Wathes et al., 1998).  
More recently, Young et al. (2001) described a correlation between epigenetic modifications in 
the ovine IGF2R gene and fetal overgrowth in IVF gestations.  IGF2R is maternally imprinted to 
be inactive.  The imprinting process seems vulnerable to environmental effects that can 
deregulate methylation patterns and result in abnormal phenotypes (Reik et al., 2001).   
Despite the abundance of information on placental function, data on the expression and 
interactions of IGF’s and their binding proteins during early bovine gestation and in placentas 
and fetuses derived from cloning and IVF are scarce, and no convincing explanation of the 
molecular cause of the observed abnormalities is available. Based on our data of lower IGF-1 
and IGF-2 concentrations in arterial blood of late- term clone fetuses (Garry et al., 1998), and the 
publication of Blondin et al. (2000) indicating a 2 fold rise in IGF-2 levels in the fetal liver of 
IVF pregnancies at day 70 of gestation, we collected tissues after hysterectomy of Day 75 control 
and nuclear-cloned bovine pregnancies.  In a previous study with nuclear transfer embryos from 
the same origin, we identified that most recipient cows pregnant at day 70, would carry 
pregnancies to term (Seidel et al., 1997).   Day 75 bovine pregnancies have a fully functional 
placenta.  By this time point, gestational losses due to embryonic failure or severely 
underdeveloped placentation have been eliminated.  However in these pregnancies stillbirth, 
hydroallantois, dystocia or perinatal morbidity still occur frequently.   
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In this study we evaluated relative mRNA concentrations for the insulin-like growth 
factor family; IGF-1, IGF-2, IGF1R, IGF2R, IGFBP1, IGFBP2, IGFBP3, by means of real time 
RT-PCR in the fetal cotyledon and maternal caruncle of large placentomes, and the fetal liver of 
day 75 cloned and control gestations.   
 
 
MATERIALS AND METHODS 
 
RNA isolation 
Total cellular RNA was isolated from frozen tissues (-80
o
C) previously collected, (cfr. 
Chapter 2)  by means of the RNeasy Maxi Kit (Qiagen, Valencia, CA).  To disrupt cells, frozen 
tissues were ground under LN2 using a mortar and pestle.  One gram of powdered tissue was 
subsequently added to a lysing buffer (RLT) containing 4M guanidium isothiocyanate and 0.1M 
-mercaptoethanol and homogenized with a rotor-stator homogenizer for 45-90 sec.  An equal 
volume of 70% ethanol was then added to the lysate, creating conditions that promote selective 
binding of RNA to the RNeasy membrane in the spin column.  After centrifugation, total cellular 
RNA was bound to the membrane, contaminants were washed away, and RNA was eluted in 
RNase-free water.  DNase digestion was not required since the RNeasy silica membrane 
efficiently removes the DNA.  To concentrate the RNA eluates, we added 1/10
th
 volume of 8M 
LiCl and 2.5x volumes of ice cold 100% EtOH and mixed these thoroughly.  This mixture was 
chilled for 20 min at –80
o
C, and subsequently centrifuged for 15 min at 10,000 x g at 4
o
C.  
Supernatant was removed, and the pellet was dissolved at the desired concentration.  To evaluate 
the concentration and quality of the isolated tcRNA, a 1 g aliquot of each sample was separated 
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by gel electrophoresis on a denaturing formaldehyde gel as per instructions of the manufacturer 
(NorthernMax kit, Ambion, TX).  Samples were electrophoresed at 75 volts initially; once the 
samples had migrated out of the wells, the voltage was increased to 100V.  Electrophoresis 
continued until the bromophenol blue dye front had migrated three quarters of the length of the 
gel.  To evaluate the tcRNA integrity, the gel was exposed with UV light and photographed.  If 
the RNA was not degraded, the 18S and 28S ribosomal bands were distinct and sharp without 
smearing. 
 
Oligonucleotide primer design for real time PCR 
β-actin primer design was based upon the cloned sheep cDNA sequence provided by 
R.V. Anthony (Colorado State University).  The 5’ primer was GGGACCTGACCGACTACC 
and the 3’ sequence was GACAGCGAGGCAGGATGG.  This resulted in a 519 bp cDNA with 
an annealing temperature of 55
o
C, corresponding to bp 634-1152 of complete coding sequence of 
the ovine beta actin mRNA (accession number gi 2182268). 
IGF-1 primer design was based upon the published sequence of bovine mRNA for the 
insulin-like growth factor I (accession number X15726).  The 5’ primer was 
CACATCCTCGCATCTCTT, and the 3’ primer was TTGAGAGGCGCGCAGTACATC.  This 
resulted in a 260 bp cDNA with an annealing temperature of 57
o
C, corresponding to bp 78-338 
in the protein coding sequence. 
We designed two primer sets for IGF-2.  The first set was used to identify IGF-2 in the 
fetal liver.   The 5’ primer sequence was ACTTCAGCCGACCATC CAGCC, and the 3’ primer 
sequence was TCAGCGGACGGTGACTCTTGG.  This corresponds to bp 66-389 of the partial 





C.  Because of unclear results with the above mentioned primers in the 
cotyledon and caruncle, we designed a new set of primers.  This 5’ primer sequence was 
CGGCGGGGAGCTGGTGGA and the 3’ primer sequence was TGGCGGGGGTGGCACAGT.  
This corresponds to bp 13-179 of the same coding sequence with an optimal annealing 
temperature of 61
o
C.   
Primers for the IGF1R were based upon the published sequence of bos taurus mRNA for 
the insulin-like growth factor I receptor (accession number X54980).  The 5’ primer 
GCTGTAACCATGAGGCTGAGA and 3’ primer AGAGCGATCAGGTGGAT correspond to 
bp 1038-1517 of the protein coding sequence creating a 405 bp cDNA with an annealing 
temperature of 60
o
C.   
IGF2R primer design was based upon the coding sequence of bovine cation independent 
mannose 6-phosphate receptor protein (accession numbers J03527, M15869).  The resulting 5’ 
primer GTGCCGTGGATAAGAATG and the 3’ primer CTGCCTGGGAGTCAAAGA gave a 
291bp cDNA with an optimal annealing temperature of 56
o
C, corresponding to bp 1792-2065 of 
the protein coding sequence.   
We also evaluated amounts of mRNA for the IGFBP’s.  The primer sequences for BP 1 
through 3 were provided by B. De Vrijer (Health Sciences Center, Denver, CO).   
The 5’ GCCCATCCTCTGGAATGC and 3’ TTGTTGCAGTTTGGCAGAT primer 
sequences were derived from the bovine IGFBP-1 sequence (accession number X54979).  For 
IGFBP-2 the 5’ primer GCGAGGGCACTTGCGAA
*
A and 3’ primer 
CTTGCCCATCTGCCGGTGCTG were based upon the ovine IGFBP-2 sequence (accession 
number S44612).  However, we had to modify one nucleotide (
*
) in the 5’ primer since the 
published Bos taurus BP2 sequence indicated a mismatch.  The IGFBP-3 primers were designed 
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from the bovine mRNA sequence for IGFBP-3 (accession number M76478).  The 5’ primer was 
CTCAGAGCACAGACACCCA and the 3’ primer GGCATATTTGAGCTCCAC.  Resulting 
cDNAs were 180 bp, 233 bp, and 335 bp long, respectively; optimal annealing temperatures 
were 57, 62 and 57
o
C, respectively.   
 
Reverse transcription 
After tcRNA isolation of the tissues as described above, 2.5 g of tcRNA quantified by 
spectrophotometry and gel electrophoresis, was reverse transcribed to synthesize first strand 
cDNA for PCR by use of the Superscript TM First-Strand Synthesis System for RT-PCR 
(Invitrogen, Carlsbad, CA).  The tcRNA, 0.5mM dNTP, 0.5g Oligo(dT)12-18 and DEPC-
treated water were mixed and incubated for 5 min at 65
o
C and placed on ice for 1 min.  A 
mixture of 5 mM MgCl2, 0.01mM DTT and 40 units of RNaseOUT recombinant RNase inhibitor 
in a final volume of 20 l (20mM Tris-HCl (pH 8.4), 50mM KCl) was added and incubated for 2 
min at 42
o
C.  Finally, 50 units of Superscript II RT were added and the reaction was incubated 
for 50 min at 42
o
C.  The reaction was terminated at 70
o





Real Time PCR 
For each gene of interest: IGF-1, IGF-2, IGF1R, IGF2R, IGFBP-1, -2, -3, and β-actin, we 
determined the optimal annealing temperature of the specific primers empirically by 
conventional PCR over a gradient of annealing temperatures.  cDNA was generated by RT from 
cotyledon, caruncle or liver mRNA, as described above.  A 50 μl PCR reaction consisted of 2l 
of this RT product, water, 2.5 U Taq polymerase, and appropriate volumes of the following to 
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obtain concentrations of 20 mM Tris-HCl (pH 8.0), 50 mM KCl, 1.5mM MgCl2, 0.2 mM dNTP 
mix, and 0.2 M of each primer.  The reaction was then overlayed with 20 μl mineral oil.  
Subsequently, four vials of 50 l of PCR product were generated by conventional PCR under 
optimal conditions, pooled and electrophoresed on a 1% agarose gel, and purified by QIAquick 
Gel Extraction Kit (Qiagen, Valencia, CA) following the instructions of the manufacturer.   
The cDNA product from the PCR reaction was sequenced at our University 
Macromolecular Resources Center by use of the specific primers, or cloned into a vector and 
sequenced by means of the T3 and T7 promotors (PCR-ScriptTM Amp Cloning Kit, Stratagene, 
La Jolla, CA).  Purified amplicon was serially diluted over a 10ng/μl – 10
-10
ng/μl range, for 
standard curve purposes. 
To determine intra- and interassay variation, 10 parallel reactions were run with the same 
cDNA (intra-assay) and the same cDNA was run in 10 independent assays (interassay) 
(Leutenegger et al., 2001; Bertolini et al., 2002).  Each assay was evaluated by determination of 
amplification efficiency on standard curve DNA dilutions, correlation coefficients, and melting 
curve analysis.  Because of the good reproducibility, one assay was run per transcript, provided 
that the correlation coefficient of the standard curve was ≥ 0.99.   
 
The initial lightcycler run was used to determine the optimal MgCl2 concentration, and 
the optimal range of standards for both cotyledon and caruncle.  Final Mg
2+
 concentrations of 
1,2,3,4 and 5 mM were evaluated with 2l of RT cDNA in Lightcycler-DNA Master SYBR 
Green I ready-to-use mix for PCR, which contained Taq DNA polymerase, reaction buffer, 
dNTP mix, SYBR Green I dye and MgCl2 (Roche, Mannheim, Germany), 0.5M of each primer, 
0.16l anti-Taq antibody and water to obtain a 20l reaction volume.  For example, a reaction 
was cycled 45 times with a 95
o
C denaturation step for 0 sec, a 60
o





C extension step for 20 sec with slopes of 20
o
C/s each.  The number of cycles necessary 
depends on the abundance of template copy number; the annealing temperature is dependent on 
the primer sequence; and the length of the extension phase depends on the length of the amplicon 
with 1 sec / 25 bp.  Fluorescence was measured at the end of the extension phase.  The melting 













After identification of the optimal conditions for PCR for each gene of interest, initial 
concentrations of mRNA were determined in the cotyledon and caruncle of five control and eight 
cloned day 75 pregnancies. Every lightcycler run included a negative control in which template 
was replaced by water, 5 standard samples with known concentrations, and the respective 
samples of day 75 cotyledons and caruncles.  All genes of interest were evaluated from the same 
batch of RT product generated for each tissue sample.  Quantification data was analyzed using 
the Lightcycler analysis software.  Background fluorescence was removed by setting a noise 
band.  The standard curve was prepared as described above, and by determining the intersection 
point (expressed as the cycle number) of an amplification signal on the standard curve, the initial 
template concentration could be derived. Values were normalized with those generated for β-
actin. 
The specificity of the amplification reactions detected with SYBR Green I dye was 
determined by performing a melting curve analysis.  The products of a PCR reaction can be 
melted by increasing the temperature of the sample.  At the Tm of the product, a sharp reduction 
in the level of fluorescence is seen.  Non-specific products tend to melt at a much lower 




The cDNA generated from each real time PCR reaction was also separated on a 1% 
agarose gel with EtBr to verify product specificity by Southern blotting.  After gel 
electrophoresis, the gel was exposed to UV light and photographed.  Subsequently, the DNA was 
denatured by soaking the gel in 1.5 M NaCl/0.5 M NaOH for 1 hour, neutralizing in 1M Tris (pH 
8) /1.5M NaCl for 1 hour, and capillary transferring to Zetabind nylon membrane (CUNO 
Laboratory Products, Meriden, CT) overnight by upward capillary transfer using 10X SSC as the 
transfer buffer. After transfer, the membranes were rinsed 5min in 6X SSC to remove salt and 
agarose and cross-linked by UV irradiation. Membranes were wrapped in Saran wrap and stored 
at –20
o
C until hybridization. 
The membranes were prehybridized in 15 ml of prehybridization buffer containing 50% 
formamide, 5X Denhardt’s solution, 6X SSPE, 1% SDS, 200g/ml herring sperm DNA and 
50g/ml yeast t RNA, for 5 hours to overnight at 42
o
C.  After incubation, the matching cDNA 
fragment (519bp β-actin, 260 bp IGF-1, 323bp IGF-2, 405bp IGF1R, 291bp IGF2R, 180bp 
IGFBP1, 233bp IGFBP-2, 335bp IGFBP-3 ) was random prime labeled (Amersham Pharmacia 
Biotech, Little Chalfont, Buckinghamshire, England or Ambion, Austin, TX) with [-
32
P-
deoxycytidine-5’-triphosphate (ICN Pharmaceuticals, Costa mesa, CA) to a specific activity 1 x 
10
8
 cpm/g DNA.  Radiolabeled cDNA was denatured by boiling for 5 min followed by 5 min 
on ice, and then added to the prehybridization solution at 2 x 10
6
 cpm/ml.  After overnight 
hybridization at 42
o
C, the hybridization buffer was discarded, and the membranes were rinsed 
for 15 min at room temperature in 2X SSC/0.1% SDS, 15 min at 42
o
C in 2X SSC/0.1% SDS, and 
twice for 30 min in 0.1X SSC/0.1% SDS at 60
o
C to remove non-specifically bound probe.  
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Membranes were then exposed to radiographic film (Sterling
TM
 Brand X-Ray Film, Life Science 
Products, Denver, CO) until sufficient band intensity was established for analysis. 
 
Data analysis 
For quantitative analysis of real time PCR data, the initial template concentration of the 
target mRNA was directly derived from its measured fluorescence signal and the standard curve.  
Relative levels of mRNA for the gene of interest within each sample were calculated as a ratio of 
the initial template concentration of the gene of interest to the initial β-actin concentration of the 
sample.  Values are expressed as mean arbitrary units ± standard error of the mean (SEM).   
Due to the low number of samples and non normality, we analyzed data by the non-parametric 
Wilcoxon rank sum test.  We compared treatment groups (controls vs. clones) for the cotyledon, 
caruncle of large placentomes and for the liver.  To evaluate whether twin effects confounded 
our findings, we also analyzed data leaving out the measurements from twin pregnancies.  
Preliminary least-squares analyses of variance indicated no significant effects of sex of fetus or 
twinning for any response.       
Furthermore, since fetal sexes were reasonably balanced in both clones and controls, sex 
of fetus was ignored in the analyses presented.  Equality of variances was evaluated by 2 tailed 
F-tests.  Amounts of mRNA transcripts were also compared in the cotyledon vs. the caruncle 
within treatment groups.  Pearson correlation coefficients were determined among all mRNA 
signals from all genes and fetal weight, placental weight, liver weight and umbilical cord 







Relative gene expression patterns in the cotyledon and caruncle 
In cotyledons and caruncles, levels of IGF-1 mRNA were low, about 100- fold less than 
β-actin.  There was significantly less IGF-1 mRNA in cotyledons of control pregnancies (P < 
0.05) compared to clones.  In caruncles, however, no such difference was observed (tables 3.1, 
3.2, 3.3, Fig. 3.1a).  However, the variance was significantly more variable in clones in both 
cotyledons and caruncles (P = 0.03; P = 0.0003).   
IGF-2 mRNA levels were high in cotyledons with concentrations similar to the amount of 
β-actin mRNA copies.  In contrast to IGF-1, IGF-2 mRNA was higher in controls than clones, 
although of borderline significance (P = 0.065).  In the caruncle, levels were 10 fold less IGF-2 
mRNA for both clones (P < 0.001) and controls (P < 0.001) (tables 3.1, 3.2, 3.3, Fig 3.1b).  In 
caruncles, variances for IGF-2 mRNA were significantly more variable in clones (P = 0.026).   
mRNA levels for the IGF1R were quantified in both parts of the placentome, the cotyledon and 
caruncle; concentrations of mRNA were 100-fold less than β-actin.  The cotyledons of four day 
75 cloned pregnancies had a weak signal for IGF1R and showed double peaking in the melting 
curve.  When the real time PCR products were evaluated by EtBr gel and Southern blotting, very 
faint signals for these samples were observed in comparison with others (table 3.1, 3.2, Fig 3.1c).  
When mRNA concentrations for the IGF2R were measured, a trend towards higher 
concentrations of mRNA for IGF2R in control cotyledon was observed (P = 0.9).  Copy numbers 
were about 10-fold less abundant than β-actin, and there was slightly more IGF2R message in the 




mRNA for the IGFBP’s 1, 2 and 3 was measured in cotyledons, caruncles and fetal livers 
of Day 75 pregnancies. IGFBP-1 transcripts were scarce in the placentome, 1000 fold less than 
β-actin.  In the cotyledons of two pregnancies, one control and one clone, there was a double 
peak in the melting curve.  This was manifest by two PCR products on an EtBr stained gel.  The 
very low concentrations might be nearing the limits of the sensitivity of the assay.  When twin 
pregnancies were left out, a tendency to higher levels of BP-1 mRNA in the caruncles of control 
pregnancies was observed (P = 0.056). IGFBP-2 mRNA copy levels in cotyledons and caruncles 
also were very low.  In caruncles, message for BP-2 was substantially (10 fold) higher in control 
pregnancies than in most cloned pregnancies (P = 0.02), regardless of twinning. 
The most abundantly expressed gene of those studied in both cotyledons and caruncles 
was IGFBP-3.  mRNA concentration for BP-3 was 10-fold higher than β-actin in the placentome.  
No significant differences were observed between treatment groups, nor were gender effects 
observed. 
When considering the hierarchy of mRNA abundance in cotyledons, BP-3 was the most 
abundant, 10-fold higher than for IGF-2 and β-actin.  IGF2R transcripts were present about 10 
fold less than β-actin, and IGF-1, IGF1R, BP-1 and BP-2, 100-fold less.  In caruncles BP-3 
transcripts were again the most abundant, 10 fold more than β-actin.  For the IGF2R, mRNA 
content was about 10-fold less, and for IGF-1 and -2 there was about a 100-fold less of these 
gene products in comparison to β-actin.  For IGF1R, there was a 1000-fold difference in the 
number of mRNA molecules compared to β-actin, while BP-2 and BP-1 message is very low, 







Table 3.1 Relative mRNA concentrations of IGF family genes in cotyledons 
 (n=5)  w/ twins (n=8)  w/o twins (n=5) 
Gene mean cont (SE)  mean clone (SE) Pmean Pvar  mean clone (SE) Pmean Pvar 
β-actin 282.98 (40.61)  281.33 (36.89) 0.72 0.83  295.02 (59.42) 1.00 0.48 
IGF1/Act 0.012 (0.003)  0.020 (0.0086) 0.03 0.03  0.034 (0.007) 0.016 0.13 
IGF2/Act 1.45 (0.16)  0.97 (0.14) 0.065 0.89  1.02 (0.13) 0.095 0.70 
1R/Act  0.0086 (0.0013)  0.0044 (0.002) 0.13 0.23  0.0063 (0.003) 0.55 0.16 
2R/Act  0.10 (0.015)  0.071 (0.0076) 0.09 0.29  0.063 (0.009) 0.095 0.36 
BP1/Act 0.0025 (0.0006)  0.020 (0.016) 0.72 <0.0001  0.0033 (0.0009) 1.00 0.53 
BP2/Act 0.0032 (0.0015)  0.023 (0.02) 0.94 <0.0001  0.0033 (0.0024) 1.00 0.40 
BP3/Act 8.21 (1.22)  8.18 (0.92) 0.95 0.85  7.51 (1.04) 1.00 0.77 
 
 
Table 3.2 Relative mRNA concentrations of IGF family genes in caruncles 
 (n=5)  w/ twins (n=8)  w/o twins (n=5) 
Gene mean cont (SE)  mean clone (SE) Pmean Pvar  mean clone (SE) Pmean Pvar 
β-actin 227.4 (56.98)  245.13 (49.53) 0.83 0.90  177.4 (28.02) 0.84 0.0002 
IGF1/Act 0.054 (0.0048)  0.13 (0.04) 0.13 0.0003  0.17 (0.06) 0.10 0.04 
IGF2/Act 0.12 (0.016)  0.17 (0.04) 0.4 0.026  0.21 (0.06) 0.31 0.024 
1R/Act  0.01 (0.0016)  0.0091 (0.0016) 0.4 0.76  0.0098 (0.0024) 0.69 0.50 
2R/Act  0.32 (0.067)  0.21 (0.057) 0.28 0.94  0.17 (0.02) 0.15 0.04 
BP1/Act 0.0075 (0.0025)  0.0033 (0.0008) 0.13 0.05  0.0024 (0.0009) 0.056 0.08 
BP2/Act 0.011(0.0021)  0.004 (0.0013) 0.02 0.51  0.0034 (0.0012) 0.03 0.30 
BP3/Act 14.92 (1.9)  13.1 (1.4) 0.62 0.78  14.77 (1.5) 1.00 0.63 
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Table 3.3 Probabilities of mean differences in mRNA content of cotyledons vs. caruncles within 
treatments. (includes twin data) 
 
 
 Controls   Clones  
Gene P-value (cot/car)  P-value (cot/car)  
IGF1/Act  0.008* (<)  0.03* (<)  
IGF2/Act  0.008* (>)  < 0.001* (>)  
1R/Act  0.54 (=)  0.13 (=)  
2R/Act  0.056 (<)  < 0.001* (<)  
BP1/Act 0.032* (<)  0.96 (=)  
BP2/Act  0.032* (<)  0.44 (=)  
BP3/Act 0.032* (<)  0.015* (<)  























controls    clones    controls    clones




















controls    clones         controls    clones




















controls    clones      controls    clones























controls    clones      controls    clones















Figure 3.1 Median, 25-75
th
 percentile and ranges of mRNA concentrations for IGF-1 and IGF-2 
and their receptors in day 75 placentomes.  
Boxed numbers are recipient numbers (see table 2.2)   
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Figure 3.2 Median, 25-75
th
 percentile and ranges of mRNA concentrations for the IGFBP’s in 
day 75 placentomes.   
Boxed numbers are recipient numbers (see table 2.2.)  
* P < 0.05 
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Relative mRNA concentrations in fetal liver 
In day 75 fetal livers, IGF-1 mRNA levels were a 1000-fold less abundant than β-actin, 
and no differences were seen between fetuses from cloned or control pregnancies (table 3.4). 
IGF-2 mRNA levels were high in the liver, at the same relative concentration as β-actin mRNA.  
Fetal livers from cloned pregnancies contained more (3-4 fold) IGF-2 mRNA than controls, 
whether twin gestations were taken into consideration or not (P = 0.008 vs.  P = 0.019). 
In contrast to the placentome, IGFBP-1 mRNA was abundant in the fetal liver and 
expressed at the same level as β-actin.  IGFBP-2 mRNA was also found in the liver, in relative 
abundance at about 10-fold less than β-actin.  mRNA concentration for IGFBP-3 was high in 
fetal liver, at the same level of expression as β-actin.   
Considering the overall hierarchy of abundance for the genes of interest in the fetal liver, 
BP-1, BP-3 and IGF-2 transcripts were present in similar amounts as β-actin, BP-2 about 10 fold 













Table 3.4 Relative mRNA concentrations of IGF family genes in the liver 
 
 (n=4)  w/ twins (n=8)  w/o twins (n=5) 
Gene mean cont (SE)  mean clone (SE) Pmean Pvar  mean clone (SE) Pmean Pvar 
β-actin 569.75(69.76)  576 (70.63) 1.0 0.19  519.8 (65.8) 0.73 0.97 
IGF1/Act 0.0008 (0.0002)  0.0008 (0.0001) 0.93 0.26  0.0007 (0.0001) 1.0 0.46 
IGF2/Act 0.24 (0.03)  0.8 (0.29) 0.008 0.0014  1.01 (0.44) 0.03 0.0008 
BP1/Act 0.87 (0.2)  0.95 (0.14) 0.57 0.82  0.92 (0.16) 0.41 0.84 
BP2/Act 0.037 (0.014)  0.078 (0.022) 0.21 0.22  0.079 (0.033) 0.41 0.14 



























































































































Figure 3.3 Median, 25-75
th
 percentile and ranges of mRNA concentrations for the genes of the 
IGF system in day 75 fetal liver.  
Boxed numbers are recipient numbers (see table 2.2.) 




Correlation analyses between and within physical and molecular traits 
Correlation coefficients were calculated using all data and by treatment to evaluate 
whether different trends existed for each group. Interestingly, clones occasionally revealed 
correlation coefficients with an opposite sign (negative vs. positive or vice versa) in comparison 
to controls.  It was of utmost importance to graph the data, since distortion sometimes occurred 
due to outlier effects.  These outlier effects were mostly due to extreme variability of cloned 
gestations.  In controls, a positive correlation was observed between largest placentome weight 
and cotyledonary IGF-2 mRNA (r = 0.90, P = 0.03), while the correlation was opposite in clones 
for these traits (r = -0.81, P = 0.015).  Because of the low numbers, correlations were usually not 
significant in the control group.  A positive correlation between cotyledonary BP-3 and IGF-2 
content was observed in clones, pooled data, and controls, (r = 0.75, P = 0.03; r = 0.65, P = 
0.016;  r = 0.8, P = 0.1, respectively).  No significant correlation coefficients were observed 
between umbilical cord weight length ratio and gene expression levels in the fetal liver. 
 
Individual gestations 
Four pregnancies, numbers 61, 39, 49 and 31, had very faint signals for IGF1R mRNA in 
cotyledons.  The singleton cloned pregnancy number 79 had the largest fetus (+ 2SD) and largest 
fetal liver as well as large placentomes (+ 2SD) and a slightly enlarged umbilical cord (+1SD).  
Fetal liver mRNA concentrations for this pregnancy were extremely high for IGF-2, BP-1, BP-2 
and BP-3; IGF-1 mRNA content on the other hand was normal.  In the placentome, in contrast, 
this gestation had very high concentrations of mRNA for IGF-1 and IGF1R in caruncles.  Clone 
39, a twin gestation with one dead and one live conceptus, has very high IGF2R mRNA but low 
IGF1R mRNA in caruncles.  Clone 61 had aberrant mRNA concentrations for multiple genes.    
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The cotyledon had increased mRNA for the BP1, BP2 (10 -fold) and PLGF genes; 
however, IGF-2 and IGF1R mRNA levels were low in the cotyledon.  This twin pregnancy had 
the largest placentomes (+6SD) in the study, and both fetuses were relatively large (+ 1SD).  
However, the umbilical cord of one of the fetuses was the smallest one of the clones.  mRNA for 
BP-3 was very low in the caruncles of this pregnancy.  Unfortunately, livers were not saved for 





In vitro manipulations of bovine embryos have been associated with detrimental 
consequences during gestation.  Abortion rates are above 50% early in gestations resulting from 
cloning, and further pregnancy attrition occurs throughout gestation at higher than normal rates.  
Despite the abundance of information on placental function, data on the expression and 
interactions of IGF’s and their binding proteins after implantation in natural bovine gestations 
and in cloned or IVF placentas and fetuses is scarce, and no convincing explanation of the 
molecular cause of observed abnormalities is available. In this study, we evaluated if 
disturbances in the pattern of gene expression in the IGF system could be detected in the 
placentomes and fetal liver of nuclear transfer clones.  
 
Insulin-like growth factor 1 
In the ewe, Reynolds et al. (1997) found that uterine IGF-1 mRNA levels were low 
following implantation, highest in the maternal stroma surrounding the uterine glands (although 
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this declined during early pregnancy), and undetectable in the caruncles after fetal villus invasion 
(Reynolds et al., 1997).    Fetal placental tissues did not hybridize for IGF-1 mRNA (Reynolds et 
al., 1997).  These findings suggest that local IGF-1 production might not be important in 
placental development (Reynolds et al., 1997).  Also, in IGF-1 knockout mice (Baker et al., 
1993), placental growth is normal.  In this study we also found IGF-1 mRNA levels to be 
relatively low in both cotyledon and caruncle.  However, in cotyledons of cloned pregnancies, 
relative mRNA for IGF-1 was double (P = 0.03) that of controls.  The fetal livers produced little 
IGF-1 mRNA, and no difference was observed between clones and controls.  If IGF-1 production 
is indeed upregulated, then one wonders what its paracrine effect on placental development 
might be, since both IGF-1 and IGFBP-1 stimulate trophoblast proliferation in early human 
pregnancy (Hills et al., 1999).  
 
Insulin-like growth factor 2  
Our studies revealed relatively high amounts of IGF-2 mRNA in the cotyledon, at a 
similar level to the housekeeping gene β-actin.  In the caruncle, levels were about 10 fold less.  
There was a trend towards reduced IGF-2 mRNA in the cotyledon of the cloned pregnancies (P = 
0.065).  However, livers of cloned fetuses produced 3-4- fold higher concentrations of IGF-2 
mRNA than controls.  IGF-2 is secreted in large quantities in the fetus (Hossner et al., 1997) and 
serves as a constant signal for growth in the fetal circulation (McCusker, 1998); there is also 
considerable expression of IGF-2 mRNA in the placenta throughout gestation (Reynolds et al., 
1997; Wakayama et al., 1998; Wathes et al., 1998).  In early gestation, IGF-2 mRNA is most 
abundantly expressed at the invading front of intermediate trophoblast in the anchoring villi, 
stimulating migration through the IGF2R and MAPK pathway (Han et al., 1996; Hamilton et al., 
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1998; McKinnon et al., 2001).  In late human pregnancy, IGF-2 is found mainly at the 
syncytiotrophoblast (Han et al., 1996).  Surgical reduction of placental size in sheep causes 
intrauterine growth retardation and is accompanied by an increase of maternal plasma IGF-2 
(Jones et al., 1988).   In preeclampsia in humans, increased IGF-2 mRNA is found in 
trophoblasts of peri-infarct regions, suggesting a role for IGF-2 in placental repair or remodeling 
(Gratton et al., 2002).  In human diabetic pregnancies, fetuses receive a large influx of glucose; 
this may stimulate expression of IGF-2 in the placenta, resulting in higher utilization of glucose 
and overgrowth of the placenta (Shen et al., 1986). 
Genetically engineered mice heterozygous for a disrupted IGF-2 allele showed a 40% 
growth deficiency at birth (DeChiara et al., 1990).  Fetal overabundance of IGF-2, by disruption 
of the IGF-2/M6PR, causes fetal overgrowth and perinatal lethality in mice (Filson et al., 1993; 
Lau et al., 1994).  IGF-2 also possesses local growth promoting effects in fetal tissues, as 
demonstrated in H19 null mice (Eggenschwiler et al., 1997) in which pups were 30% overgrown 
at birth, and IGF-2 was only elevated in tissues, not in circulation.   
When Constancia et al. (2002) abolished the IGF-2 promotor (P0) transcript in mice, a 
marked reduction in IGF-2 signal was observed specifically in the labyrinth trophoblast of the 
mutant placentae.  The absence of the P0 transcript of the IGF-2 gene resulted in 30% reduction 
of placental and fetal weights near term.  Therefore, eliminating this IGF-2 transcript exclusively 
from the placenta has a profound growth retarding effect.  Mutant placentae had the same 
morphological organization as wild type, but volume fraction determinations were proportionally 
smaller for all areas.  Reduction of organ size - with exception of the brain – was largely 
proportionate.  Therefore, the IGF system seems to coordinate growth effects (demand and 
supply) on organ systems, suggesting that brain growth is apparently independent of nutritional 
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demand and supply (Reik et al., 2001) and/or that a preferential distribution of nutrients towards 
the brain exists. 
Because of the observed growth restriction later in gestation in this knockout, a 
reasonable hypothesize is that lack of IGF-2 transcript affects placental function via the supply of 
nutrients.  Either placental size became limiting for fetal growth only at later stages of gestation, 
or at earlier stages of gestation, the smaller placenta compensated by increased efficiency of 
nutrient transfer.  To evaluate placental transport, Constancia et al. (2002), tested the P0 
knockout model by placental function assays.  They concluded that reduced fetal size can be the 
outcome of reduced supply or reduced demand.  And, that the mouse IGF2 gene is remarkable in 
combining the control of both supply and genetic demand for maternal nutrients in a single gene!   
In humans and mice, fetal overgrowth can result from altered expression of several imprinted 
genes (H19, IGF-2, IGF2R).  For example, in the human Beckwidth Wiedemann Syndrome, the 
mechanism of overgrowth is induced by the loss of imprinting and overexpression of IGF-2 
(O’Dell & Day, 1998).  In sheep, on the other hand, in vivo fertilized embryos that were cultured 
in vitro for 5 days with co-cultured granulosa cells and/or serum before transfer into ewes, led to 
interesting results after embryo transfer; 25% of the fetuses were defined as large offspring (LO), 
and IGF-2R expression was reduced by 30-60% in these LO fetuses (Young et al., 2001).  Then 
again, in cattle at day 70 of gestation, Blondin et al. (2000) found that fetuses originating from in 
vitro production systems possessed higher levels of IGF-II mRNA in the liver and a trend to 
lower levels in skeletal muscle.  Different results were obtained by Schrader et al. (2003), who 
compared differential gene expression of two day 45 cloned bovine fetal livers to the original 
nuclear transfer cell donor day 45 fetal liver.  IGF-2-specific primers used in the RT-PCR 
reaction did not reveal differential expression in these livers.   
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From this information we might conclude that IGF-2 can act both in a paracrine and 
endocrine function.  Even though the underlying cause for overexpression of IGF-2 mRNA by 
the fetal liver of clones is unknown, this presence of extra IGF-2 in fetal circulation might affect 
placental development. Perhaps the cotyledon expresses less IGF-2 for paracrine action in clones 
in a compensatory way.   
 
Insulin-like growth factor receptors 
In day 75 cloned and control gestations, placentomal IGF1R mRNA was low, 10- fold 
less than the IGF2R.  Interestingly, four cloned pregnancies had only a very faint signal in the 
cotyledon in comparison with other clones and controls.  Bovine placental membranes contain 
both type 1 and type 2 IGF receptors, while there is a preponderance of type 1 receptor in 
humans and type 2 in sheep (Van Buul-Offers et al., 1988). Term placentas from pregnancies 
complicated with intrauterine growth retardation have significantly higher levels of IGF-2 and 
IGF1R expression; this may represent a counter regulatory mechanism in response to the growth 
retardation (Abu-Amero et al., 1998).  Since IGF2R receptor mainly acts as a scavenger of IGF-
2, most growth effects of IGF-2 are mediated by the IGF1R.  In the placenta it remains a 
conundrum why local IGF-2 mRNA expression is abundant but IGF1R mRNA is rather scarce; 
this raises questions about which receptor binds the local IGF-2.  McKinnon (2001) suggested 
that human trophoblast migration is mediated by the IGF2R – MAPK pathway.  However, strong 
evidence from murine knockout studies raises the question of the existence of an unknown XR.  
In vitro studies with human placental tissues have indicated the presence of an unknown, high 
affinity IGF receptor, XR, with equal affinity for IGF-1 and –2, and only slightly less affinity for 
insulin (Hintz et al., 1984).  LeRoith and others (1995) detected IGF1R discrepancies in 
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molecular mass and antibody neutralizing binding activity, and therefore suggested the existence 
of another receptor.  IGF-1 or IGF1R murine knockouts have little effect on placental weight, 
while IGF-2 knockout of the paternal allele in mice severely diminishes placental development 
(Baker et al., 1993).  The placentas of murine IGF-2/IGF1R double mutants were equally 
affected by growth retardation as seen in the IGF-2 single mutants.  Four of our eight cloned 
conceptuses had extremely low concentrations of mRNA for the IGF1R gene; this might be a 
compensatory mechanism against the high levels of fetal IGF-2 in circulation.  If the XR exists, 
and it has been suggested that this is the insulin receptor A (IR-A) (Vella et al., 2002), then 
maybe this XR is upregulated in the cotyledon of these gestations. 
IGF2R mRNA copies were present in the placentome, about 10-fold more than the 
IGF1R.  No differences in relative amounts of mRNA for these genes were observed between the 
treatment groups.  One twin pregnancy (#39) featured a 3 fold higher level of IGF2R mRNA.  In 
this gestation, one dead fetus occupied one horn deprived of placentomes; therefore, the other 
fetus was supported by few placentomes.  One would expect lower levels of the scavenger 
receptor, unless the IGF2R mediates IGF-2 induced trophoblast invasion as suggested by 
McKinnon (2001).   
 
Insulin-like growth factor binding proteins 
All IGFBP’s studied so far are synthesized either in the uterine luminal epithelium or in 
underlying subepithelial stromal cells.  This suggests that the IGFBP’s are important for 
regulating transfer of IGF-1 and –2 between fetal and maternal compartments (Wathes et al., 




IGFBP-1 transcripts are scarce in the placentome, 1000 fold less than the housekeeping 
gene β-actin.  In the cotyledons of two gestations, one control and one clone, BP-1 was barely 
detectable.   When twin pregnancies were left out, a tendency to lower levels of BP-1 mRNA in 
the caruncles of cloned pregnancies was observed (p=0.056).  On the other hand, one cloned 
pregnancy (#61) with the largest placentomes revealed 15 fold higher BP-1 and BP-2 mRNA in 
cotyledons in comparison to cotyledons of all other clones and controls, a finding confirmed by a 
repeated measurement. 
Phosphorylated IGFBP-1 inhibits metabolic actions of IGF-1 on trophoblast cells in vitro.  
Conversely, non-phosphorylated BP-1 has the opposite effect, enhancing IGF activity (Yu et al., 
1998).  IGFBP-1 stimulates trophoblast proliferation in early human pregnancy (Hills et al., 
1999).  The BP-1 gene has putative progesterone response elements that mediate endometrial 
stromal cell BP-1 gene expression early in gestation (Crossey et al., 2002).  Therefore, migration 
of first trimester human invasive trophoblast in vitro is stimulated by IGFBP-1, likely by 
interaction with the RGD-binding site of the 51-integrin (Irving & Lala, 1995).  Gleeson et al. 
(1999), furthermore indicated that IGFBP-1 seems to stimulate extravillous trophoblast 
migration and invasion by signaling through 51-integrin, leading to signal transduction via 
FAK and MAPK.   
IGFBP-1 also increases the activity of gelatinases and tissue inhibitor of 
metalloproteinase 1 (TIMP-1) in first trimester cytotrophoblastic cells independently of IGF-1 
(Bischof et al., 1998). Even though IGFBP-1 is abundant in baboon uteri during implantation, 
this is not the case in ruminants (Tarantino et al., 1992; Han et al., 1996).  This might be 
explained by the fact that IGFBP-1 appears to facilitate trophoblast penetration of the maternal 
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interface, a much more invasive process in primate vs. ruminant placental development 
(Tarantino et al., 1992; Wathes et al., 1998).   
Crossey et al. (2002) modeled the effects of excess IGFBP-1 on fetoplacetal growth in 
transgenic mice overexpressing human IGFBP-1.  As explained in a comment by Regnault et al. 
(2002b), their findings need cautious interpretation, since it is important to keep in mind that no 
IGF binding proteins are expressed in the deciduas of wild-type rodents, only in the 
myometrium.  In mice, however, BP-1 - like actions may be ascribed to decidual alpha 2 
macroglobulin, which can bind IGF’s (Han & Carter, 2000).  In the BP-1 overexpression model, 
Crossey et al. (2002) found marked effects early in pregnancy such as early placental failure.   
Effects on later placental development seemed rather minimal since normal term placental and 
fetal weights were obtained, suggesting that other factors may overcome the initial BP-1 related 
deficiencies (Regnault et al., 2002b).  In conclusion, Crossey et al. (2002) found that excess 
decidual BP-1 was associated with increased placental mass (mainly in the labyrinth zone).  
Placental IGF-2 expression was unchanged, but IGF-2 bioavailability at the fetomaternal 
interface might have been altered.  In this study phosphorylated BP-1 predominated, which 
would suggest reduced IGF bioavailability.  In the placentomegaly of the transgenic dams, 
trophoblast invasion of the decidualized endometrium was less pronounced.  Crossey et al. 
(2002) suggested the following potential explanatory mechanisms: BP-1 excess might attenuate 
trophoblast invasion and proliferation as a consequence of reduced local IGF bioavailability.  
Alternatively, reduced IGF might influence trophoblast differentiation, perhaps favoring growth 
of noninvasive over invasive trophoblast lineages.  On the other hand, BP-1 may have direct 
IGF-independent effects on trophoblast invasion.  Irwin & Giudice (1998) reported that BP-1 
inhibited trophoblast invasion of endometrial stromal cells in vitro.  In contradiction, however 
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Gleeson et al. (2001) showed increased trophoblast invasion in response to BP-1.  Both studies 
show that these effects are mediated through binding of BP-1 to α5β1 integrin.  In comparison 
with IGF-2 deficient mice, in both cases spongiotrophoblast cells account for a greater 
proportion of the junctional zone.  However, in the IGF-2 null mice, placental mass is reduced, 
whereas there is a large increase in labyrinthine zone, and therefore an increase in placental mass 
in IGFBP-1 mutants.  The exchange functions of the rodent placenta are largely confined to the 
labyrinthine zone.  Thus, compensatory changes in fetal vascularization could result in an 
increase in labyrinthine tissue volume. 
 DeVrijer et al. (2002) studied fetal gene expression in a placental insufficiency - 
intrauterine growth retardation (PI-IUGR) model. With ribonuclease protection assays, they 
found fetal liver IGFBP-1 to be upregulated in the model, but no significant differences were 
seen for IGF-1, IGF-2 and IGFBP-3 prior to maximal growth.  
Apparent controversy exists about the function of BP-1.  Phosphorylated BP-1 inhibits 
IGF-1 action; dephosphorylation favors it.  Opposing in vitro results on the IGF independent 
effect on trophoblast proliferation and invasion have been published (Irwin & Giudice, 1998; 
Gleeson et al., 2001), and what happens in a mouse overexpression model is not necessarily 
transposable to other species.  However, our clone twin pregnancy (#61) that was largely 
overexpressing BP-1 and BP-2 mRNA in the cotyledon had the largest placentomes, 6 standard 
deviations higher than the mean placentomal size of the controls.  This pregnancy however also 
featured the lowest IGF-2 mRNA levels in the cotyledon and the lowest IGF-1 mRNA levels in 
the caruncle.  The umbilical cord of one of the fetuses had the lowest weight/length ratio in our 




IGFBP-2 mRNA concentrations were low in day 75 placentomes.  It is, however, 
remarkable that cloned caruncles had a 10 fold lower BP-2 mRNA concentration in comparison 
with controls (P = 0.02). From day 29 on in ovine gestation, IGFBP-2 is exclusively detected in 
the dense caruncular-like stroma underlying the luminal epithelium (Reynolds et al., 1997).  This 
finding agrees with a previous study by (Delhanty & Han, 1992), which showed IGFBP-2 was 
present in close proximity to IGF-2 in rapidly proliferating tissues.  Plasma concentrations of 
BP-2 were higher in somatic cell cloned cattle immediately after birth (Chavatte-Palmer et al., 
2000; Matsuzaki & Shiga, 2002). 
We found message copy number for IGFBP-3 mRNA to be extremely high in the day 75 
placentome, 10 fold higher than the housekeeping gene, β-actin.  IGFBP-3 is a major carrier of 
IGF’s in circulation.  In pregnant ewes, IGFBP-3 is present in the caruncles, endometrial stroma, 
placentome capsule and some allantochorion (Reynolds et al., 1997).  Remarkably high levels of 
IGFBP-3 mRNA were localized to maternal blood vessel walls of the caruncles in the region of 
fetal villi penetration (Reynolds et al., 1997).  This might be important in regulation of placental 
blood flow and in the rate of transfer of IGF-1 and –2 from the maternal circulation to the uterus 
(Wathes et al., 1998).  It is important to remember that both IGF-1 and –2, when complexed to 
IGFBP-3, cannot cross the placental epithelium (Bar et al., 1990).  There is a strong correlation 
of IGF-1 and IGFBP-3 serum levels with birth weight as well as placental weight (Osorio et al., 
1996).  Serum from pregnant women and rats contains a placental protease that cleaves IGFBP-
3, reducing its affinity for IGF’s (Davenport et al., 1992; Han & Carter, 2000).  The liver of day 






We did not observe any gender effects, most likely due to the small number of 
individuals per treatment group.  Two out of five control fetuses were female and three out of 
eight cloned fetuses were female.  Removing twins from data analyses, did not have a major 
effect on means or P-values.  Removing twin data increased the P-value for IGFBP-1 mRNA 
concentration in the caruncle from P = 0.13 to P = 0.056. 
 
Correlations 
  In controls a positive correlation was observed between weight of the largest placentome 
and cotyledonary IGF-2 mRNA concentration (r = 0.90, P = 0.03).  Interestingly, this 
relationship was reversed in clones (r = -0.81, P = 0.015).  A trend towards a negative correlation 
(r = -0.55, P = 0.077) was observed between IGF-2 mRNA levels in the fetal liver and cotyledon, 
and larger livers did express more IGF-2 mRNA (r = 0.63, P = 0.03).  Fetal liver weight also 
positively correlated with largest placentome weight if twins were excluded (r = 0.03, P < 
0.0001).  In conclusion, this means that when the weight of the largest placentome goes up, liver 
weight and liver IGF-2 mRNA follows this trend; however, in clones this will lead to a decrease 
in cotyledonary IGF-2, but an increase in controls.  If placentome size in clones is aberrant, then 
the decrease in cotyledonary IGF-2 mRNA is probably an indication of a homeostatic effort.  
This might also be the explanation why a positive correlation between IGFBP-3 and IGF-2 
mRNA was observed in the cotyledon of clones, since BP-3 has a high affinity for IGF-2, which 
was overexpressed by the fetal liver. 
When considering two populations, controls and clones, we observed numerous 
differences and trends in aberrant gene expression in the IGF system.  When we paid close 
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attention to individual gestations, it was clear that the clones in this data set are very 
heterogenous, with extremes in both directions for mRNA of certain genes and physical 
measurements. 
In conclusion, even though these day 75 gestations survived embryonic death and were 
able to develop a vascularized placenta, aberrancies in the gene transcription of the insulin-like 
growth factor system were observed.  These underlying variations in gene expression, may well 



















CHAPTER IV: mRNA FOR VASCULAR ENDOTHELIAL GROWTH FACTOR FAMILY 





Development of an adequate placental blood supply is imperative for normal fetal growth 
and developmental rates (Barcroft & Barron, 1946; Rosenfeld et al., 1974; Reynolds, 1986; 
Reynolds et al., 1987).  About 40 days after conception in cattle, placental functioning becomes 
a sine qua non, since hemotrophic exchange of substrates from the mother to the fetus is 
mediated by the placenta, an organ in which the fetal and maternal circulation are brought into 
close apposition.  During the process of placentation, fetal chorionic villi invade the maternal 
crypts.  New blood vessels sprout and branch abundantly, forming a complex structural 
architecture.  This process is induced and controlled by complex interactions among numerous 
angiogenic factors.  Moreover, growth and remodeling of the placental vascular beds takes place 
throughout gestation in correspondence with increasing rates of uterine and umbilical blood flow 
as well as fetal oxygen and nutrient uptake (Rosenfeld et al., 1974; Reynolds, 1986; Reynolds et 
al., 1987).  The underlying mechanism of control of this vascular architecture is delicately 
balanced, and can easily be disrupted by environmental stressors (e.g. hypoxia) which induce 
structural adaptations in an attempt to enhance the capacity for exchange (Penninga & Longo, 
1998).     
In gestations from in vitro produced embryos, numerous problem related to abnormal 
placentation have been published.  Parturition is frequently lengthy, lacking normal signs of 
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impending birth or pronounced uterine contractions (Avery & Greve, 1995).  In the last 
trimester, the incidence of hydroallantois is about 1% for pregnancies from IVF (1,376 
pregnancies) (Hasler, 1998), about 10 fold higher than with conventional reproduction, and is 
accompanied by a very high rate of mortality among recipient cows. Furthermore, at birth, 
cotyledons from cloned pregnancies often are edematous, and intercotyledonary areas are 
thickened with a gelatinous-like material at parturition (Garry et al., unpublished).  Enlarged 
umbilical vessels, edematous membranes, and a greater than usual allantoic volume also were 
observed by Wells et al. (1999).  In the first trimester, Peterson & McMillan (1998) observed 
impaired allantoic development and vascularization in 24% of in vitro derived embryos at day 
25.  Allantochorion colonizes the maternal caruncles between day 20 to 35 (Melton et al., 1951) 
so that growth restriction during this period can limit numbers of placentomes.  Later in 
pregnancy, size and morphology rather than number of placentomes are affected (Melton et al., 
1951).   
 
Nuclear transfer pregnancies from pluripotent embryonic cell lines were all lost before 60 
days of gestation in one study (Stice et al., 1996).  These fetuses developed through 
organogenesis (by day 42); however, a deficiency in placentome development occurred where 
cotyledons and villi were absent, and a hemorrhagic response was noted in the caruncles void of 
crypts, indicating a maternal response, but aberrant fetal interaction (Stice et al., 1996). Abortion 
in the first trimester coincides with timing of normal placentome formation.  These data infer a 
genetically or epigenetically abnormal placenta, and we believe that aberrant placental 
development may explain much of the attrition and pathologies of nuclear-cloned pregnancies.   
Our objective was to compare gene expression for the vascular endothelial growth factor 
system in nuclear-cloned and control day 45 and day 75 bovine pregnancies.  Up to day 30, 
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embryonic loss is not related to placentation.  Tissue collection at day 45 should provide insight 
in primitive placentation.  In a previous study with nuclear transfer embryos from the same 
origin, we determined that most recipient cows pregnant at day 70, would carry pregnancies to 
term (Seidel et al., 1997). By this time point, gestational losses due to embryonic failure or 
severely underdeveloped placentation have been eliminated.  However, in these pregnancies 
stillbirth, hydroallantois, dystocia or perinatal morbidity still occur, and this usually seems 
related to placental pathology.  Therefore, although day 75 placentas might be grossly normal, 
underlying molecular abnormalities may be present.  Basic information in this area can be 
applied to reducing the huge amount of pregnancy attrition in cloning and in vitro fertilization 
gestations, as well as provide information to decrease the substantial incidence of fetal and 




MATERIALS AND METHODS 
 
RNA isolation 
Total cellular RNA was isolated from frozen tissues (-80
o
C) previously collected, (cfr. 
chapter 2) by means of the RNeasy Maxi Kit (Qiagen, Valencia, CA) as described in detail in 
chapter 3.   
 
cDNA preparation for Northern Blotting 
Ovine VEGF cDNA specific for mRNA encoding for the VEGF120 isoform (exons 1-5 
and 8) was kindly provided by D.A. Redmer (Redmer et al., 1996).  Ovine PlGF cDNA was 
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kindly provided by T. Regnault (University of Colorado Health Sciences Center) and ovine -
actin cDNA was previously cloned by R.V. Anthony (Colorado State University).  Each cDNA 
was digested from respective vectors and separated from plasmid DNA in a 1% (w/v) agarose 
gel.  The cDNA was then isolated from the gel by binding to DEAE cellulose membrane 
(Schleicher and Schuell NA45, Keene, NH), and was recovered by the methods outlined by the 
manufacturer.  Purified cDNA concentration was determined by spectrophotometry absorbance 
at 260 nm and agarose gel electrophoresis and stored at –20
o
C until radiolabeled. 
 
Oligonucleotide primer design for PCR 
Primers for β-actin were designed as described in chapter 3.  Primers designed for the 
VEGFR1 (Flt-1) were based upon the cloned ovine cDNA sequence from T. Regnault 
(University of Colorado health sciences center), and the published inside primers from the nested 
design from Redmer et al. (1996).  This 5’ primer sequence was CAGCGCACGGCAG TGATA 
and the 3’primer sequence was CCGCAGTAAAATCCAGGTAA.  This corresponds to bp 1518-
1779 (262 bp) of the complete coding sequence of human Flt-1 mRNA (accession number 
AF063657).   
Primers for VEGFR2 (KDR) were based upon the cloned ovine cDNA sequence and the 
primers designed by T. Regnault (University of Colorado health sciences center).  The 5’ primer 
ATTTATGATG TGGTTCTGAG and 3’ primer GGGATTGGTAAGGATGAC correspond to 
bp 1038-1517 of the complete coding sequence human KDR mRNA (accession number 
AF035121), creating a 479 bp cDNA with an annealing temperature of 58
o
C. 
VEGF primers were designed based upon the published sequence for bovine VEGF 
(accession number M32976) by means of the Oligo program.  The primers were designed to fall 
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within the exon 1-5 region, since this section of the coding sequence is present in all isoforms.  
The 5’ primer TACCCAGATGAGATTGAGTTC falls within exon 3 and the 3’ primer 
CTGGCTTTGGTGAGGTTTGAT falls within exon 4, creating a 153bp cDNA with an 
annealing temperature of 52.4
o
C, corresponding to bp 735 – 887 of the published sequence. 
PlGF primer design was based upon the primers used to clone the ovine cDNA from T. Regnault 
(University of Colorado health sciences center), but corrected for sequence incongruency with 
the published bovine PlGF sequence (accession number AB004272).  The resulting 5’ primer 
TTCATCGGAGGTGGAAGTGG falls within the coding sequence, and the 3’primer 
CTGAGAACGTGACGGTAATA falls within the 3’untranslated region, creating a 415bp cDNA 
with an optimal annealing temperature of 55.4
o
C, corresponding to bp 410 – 824 of the published 
sequence. 
VEGF-B primers were designed from the published sequence of bos taurus mRNA for 
vascular endothelial growth factor B186 precursor, partial coding sequence (accession number 
AB004274) with 93% sequence homology to the human vascular endothelial growth factor B 
(VEGFB), mRNA (accession number NM003377).  The resulting 5’ primer 
GTGGTGGTGCCCCTGAAC and 3’ primer GAGTGGAAGCCCTGTCTG created a 268bp 
cDNA with an optimal annealing temperature of 61
o
C, corresponding with bp 114-381 of the 
published sequence. 
All primers were prepared by One Trick Pony Oligos (Ramona, CA). 
 
Northern Blotting 
Northern analyses for VEGF, PlGF and β-actin mRNA were performed on 15 g samples 
of tcRNA electrophoresed in a 1% (w/v) agarose, 1M formaldehyde and 1X MOPS gel 
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(NorthernMax, Ambion, Austin, TX).  For day 45 pregnancies, allantochorion and cotyledons 
from 4 control and 6 cloned pregnancies, and for day 75 pregnancies, caruncles and cotyledons 
from 5 controls and 8 cloned pregnancies were evaluated.  After electrophoresis, the separated 
RNA was transferred to Zetabind nylon membrane (CUNO Laboratory Products, Meriden, CT) 
by means of downward capillary action for 1.5 hours using transfer buffer (NorthernMax, 
Ambion, Austin, TX).  After transfer, the membranes were rinsed briefly (10 sec) in MOPS to 
remove salt and agarose, and cross-linked by UV irradiation.  To evaluate efficiency of transfer, 
RNA integrity and even loading, the membranes were placed in 5% acetic acid for 10 min, and 
then stained 10 min with 0.04% methylene blue (Sigma Chemical, St. Louis, MO) in 0.5 M 
sodium acetate, pH 5.2.  Destaining was performed with DEPC-treated water until the 18S and 
28S ribosomal bands were clearly distinguished.  Membranes were wrapped in Saran wrap and 
stored at –20
o
C until hybridization. 
The membranes were prehybridized in 15 ml of Ultrahyb 
TM
 (Ambion, Austin, TX) in 
hybridization tubes in a roller hybridization oven at 42
o
C for at least 60 min.  Ultrahyb is a 
complete prehybridization/hybridization buffer, and it is not necessary to add any additional 
blocking agents.  The 409bp oPLGF, 479bp oVEGF, and the 519bp oβ-actin cDNA fragments 
were random prime labeled (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, 
England or Ambion, Austin, TX) with [-
32
P-deoxycytidine-5’-triphosphate (ICN 
Pharmaceuticals, Costa Mesa, CA) to a specific activity 1 x 10
8
 cpm/g DNA.  Radiolabeled 
cDNA was denatured by boiling for 5 min followed by 5 min on ice; it then was added to the 
prehybridization/ hybridization solution at 2 x 10
6
 cpm/ml.  Hybridization was carried out for 22-
24 hours at 42
o
C.  Thereafter, the hybridization buffer was discarded, and the blot washed 2 x 5 
min in 25 ml 2X SSC/ 0.1% SDS at 42
o





Membranes were then exposed to radiographic film (Sterling
TM
 Brand X-Ray Film, Life Science 
Products, Denver, CO) until sufficient band intensity was established.  Subsequently, membranes 
were exposed to a phosphorimager screen. Intensities of respective bands were quantified using 
phosphorimage analysis (ImageQuant, Molecular Dynamics, Sunnyvale, CA) and normalized 
relative to band intensities of β-actin to correct for differences of initial sample tcRNA amount. 
Results were used to quantify differences in mRNA content between clone and control day 75 
tissues.  Membranes were stripped of radiolabeled cDNA by incubation with boiling 0.5% SDS 
on a shaker for 30 min.  Subsequently membranes were hybridized with another 
32
P-labeled 
cDNA fragment following the same procedure as above. 
 
Reverse transcription – Real time PCR – Southern blotting 
 Techniques used are described in detail in chapter 3. 
 
Data analysis 
Northern blot data are expressed as relative band intensity and quantified by 
phosphorimage analysis (ImageQuant, Molecular Dynamics, Sunnyvale, CA), and data were 
analyzed by the Wilcoxon rank sum test (SAS institute, NC). 
For quantitative analysis of real time PCR data, the initial template concentration of the 
target mRNA was directly derived from its measured fluorescence signal and the standard curve.  
Relative levels of mRNA for each gene of interest within each sample were calculated as a ratio 
of the initial template concentration of the gene of interest to the initial β-actin concentration of 
the sample.  Values are expressed as mean arbitrary units ± standard error of the mean (SEM).   
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Due to the low sample number and non normality, we analyzed data by the non-parametric 
Wilcoxon rank sum test.  We compared treatment groups (controls vs. clones) within the 
cotyledon, caruncle of large placentomes and within the liver.  To evaluate whether twin effects 
confound our findings, we also analyzed data leaving out the measurements from twin 
pregnancies.  Preliminary least-squares analyses of variance indicated no significant effects of 
sex of fetus and twinning for any response.  Furthermore, since fetal sexes were reasonably 
balanced in both clones and controls, sex of fetus was ignored in the analyses presented.  
Equality of variances was evaluated by the 2 tailed F-test.  Amounts of mRNA transcripts in the 
cotyledon vs. the caruncle were also compared within treatment groups.  Pearson correlation 
coefficients were calculated to test relationships among all mRNA signals from all genes and 







Northern analysis of day 45 bovine allantochorion and cotyledon resulted in three 
transcripts of 3.7kb, 2.2kb and 1.7kb for VEGF and one 1.7 kb band for PlGF mRNA (figure 
4.1).  The 2.2 kb band of VEGF mRNA is very faint, while the 3.7kb band was the most 
prominent.  Both VEGF and PlGF mRNA were present, but no significant differences in mRNA 
concentration were detected between cloned and control tissues for day 45 allantochorion and 
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cotyledon respectively; data follow: VEGF 3.7 kb: P = 0.17, P=0.91; VEGF 2.2kb P = 0.48, P = 
not measurable; VEGF 1.7 kb P = 0.35, P = 0.35; PlGF 1.7 kb:  P = 0.61, P = 0.76.    
Subsequently, we detected VEGF and PlGF mRNA in bovine placentomes that were 
further advanced in development (day 75).  PlGF mRNA was barely detectable by Northern 
analysis at this stage, with the exception of the cotyledon of one clone (#61) which had a clear, 
distinguished band for PlGF.   In the day 75 placentome, all three VEGF bands were present, but 
shifts in concentration between the transcripts were observed.   Cloned pregnancies had less 
VEGF mRNA of the 3.7kb band (P = 0.0016) in the cotyledon than controls.  In the caruncles 
however, we could detect the 2.2kb VEGF mRNA band in most clones, but this band was hard to 




Figure 4.1 Northern blot analyses of VEGF and PlGF mRNA 
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Real time PCR   
We measured transcriptional activity for the VEGF, PLGF, KDR and Flt-1 genes in 
bovine placentomes of day 75 cloned and control gestations (tables 4.1, 4.2, 4.3; figure 4.2 a, b, 
c, d).  VEGF mRNA was fairly abundant in both cotyledons and  caruncles, while about a 
hundred fold less message for PlGF was detected; in caruncles a trend occurred in which cloned 
gestations had about half the amount of mRNA for PlGF in comparison to matching control 
gestations, including and excluding twins (P = 0.06, P = 0.056).  Interestingly, clone number 61, 
a twin pregnancy with extremely large placentomes (+ 6 SD) had about a 10 fold stronger than 
average signal for PlGF in the cotyledon in comparison with controls as well as other clones. 
PlGF signal for the caruncles of this pregnancy were normal. This is in agreement with our 
findings from Northern analysis.  As mentioned in chapter 3, this clone had very aberrant gene 
expression for multiple genes. 
The KDR receptor seems to be the primary receptor in the VEGF system in the 
placentome of bovine day 75 gestations.  In the cotyledon, the Flt-1 receptor was barely 
detectable, and was expressed a 100 fold less than the KDR receptor (table 4.1).  Both KDR and 
Flt-1 were more abundant in the caruncle than in the cotyledon (table 4.3).  Clone 29 had 10 fold 
more expression of Flt-1 mRNA than the average clone.  For Flt-1, it is important to mention that 
our primer set spans a region of the extracellular ligand binding domain present in the coding 
sequence for both the membrane bound and soluble form of Flt-1.  We detected VEGF-B mRNA 
expression in bovine placentomes by reverse transcription PCR.  No relative quantification by 
real time PCR was performed.   
Clones had a significantly higher variance for Flt-1 mRNA than controls in cotyledons, 
both when results from twin gestations were incorporated or not (P = 0.0035, P = 0.0017) (table 
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4.1).  One singleton cloned gestation (#29, see figure 4.2.d) had a Flt-1 mRNA concentration in 
the cotyledon 5-fold higher than others; this of course contributed to variability of the clone 
population. We also observed one cloned twin conceptus with extremely high concentrations of 
PlGF mRNA in cotyledons.  When twins were removed from the data set, the variance did not 
differ significantly from the control population.  This is an example of how individual 
pregnancies can exhibit statistical outlier behavior.  In the caruncle, PlGF mRNA concentration 
was 2-fold higher in controls versus clones, and variability was significantly higher in the control 
population; melting curves indicated that we neared detection limits, therefore preventing 
detection of variability in the clones. No significant correlations were observed between or 
within placentome and liver mRNA concentrations and weight measurements. 
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Table 4.1 Relative mRNA concentrations of VEGF family genes in day 75 cotyledons 
 
 (n=5)  w/ twins (n=8)  w/o twins (n=5) 
Gene mean cont (SE)  mean clone (SE) Pmean Pvar  mean clone (SE) Pmean Pvar 
VEGF 0.15 (0.03)  0.12 (0.02) 0.62 0.44  0.11 (0.02) 0.54 0.36 
PlGF 0.0063 (0.0022)  0.0095 (0.0046) 1.00 0.08  0.005 (0.0016) 0.69 0.51 
KDR 0.0072 (0.0034)  0.0087 (0.0013) 0.28 0.09  0.0072 (0.0014) 0.55 0.10 
Flt-1 3.9E-05 (1.3E-05)  0.0001 (6.1E-05) 0.21 0.0035  0.0002 (0.0001) 0.25 0.0017 
 
 
Table 4.2 Relative mRNA concentrations of VEGF family genes in day 75 caruncles 
 
 (n=5)  w/ twins (n=8)  w/o twins (n=5) 
Gene mean cont (SE)  Mean clone (SE) Pmean Pvar  mean clone (SE) Pmean Pvar 
VEGF 0.3038 (0.08)  0.27 (0.045) 0.72 0.38  0.21 (0.04) 0.84 0.15 
PlGF 0.0119 (0.0027)  0.0056 (0.0007) 0.06 0.016  0.0047 (0.0006) 0.056 0.011 
KDR 0.049 (0.017)  0.062 (0.014) 0.62 0.98  0.084 (0.01) 0.15 0.47 




Table 4.3 Probabilities of differences in mRNA concentration in cotyledons vs. caruncles within 
treatments (includes twins) 
 
 Controls   Clones  
Gene P-value (cot vs. car)  P-value (cot vs. car)  
VEGF 0.01* (<)  0.01* (<)  
PlGF 0.15 (=)  0.57 (=)  
KDR 0.01* (<)  0.01* (<)  
Flt-1 0.008* (<)  0.01* (<)  
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Figure 4.2 Median, 25-75
th
 percentile and ranges of mRNA concentrations for genes of the 










During placentation, new blood vessels sprout and branch abundantly, and growth and 
remodeling of the placental vascular beds takes place throughout gestation, corresponding to 
increasing rates of uterine and umbilical blood flow rate as well as fetal oxygen and nutrient 
uptake (Rosenfeld et al., 1974; Reynolds et al., 1987).  Secretion of angiogenic activity by 
bovine placental tissues was observed by Reynolds & Redmer, (1988).  In their study, coculture 
of placental tissue explants was mitogenic to bovine aortic endothelial cells (BAEC), but no 
angiogenic growth factors were identified.   
VEGF is a potent-endothelium specific mitogen with a key role in the induction of 
angiogenesis in the placenta (Cheung, 1997); it also is important in development, continuous 
remodeling and maintenance of placental vascular function during gestation.  Even though 
transcriptional activity for the VEGF family genes has been demonstrated in sheep placental 
tissues, this is the first such report in bovine placentomes (Cheung et al., 1995; Cheung & Brace, 
1998; Bogic et al., 2000, 2001; Regnault et al., 2002a).  Although VEGF and PlGF mRNA were 
present in day 45 bovine allantochorion and cotyledon, it may be too early to detect differences 
between clones and controls due to the primitive development of placentome microvilli at this 
stage.  At day 75 of bovine gestation, placentome development is well underway.  At this point 
in gestation, fetal villi infiltration into caruncular crypts has established a tight attachment of the 
cotyledon and caruncle within the placentomes surrounding the umbilical cord.   
Data obtained from Northern blot analyses in this study revealed less VEGF mRNA (3.7 
kb) in the cotyledons of day 75 clones than in controls, while more of the 2.2kb band was present 
in caruncles of clones than controls.  However, in our findings from real time PCR, no 
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significant differences in VEGF mRNA concentration were detected.  This discrepancy may be 
explained by the fact that our PCR primer set for VEGF generates a cDNA fragment that is 
present in all five splice forms of the VEGF gene.  Therefore, transcripts from differential 
splicing are not distinguished in this assay.  Northern analyses, in contrast, will separate 
transcripts by size and reveal information on differential splicing or mRNA protection.  Initially 
VEGF was identified as a potent permeability factor (VPF) (Senger et al., 1983; Connolly et al., 
1989).  Therefore VEGF might be involved in the regulation of amniotic fluid volume and 
composition (Cheung, 1997) and have a causative role in the manifestation of hydroallantois in 
the last trimester of gestation. 
Placental growth factor (PlGF) is another angiogenic factor expressed in the placenta 
(Maglione et al., 1991).  Ziche et al., (1997) have shown that PlGF can induce angiogenesis in 
vivo and stimulate migration and proliferation of endothelial cells in vitro.  PlGF appears to 
function in a paracrine manner on vascular endothelial cells in placental angiogenesis, and as an 
autocrine mediator of trophoblast function (Sherer & Abulafia, 2001).  Concentrations for PlGF 
mRNA were about a hundred fold less than for VEGF at Day 75.  In caruncles, cloned gestations 
only expressed about half the amount of mRNA for PlGF in comparison to matching control 
gestations both in twins and singletons (P = 0.06, P = 0.056), whereas PlGF mRNA 
concentrations in the cotyledon were unaltered.  If aberrant vascularization is developing, this 
finding may suggest a homeostatic response from the maternal component.  Interestingly, clone 
number 61, a twin pregnancy with extremely large placentomes (+ 6 SD), overexpressed PlGF 
mRNA in the cotyledon, while VEGF mRNA concentrations were within normal ranges.  In 
sheep, VEGF and PlGF mRNA concentration increases with gestational length (Regnault et al., 
2002a).  One could consider the placentomes in this particular gestation advanced in 
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development because of their size; twinning may have a similar effect.  However, one would 
then also expect VEGF mRNA to be more abundant.  No elevated levels of PlGF were observed 
in other cloned twin gestations.  Athanassiades et al. (1998) suggested that PlGF might act 
primarily on migration of trophoblast cells that express Flt-1.  Even though Flt-1 mRNA 
expression was not abnormally high in this gestation, the PlGF stimulatory effect on trophoblast 
migration might be the culprit for these abnormally large placentomes.  Therefore, we conclude 
that in this gestation, cloning induced overexpression of PlGF mRNA, and together with other 
aberrancies observed for gene expression levels in this gestation, contributed to a remarkable 
increase in placentome size.    
To evaluate our findings further, we quantified mRNA of the receptors for VEGF and 
PlGF (Flt-1 or VEGF1R and KDR or VEG2R).  VEGF interacts with both VEG1R and VEGF2R 
(Terman et al., 1992), while PlGF interacts only with VEGF1R (Park et al., 1994a).  Upon 
ligand binding, both receptors autophosphorylate and activate Ras pathways (Hanahan, 1997).   
VEGF2R seems to be the primary receptor in the VEGF system in the placentome of day 75 
bovine gestations.  Flt-1 appears to be the predominant receptor in human pregnancies, whereas 
in sheep, KDR is the major receptor (Cheung, 1997).  Bogic et al., (2001) could not detect Flt-1 
mRNA in sheep placentas or fetal membranes by methods of in situ hybridization.  However, 
Regnault et al. (2002a) did identify Flt-1 mRNA in sheep placentomes, and levels of mRNA 
were similar as for KDR mRNA.    
In the cotyledon, the VEGF1R was barely detectable and expressed 100-fold less than the 
KDR receptor.  Both VEGF2R and VEGF1R were more abundant in the caruncle than in the 
cotyledon.  VEGF2R appears to be required for the early development of the endothelial cell 
lineage and the mitogenic and chemotactic responses of endothelial cells, while Flt-1 may be 
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important for regulation of normal endothelial cell adhesion and interaction with the extracellular 
matrix (Bogic et al., 2001), and the maintenance of mature blood vessels (Waltenberger et al., 
1994; Fong et al., 1995; Dumont et al., 1995; Orbus, 1999).  In situ binding studies with 
recombinant VEGF in ovine placentas and fetal membranes suggest KDR plays a key role in 
maintaining vascularity and permeability (Bogic et al., 2001).  
Mice homozygously deficient for VEGF2R show failure of blood-island formation and 
vasculogenesis, and severe reduction in haematoangioblast progenitors and then endothelial 
cells; they die mid-gestation (Shalaby et al., 1995).  Embryos lacking the VEGF1R gene 
homozygously have normal hematopoietic progenitors and abundant endothelial cells that 
migrate and proliferate; however, there is a failure to assemble these cells into normal vascular 
cells (Fong et al., 1995).  For both knockouts, heterozygous mutants are essentially normal.  
Therefore, other genes or mechanisms seem to be able to correct aberrant levels of these 
receptors to a certain extent.  In one clone (#29) there were 10-fold higher concentrations of 
VEGF1R mRNA in the cotyledon.  This pregnancy seemed normal in other aspects, except for a 
large umbilical cord.      
In conclusion, since both VEGF and VEGF2R have the highest mRNA concentrations, 
they are most likely the primary modulators of placental vascularization at this early stage in 
placentation.  Subtle changes in gene expression of the VEGF system might exacerbate into an 








Abu-Amero SN, Ali Z, Bennett P, Vaughan JI & Moore GE (1998). Expression of the insulin-
like growth factors and their receptors in term placentas: a comparison between normal and 
IUGR births. Molecular Reproduction & Development 49, 229–235. 
Adams SO, Nissley SP, Handwerger S & Rechler MM (1983). Developmental patterns of 
insulin-like growth factor-I and -II synthesis and regulation in rat fibroblasts. Nature 302, 
150–152. 
Adams TE (2000). Structure and function of the type 1 insulin-like growth factor receptor. 
Cellular & Molecular Life Sciences 57, 1050–1093. 
Ahmed A & Perkins J (2000). Angiogenesis and intrauterine growth restriction. Best Practice & 
Research in Clinical Obstetrics and Gynaecology 14, 981–998. 
Ahmed A, Dunk C, Ahmad S & Khaliq A (2000). Regulation of placental vascular endothelial 
growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a 
review. Placenta 21, S16–S24. 
Ahmed A, Li XF, Dunk C, Whittle MJ, Rushton DI & Rollason T (1995). Colocalisation of 
vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors 
12, 235–243. 
Al Salami M, Simpson-Morgan MW & Morris B (1985). Immunology of the sheep. F. Hoffman-
La Roche and Co., Basle. 
Alexander G (1964). Studies on the placenta of sheep (Ovis aries L.): effect of surgical reduction 
in the number of caruncles. Journal of Reproduction & Fertility 7, 307–322. 
Amoroso EC (1952). Placentation. In: Parkes AS, ed Marshall’s Physiology of Reproduction  
London: Longmans Green and Co127–311. 
Anderson GB & Seidel GEJ (1998). Cloning for profit. Science 280, 1400. 
Athanassiades A, Hamilton GS & Lala PK (1998). Vascular endothelial growth factor stimulates 
proliferation but not migration or invasiveness in human extravillous trophoblast. Biology of 
Reproduction 59, 643–654. 
Atkinson DE, Robinson NR & Sibley CP (1991). Development of the passive permeability 
characteristics of the rat placenta during the last third of gestation. American Journal of 
Physiology 261, R1461–R1464. 
154 
 
Avery B & Greve T (1995). Apparent abnormalities of in vitro produced bovine embryos. In: 
Reproduction and Animal Breeding Advances and Strategy (eds G Enne, GF Greppi and A 
Lauria), Elsevier, Amsterdam171–183. 
Baguisi A et al. (1999). Production of goats by somatic cell nuclear transfer. Nature 
Biotechnology 17, 456–461. 
Baker J, Liu JP, Robertson EJ & Efstratiadis A (1993). Role of insulin-like growth factors in 
embryonic and postnatal growth. Cell 75, 73–82. 
Banks RE, Forbes MA, Searles J, Pappin D, Canas B, Rahman D, Kaufmann S, Walters CE, 
Jackson A, Eves P, Linton G, Keen J, Walker JJ & Selby PJ (1998). Evidence for the 
existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth 
factor receptor, Flt-1. Molecular Human Reproduction 4, 377–386. 
Bar RS, Boes M, Dake BL, Sandra A, Bayne M, Cascieri M & Booth BA (1990). Tissue 
localization of perfused endothelial cell IGF binding protein is markedly altered by 
association with IGF-I. Endocrinology 127, 3243–3245. 
Barcroft J & Barron DH (1946). Observations upon the form and relation of the maternal and 
fetal capillaries of the placenta of the rabbit. American Journal of Anatomy 94, 569–595. 
Barker DJP & Clark PM (1997). Fetal undernutrition and disease in later life. Reviews of 
Reproduction 2, 105–112. 
Barlow DP, Stoger R, Hermann BG, Saito K & Schweifer N (1991). The mouse insulin-like 
growth factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature 349, 
84–87. 
Bauer MK, Harding JE, Bassett NS, Breier BH, Oliver MH, Gallaher BH, Evans PC, Woodall 
SM & Gluckman PD (1998). Fetal growth and placental function. Molecular and Cellular 
Endocrinology 140, 115–120. 
Baxter RC (2000). Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and 
intrinsic bioactivities. American Journal of Physiology Endocrinology Metababolism 278, 
E967–E976. 
Behboodi E, Anderson GB, BonDurant RH, Cargill SL, Kreuscher BR, Medrano JF & Murray 
JD (1995). Birth of large calves that developed from in vitro-derived bovine embryos. 
Theriogenology 44, 227–232. 




Bermont L, Lamielle F, Fauconnet S, Esumi H, Weisz A & Adessi GL (2000). Regulation of 
vascular endothilial growth factor expression by insulin-like growth factor-I in endometrial 
cells. International Journal of Cancer 85, 117–123. 
Bertolini M & Anderson GB (2002). The placenta as a contributor to production of large calves. 
Theriogenology 57, 181–187. 
Bertolini M, Beam SW, Shim H, Bertolini LR, Moyer AL, Famula TR & Anderson GB (2002). 
Growth, development, and gene expression by in vivo- and in vitro-produced day 7 and 16 
bovine embryos. Molecular reproduction and development 63, 318–328. 
Bischof P, Meisser A, Campana A & Tseng L (1998). Effects of decidua-conditioned medium 
and insulin-like growth factor binding protein-1 on trophoblastic matrix metalloproteinases 
and their inhibitors. Placenta 19, 457–464. 
Bjorkman NH (1968). Fine structure of cryptal and trophoblastic giant cells in the bovine 
placentome. Journal of Ultrastructure Research 24, 249–258. 
Blondin P, Farin PW, Crosier AE, Alexander JE & Farin CE (2000). In vitro production of 
embryos alters levels of insulin-like growth factor-II messenger ribonucleic acid in bovine 
fetuses 63 days after transfer. Biology of Reproduction 62, 384–389. 
Bogic LV, Brace RA & Cheung CY (2000). Cellular localization of vascular endothelial growth 
factor in ovine placenta and fetal membranes. Placenta 21, 203–209. 
Bogic LV, Brace RA & Cheung CY (2001). Developmental expressionn of vascular endothelial 
growth factor (VEGF) receptors and VEGF binding in ovine placenta and fetal membranes. 
Placenta 22, 265–275. 
Breier G (2000). Angiogenesis in Embryonic development - A Review. Placenta 21, S11–S15. 
Bronsens IA, Robertson WB & Dixon HG (1973). The role of spiral arteries in the pathogenesis 
of preeclampsia. Obstetrical Gynecology Annual 1, 177–181. 
Van Buul-Offers S, Hoogerbrugge CM & de Poorter TL (1988). The bovine placenta: a specific 
radioreceptor assay for both insulin-like growth factor I and insulin-like growth factor II. 
Acta Endocrinologica 118, 306–313. 
Byrne AT, Southgate J, Brison DR & Leese HJ (2002). Regulation of apoptosis in the bovine 
blastocyst by insulin and the insulin-like growth factor (IGF) superfamily. Molecular 
reproduction and development 62, 489–495. 
Campbell KHS, Loi P, Otaegui PJ & Wilmut I (1996a). Cell cycle co-ordination in embryo 
cloning by nuclear transfer. Reviews of Reproduction 1, 40–46. 
156 
 
Campbell KHS, McWhir J, Ritchie WA & Wilmut I (1996b). Sheep cloned by nuclear transfer 
from a cultured cell line. Nature 380, 64–66. 
Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, 
Flanagan JG & Tsang ML (1996). Heterodimers of placenta growth factor/vascular 
endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity 
binding to Flk-1/KDR. Journal of Biological Chemistry 271, 3154–3162. 
Cao Y, Ji WR, Qi P & Rosin A (1997). Placenta growth factor: identification and 
characterization of a novel isoform generated by RNA alternative splicing. Biochemical & 
Biophysical Research Communications 235, 493–498. 
Carlsson-Skwirut C, Jornvall H, Holmgren A, Andersson C, Bergman T, Lundquist G, Sjorgen B 
& Sara VR (1986). Isolation and characterization of variant IGF-1 and IGF-2 from adult 
human brain. FEBS Letters 201, 46–50. 
Carmeliet P & Collen D (1999). Role of vascular endothelial growth factor and vascular 
endothelial growth factor receptors in vascular development. Current Topics in 
Microbiology & Immunology 237, 133–158. 
Carmeliet P, Ferrera V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, 
Vandenbroek A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Colle D, Risau 
W & Nagy A (1996). Abnormal blood vessel development and lethality in embryos lacking 
a single VEGF allele. Nature 380, 435–439. 
Carolan C, Lonergan P, Monget P & Mermillod P (1995). Role of insulin family of growth 
factors in bovine oocyte matruation (IVM) and embryo development (IVC) in vitro. Journal 
of Reproduction & Fertility. 
Carr JM, Owens JA, Grant PA, Walton PE, Owens PC & Wallace JC (1995). Circulating insulin-
like growth factors (IGFs), IGF-binding proteins (IGFBPs) and tissue mRNA levels of 
IGFBP-2 and IGFBP-4 in the ovine fetus. Journal of Endocrinology 145, 545–557. 
Carter AM (1975). Placental circulation. In: Steven DH, ed Camparative Placentation  Essays in 
Structure and Function New York Academic Press108–160. 
Charnock-Jones DS (2002). Soluble Flt-1 and the angiopoietins in the development and 
regulation of placental vasculature. Journal of Anatomy 200, 607–615. 
Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N & Smith SK 
(1994). Vascular endothelial growth factor receptor localization and activation in human 
trophoblast and choriocarcinoma cells. Biology of Reproduction 51, 524–530. 
Chavatte-Palmer P, Heyman Y, Monget P, Richard C, Kahn G, Le Bourhis D, Vignon X & 
Renard JP (2000). Plasma IGF-I, IGF-BP and GH concentrations in cloned neonatal calves 
from somatic and embryonic cells: preliminary findings. Theriogenology 53, 213 (abstr.). 
157 
 
Chen H, Chedotal A, He Z, Goodman CS & Tessier-Lavigne M (1997). Neuropilin-2, a novel 
member of the neuropilin family, is a high affinity recepetor for the semaphorins Sema E 
and Sema IV but not in Sema III. Neuron 19, 547–559. 
Cheung CY (1997). Vascular endothelial growth factor: possible role in fetal development and 
placental function. Journal of the Society for Gynecologic Investigation 4, 169–177. 
Cheung CY & Brace RA (1998). Ovine vascular endothelial growth factor: nucleotide sequence 
and expression in fetal tissues. Growth Factors 16, 11–22. 
Cheung CY, Singh M, Ebaugh MJ & Brace RA (1995). Vascular endothelial growth factor gene 
expression in ovine placenta and fetal membranes. American Journal of Obstetrics & 
Gynecology 173, 753–759. 
Cibelli JB, Stice SL, Golueke PJ, Kane JJ, Jerry J, Blackwell C, Ponce de Leon FA & Robl JM 
(1998). Cloned transgenic calves produced from nonquiescent fetal fibroblasts. Science 280, 
1256–1258. 
Claffey KP, Shih SC, Mullen A, Dziennis S, Cusick JL, Abrams KR, Lee SW & Detmar M 
(1998). Identification of the human VPF/VEGF 3’ untranslated region mediating hypoxia-
induced mRNA stability. Molecular Biology of the Cell 9, 469–481. 
Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R & Charnock-Jones 
DS (1998a). A vascular endothelial growth factor antagonist is produced by the human 
placenta and released into the maternal circulation. Biology of Reproduction 59, 1540–1548. 
Clark DE, Smith SK, Licence D, Evans AL & Charnock-Jones DS (1998b). Comparison of 
expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), 
VEGF-B and VEGF-C in the human placenta throughout gestation. Journal of 
Endocrinology 159, 459–467. 
Clemmons DR (1991). Insulin-like growth factor binding proteins: roles in regulating IGF 
physiology. Journal of Developmental Physiology 15, 105–110. 
Connolly DT, Heuvelman DM & Nelson R (1989). Tumor vascular permeability factor 
stimulates endothilial cell growth and angiogenesis. Journal of Clinical Investigation 84, 
1470–1478. 
Constância M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, Stewart F, 
Kelsey G, Fowden A, Sibley C & Reik W (2002). Placental-specific IGF-II is a major 
modulator of placental and fetal growth. Nature 417, 945–948. 
Cramer S, Beveridge M, Kilberg M & Novak D (2002). Physiological importance of system A-
mediated amino acid transport to rat fetal development. American journal of physiology 
Cell physiology 282, C153–C160. 
158 
 
Crossey PA, Pillai CC & Miell JP (2002). Altered placental development and intrauterine growth 
restriction in IGF binding protein-1 transgenic mice. The Journal of Clinical Investigation 
110, 411–418. 
Cullinan-Bove K & Koos RD (1993). Vascular endothelial grwoth factor/vascular permeability 
factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-
induced increases in uterine capillary permeability and growth. Endocrinology 133, 829–
837. 
Dantzer V, Leach L & Leiser R (2000). Angiogenesis and placental vasculature - A workshop 
report. Placenta 21, S69–S70. 
Dantzer V, Leiser R, Kaufmann P & Luckhardt M (1988). Comparative morphological aspects of 
placental vascularization. Trophoblast Research 3, 221–244. 
Davenport ML, Pucilowska J, Clemmons DR, Lundblad R, Spencer JA & Underwood LE 
(1992). Tissue-specific expression of insulin-like growth factor protein-3 protease activity 
during rat pregnancy. Endocrinology 130, 2505–2512. 
Davies J & Wimsatt WA (1966). Observation on the fine structure of the sheep placenta. Acta 
Anatomia (Baswl) 65, 182–223. 
DeChiara TM, Efstratiadis A & Robertson EJ (1990). A growth-deficiency phenotype in 
heterozygous mice carrying an insulin-like grwoth factor II gene disrupted by targeting. 
Nature 345, 78. 
Dean W, Bowden L, Aitchison A, Klose J, Moore T, Meneses JJ, Reik W & Feil R (1998). 
Altered imprinted gene methylation and expression in completely ES cell-derived mouse 
fetuses: association with aberrant phenotypes. Development 125, 2273–2282. 
Dean W, Santos F, Stojkovic M, Zakhartchenko V, Walter J, Wolf E & Reik W (2001). 
Conservation of methylation reprogramming in mammalian development: Aberrant 
reprogramming in cloned embryos. Proceedings of the National Academy of Sciences of the 
United States of America 98, 13734–13738. 
Delhanty PJ & Han VK (1992). The characterization and expression of ovine insulin-like growth 
factor-binding protein-2. Journal of Molecular Biology 9, 31–38. 
Delhanty PJD & Han VKM (1993). The expression of insulin-like growth factor (IGF) binding 
protein-2 and IGF-II genes in the tissues of the developing ovine fetus. Endocrinology 132, 
41–52. 
Demir R, Kaufmann P, Castellucci M, Erbengi T & Kotowski A (1989). Fetal vasculogenesis 
and angiogenesis in human placental villi. Acta anatomica 136, 190–203. 
159 
 
Dennis PA & Rifkin DB (1991). Cellular activation of latent transforming growth factor beta 
requires binding to the cation-independent mannose-6-phosphate/insulin-like grwoth factor 
type II receptor. Proceedings of the National Academy of Sciences of the United States of 
America 88, 580–584. 
DiSalvo J, Bayne ML, Conn G, Kwok PW, Trivedi PG, Soderman DD, Palisi TM, Sullivan KA 
& Thomas KA (1995). Purification and characterization of a naturally occurring vascular 
endothelial growth factor.placenta growth factor heterodimer. Journal of Biological 
Chemistry 270, 7717–7723. 
Dibbens JA, Miller DL, Damert A, Risau W, Vadas MA & Goodall GJ (1999). Hypoxic 
regulation of vascular endothelial growth factor mRNA stability requires the cooperation of 
multiple RNA elements. Molecular Biology of the Cell 10, 907–919. 
Dinnyes A, Dai Y, Barber M, Liu L, Xu J, Zhou P & Yang X (2001). Development of Cloned 
Embryos from Adult Rabbit Fibroblasts: Effect of Activation Treatment and Donor Cell 
Preparation. Biological Reproduction 64, 257–263. 
Doherty AS, Mann MRW, Tremblay KD, Bartolomei MS & Schultz RM (2000). Differential 
effects of culture on imprinted H19 Expression in the preimplantation mouse embryo. 
Biology of Reproduction 62, 1526–1535. 
Driesch H (1893). No Title. Anat Anz 8, 348. 
Duello TM, Byatt JC & Bremel RD (1986). Immunohistochemical localization of placental 
lactogen in binucleate cells of bovine placentomes. Endocrinology 119, 1351–1355. 
Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K & Breitman ML (1995). 
Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial 
growth factor expression during development. Developmental dynamics : an official 
publication of the American Association of Anatomists 203, 80–92. 
Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A & Breitman ML 
(1994). Dominant-negative and targeted null mutations in the endothelial receptor tyrosine 
kinase, tek, reveal a critical role in vasculogenesisof the embryo. Genes & Development 8, 
1897–1909. 
Dvorak HF, Brown LF, Detmar M & Dvorak AM (1995). Vascular permeability factor/vascular 
endothilial growth factor, microvascular hyperpermeability, and angiogenesis. American 
Journal of Pathology 146, 1029–1039. 
Eatock MM, Schatzlein A & Kaye SB (2000). Tumor vasculature as a target for anticancer 
therapy. Cancer Treatment Reviews 26, 191–204. 
Efstratiadis A (1998). Genetics of mouse growth. International Journal of Developmental 
Biology 42, 955–976. 
160 
 
Eggenschwiler J, Ludwig T, Fisher P, Leighton PA, Tilghman SM & Efstratiadis A (1997). 
Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-
Wiedemann and Simpson-Golabi-Behmel syndromes. Genes & Development 11, 3128–
3142. 
Ehrhardt RA & Bell AW (1995). Growth and metabolism of the ovine placenta during mid-
gestation. Placenta 16, 727–741. 
Eigenmann JE, Patterson DF & Froesch ER (1984). Body size parallels insulin-like growth 
factor I levels but not growth hormone secretory capacity. Acta Endocrinologica 106, 448–
453. 
Eley RM, Thatcher WW, Bazer FW, Wilcox CJ, Becker RB, Head HH & Adkinson RW (1978). 
Development of the coneptus in the bovine. Journal of Dairy Science 61, 467–473. 
Elsden RP & Seidel GEJ (1995). Procedures for recovery, bisection, freezing, and transfer of 
bovine embryos. In: 6th ed, Anim Reprod Biotechnol Lab Bulletin No 09p 41. 
Enholm B (1997). Comparison of VEGF, VEGF-B, VEGF-C and Ang1 mRNA regulation by 
serum, growth factor, oncoproteins and hypoxia. Oncogene 14, 2475–2483. 
Ewton DZ, Falen SL & Florini JR (1987). The type II insulin-like growth factor (IGF) receptor 
has low affinity for IGF-I analogs: pleiotypic actions of IGFs on myoblasts are apparently 
mediated by the type I receptor. Endocrinology 120, 115–123. 
Fairbrother WJ, Champe MA, Christinger HW, Keyt BA & Starivasnik MA (1998). Solution 
structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6, 
637–648. 
Farin PW & Farin CE (1995). Transfer of bovine embryos produced in vivo or in vitro: survival 
and fetal development. Biology of Reproduction 52, 676–682. 
Farin PW, Crosier AE & Farin CE (2001). Influence of in vitro systems on embryo survival and 
fetal development in cattle. Theriogenology 55, 151–170. 
Farin PW, Stockburger EM, Rodriguez KF, Crosier AE, Blondin P, Alexander JE & Farin CE 
(2000). Placental morphology following transfer of bovine embryos produced in vivo or in 
vitro. Theriogenology 53, 474 (abstr.). 
Farnebo F, Piehl F & Lagercrantz J (1999). Restricted expression pattern of vegf-d in the adult 
and fetal mouse: high expression in the embryonic lung. Biochemical & Biophysiology 
Research Communication 21, 891–894. 
Feil R, Khosla S, Cappai P & Loi P (1998). Genomic imprinting in ruminants: allele-specific 
gene expression in parthenogenetic sheep. Mammalian Genome 9, 831–834. 
161 
 
Ferrara N, Houck K, Jakeman LB & Leung DW (1992). Molecular and biologicaql properties of 
the vascular endothelial growth factor family of proteins. Endocrine Reviews 13, 18–32. 
Ferrell CL (1991a). Maternal and fetal influences on uterine and conceptus development in the 
cow.2. Blood flow and nutrient flux. Journal of Animal Science 69, 1954–1965. 
Ferrell CL (1991b). Maternal and fetal influences on uterine and conceptus development in the 
cow. 1. Growth of tissues of the gravid uterus. Journal of Animal Science 69, 1945–1953. 
Ferrell CL & Reynolds LP (1992). Uterine and umbilical blood flows and net nutrient uptake by 
fetuses and uteroplacental tissues of cows gravid with either single or twin fetuses. Journal 
of Animal Science 70, 426–433. 
Ferrell CL, Garrett WN & Hinman N (1976). Growth, development, and comparison of the udder 
and gravid uterus of beef heifers during pregnancy. Journal of Animal Science 42, 1477–
1489. 
Filson AJ, Louvi A, Efstratiadis A & Robertson EJ (1993). Rescue of the T-associated maternal 
effect in mice carrying null mutations in Igf-2 and Igf2r, two reciprocally imprinted genes. 
Development 118, 731–736. 
Folkman J (1985). Tumor angiogenesis. Advances in Cancer Research 43, 175–203. 
Fong GH, Rossant J, Gertsenstein M & Breitman ML (1995). Role of the Flt-1 receptor tyrosine 
kinase in regulating the assembly of vascular endothelium. Nature 376, 66–70. 
Fowden AL (1995). Endocrine regulation of fetal growth. Reproduction, Fertility, & 
Development 7, 351–363. 
Foyt HL & Roberts CTJ (1991). The IGF-1 gene: structure, expression, and gene products. In: 
LeRoith D (ed) Insulin-like Growth factors: Molecular and Cellular Aspects  CRC Press, 
Boca Raton, 1991: 49–85. 
Francis GL, Upton FM, Ballard FJ & McNeil KA (1988). Purification and partial sequence 
analysis of insulin-like growth factor I from bovine colostrum. Biochemical Journal 251, 
95–103. 
Franklin GC, Adam GIR & Ohlsson R (1996). Genomic imprinting and mammalian 
development. Placenta 17, 3–14. 
Frasca F, Pandini G, Scalia L, Sciacca L, Mineo R, Constantino A, Goldfine ID, Belfiore A & 
Vigneri R (1999). Insulin receptor isoform A, a newly recognized, high-affinity insulin-like 




Froesch ER, Schmid C, Schwander J & Zapf J (1985). Actions of insulin-like growth factors. 
Annual Review of Physiology 47, 443–467. 
Gallaher BW, Breier BH, Blum WF, McCutcheon SN GP (1995). A homologous 
radioimmunoassay for ovine insulin-like growth factor-binding protein-2: ontogenesis and 
the respose to growth hormone, placental lactogen and insulin-like growth factor-1 
treatment in sheep. Journal of Endocrinology75–82. 
Gallaher BW, Oliver MH, Eichhorn K, Kessler U, Kiess W, Harding JE, Gluckman PD & Breier 
BH (1994). Circulating insulin-like growth factor II/mannose-6-phosphate receptor and 
insulin-like growth factor binding proteins in fetal sheep plasma are regulated by glucose 
and insulin. European Journal of Endocrinology 131, 398–404. 
Garry F (1999). Physiolobical problems of newborn calves. Proceedings of the 18th Annual 
Convention of the American Embryo Transfer Associationpp5–pp9. 
Garry F, Adams R, Holland MD, Hay WW, McCann JP, Wagner AP & Seidel GE (1998). 
Arterial oxygen, metabolite and energy regulatory hormone concentrations in cloned bovine 
fetuses. Theriogenology 49, 321(abstr.). 
Garry FB, Adams R, McCann JP & Odde KG (1996). Postnatal characteristics of calves 
produced by nuclear transfer cloning. Theriogenology 45, 141–152. 
Geisert RD, Lee C, Simmen FA, Zavy MT, Fliss AE, Bazer FW & Simmen RCM (1991). 
Expression of messenger RNA’s encoding insulin-like growth factor-I, -II, and insulin-like 
growth factor binding protein-2 in bovine endometrium during the estrous cycle and early 
pregnancy. Biology of Reproduction 45, 975–983. 
Gelato MC, Rutherford C, Stark RI & Daniel SS (1989). The insulin-like growth 
factor/mannose-6-phosphate receptor is present in fetal and maternal sheep serum. 
Endocrinology 124, 2935–2943. 
Genbacev O, Joslin R, Damsky CH, Pillotti BM & Fisher JS (1996). Hypoxia alters early 
gestation human trophoblast differentiation/invasion in vitro and models the placental 
defects that occur in preeclampsia. Journal of Clinical Investigation 97, 540–551. 
Giddings SJ, King CD, Harman KW, Flood JF & Carnaghi LR (1994). Allele specific 
inactivation of insulin 1 and 2, in mouse yolk sac indicates imprinting. Nature Genetics 6, 
310–313. 
Giudice LC (1997). Multifaceted roles for IGFBP-1 in human endometrium and pregnancy. 
Annual New York Academy of Science 828, 146–156. 
Giudice LC, Mark SP & Irwin JC (1998). Paracrine actions of insulin-like growth factors and 
IGF binding protein-1 in non-pregnant endometrium and at the decidual-trophoblast 
interface. Journal Reproductive Immunology 39, 133–148. 
163 
 
Giudice LC, Martina NA, Crystal RA, Tazuke SI & Druzin M (1997). Insulin-like growth factor 
binding protein-1 at the maternal fetal interface and insulin-like growth factor-1 and insulin-
like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of 
womenwith severe preeclampsia. American Journal of Obsterics & Gynecology 176, 751–
757. 
Gleeson LM, Chakraborty C, McKinnon T & Lala PK (1999). Insulin-like growth factor binding 
protein (IGFBP)-1 stimulates extravillous trophoblast (EVT) migration and invasion by 
signalling through a5b1 integrin. Placenta 20, A.26. 
Gleeson LM, Chakraborty C, McKinnon T & Lala PK (2001). Insulin-like growth factor-binding 
protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 
integrin via mitogen-activated protein kinase pathway. Journal of Clinical Endocrinology 
and Metabolism 86, 2482–2493. 
Glover MD & Seidel GEJ (2003). Increased mRNA for allograft inflammatory factor-1, LERK-
5, and a novel gene in 17.5-day relative to 15.5-day bovine embryos. Biology of 
Reproduction 69, 1002–1012. 
Gluckman PD (1995). Clinical review 68: The endocrine regulation of fetal growth in late 
gestation: the role of insulin-like growth factors. Journal of Clinical Endocrinology & 
Metabolism 80, 1047–1050. 
Gluckman PD, Breier BH & Davis SR (1987). Physiology of the somatotropic axis with 
particular reference to the ruminant. Journal of Dairy Science 70, 442–466. 
Goodhand KL, Dolman DF, Watt RG, Higgins LC, Staines ME & Broadbent PJ (1997). Calving 
outcome following transfer of in vivo and in vitro produced bovine embryos. Proceedings 
of the British Society of Animal Science. 
Gratton RJ, Asano H & Han VKM (2002). The regional expression of insulin-like growth factor 
II (IGF-II) and insulin-like growth factor binding proetin-1 (IGFBP-1 in the placentae of 
women with pre-eclampsia.q. Placenta 22, 303–310. 
Green WW & Winters LM (1945). Prenatal development of sheep. University of Minnisota 
Agricultural Experimental Station Technical Bulletin 169, 3–36. 
Greenstein JS, Murray RW & Foley RC (1958). Observatioons on the morphogenesis and 
histochemistry of the bovine pre-attachment placenta between 16 and 33 days of gestation. 
Anatomical Record 132, 321–341. 
De Groot CJ, O’Brian TJ & Taylor RN (1996). Biochemical evidence of impaired trophoblastic 
invasion of decidual stroma in women destined to pre-eclampsia. American Journal of 
Obsterics & Gynecology 175, 24–29. 
164 
 
Grosser O (1909). Vergleichende Anatomie und Entwicklungsgeschichte der Eihaute und der 
Placenta mit besonderer Beruckschtigung des Menschen. Vienna: Braumuller. 
Grosser O (1927). Fruhentwickluing, Eihautbildung und Placentation des Menschen un der 
Saugetiere. Deutsche Frauenheilkunde, Geburtshilfe, Gynakologie und Nachbargebiete in 
Einzeldarstellungen. 
Guillemot E (1995). Genomic imprinting of Mash2, a mouse gene required for trophoblast 
development. Nature Genetics 9, 235–242. 
Hagemann LJ, Weilert LL, Beaumont SE & Tervit HR (1998). Development of bovine embryos 
in single in vitro production (sIVP) systems. Molecular Reproduction & Development 51, 
143–147. 
Hamilton GS, Lysiak JJ, Han VKM & Lala PK (1998). Autocrine-paracrine regulation of human 
trophoblast invasiveness by Insulin-Like Growth Factor (IGF)-II and IGF-Binding protein-1 
(IFGBP-1). Experimental Cell Research 243, 1–10. 
Han VK, Bassett N, Walton J & Challis JR (1996). The expression of insulin-like growth factor 
(IGF) and IGF-binding protein (IGFBP) genes in the human placenta and membranes: 
evidence for IGF-IGFBP interactions at the feto-maternal interface. Journal of Clinical 
Endocrinology & Metabolism 81, 2680–2693. 
Han VKM & Carter AM (2000). Spatial and temporal Patterns of expression of messenger RNA 
for insulin-like growth factors and their binding proteins in the placenta of man and 
laboratory animals. Placenta 21, 289–305. 
Han VKM, D’Ercole AJ & Lund PK (1987). Cellular localization of somatonedin (insulin-like 
growth factor) messenger RNA in the human fetus. Science 236, 193–197. 
Hanahan D (1997). Signaling vascular morphogenesis and maintenance. Science 277, 48–50. 
Hansel W & Asdell SA (1951). The effects of estrogen and progesterone on the arterial system 
of the uterus of the cow. Journal of Dairy Science 34, 37–44. 
Harding JE, Liu L, Evans PC & Gluckman PD (1994). Insulin-like growth factor 1 alters feto-
placental protein and carbohydrate metabolism in fetal sheep. Endocrinology 134, 1509–
1514. 
Hardy K, Spanos S, Becker D, Iannelli P, Winston RML & Stark J (2001). From cell death to 
embryo arrest: Mathematical models of human preimplantation embryo development. 




Hasler JF (1998). The current status of oocyte recovery, in vitro embryo production, and embryo 
transfer in domestic animals, with an emphasis on the bovine. Journal of Animal Science 
76, 52–74. 
Hasler JF, Henderson WB, Hurtgen PJ, Jin ZQ, McCauley AD, Mower SA, Neely B, Shuey LS, 
Stokes JE & Trimmer SA (1995). Production, freezing and transfer of bovine embryos and 
subsequent calving results. 43, 141–152. 
Hauser S & Weich HA (1993). A heparin-binding form of placenta growth factor (PlGF-2) is 
expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 9, 
259–268. 
He Z & Tessier-Lavigne M (1997). Neuropilin is a receptor for the axonal chemorepellent 
semaphorin III. Cell 90, 739–751. 
Hepler JE, Van Wyck JJ & Lund PK (1990). Different half-lives of insulin-like growth factor I 
mRNA’s that differ in length of 3' untranslated sequence. Endocrinology 127, 1550–1552. 
De Hertogh R, Vanderheyden I, Pampfer S, Robin D & Delcour t J (1992). Maternal insulin 
treatment improves pre-implantation embryo development in diabetic rats. Diabetologia 35, 
406–408. 
Hiendleder S, Schmutz SM, Erhardt G, Green RD & Plante Y (1999). Tranmitochondrial 
differences and varying levels of heteroplasmy in nuclear transfer cloned cattle. Molecular 
Reproduction & Development 54, 24–31. 
Hietala R, Pohja-Nylander P, Rutanen EM & Laatikainen T (2000). Serum insulin-like growth 
factor binding protein-1 at 16 weeks and subsequent preeclampsia. Obstetrics & 
Gynecology 95, 185–189. 
Hill JR, Burghardt RC, Jones K, Long CR, Looney CR, Shin T, Spencer TE, Thompson JA, 
Winger QA & Westhusin ME (2000). Evidence for Placental Abnormality as the Major 
Cause of Mortality in First-Trimester Somatic Cell Cloned Bovine Fetuses. Biology of 
Reproduction 63, 1263–1787. 
Hill JR, Roussel AJ, Cibelli JB, Edwards JF, Hooper NL, Miller MW, Thompson JA, Looney 
CR, Westhusin ME, Robl JM & Stice SL (1999). Clinical and pathologic features of cloned 
transgenic calves and fetuses (13 case studies). Theriogenology 51, 1451–1468. 
Hills FA, Elder MG, Chard T & Sullivan MHF (1999). Regulation of human primary trophoblast 
growth by insulin-like growth factors (IGF) and IGF binding protein-1. Placenta 20, A.29. 
Hintz RL, Thorsson AV, Enberg G & Hall K (1984). IGF-II binding on human lymphoid cells: 
demonstration of a common high affinity receptor for insulin like peptides. Biochemical & 
Biophysical Research Communications 118, 774–782. 
166 
 
Holland MD, Williams SE, Godfredson JA, Field TG, Young JW, Tatum JD, Hossner KL & 
Odde KG (1989). Insulin-like growth factor (IGF-1) and bovine fetal growth. Animal 
Science 67 (Suppl , 199 (abstr.). 
Holm P, Walker SK & Seamark RF (1996). Embryo viability, duration of gestation and birth 
weight in sheep after transfer of in vitro matured and in vitro fertilized zygotes cultured in 
vitro or in vivo. Journal of Reproduction & Fertility 107, 175–181. 
Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P & Le Bouc Y 
(2003). IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 
421, 182–187. 
Hossner KL, McCusker RH & Dodson MV (1997). Insulin-like growth factors and their binding 
proteins in domestic animals. Animal Science 64, 1–15. 
Huang H, Rajkumar K & Murphy LJ (1997). Reduced fecundity in insulin-like growth factor 
binding protein-I transgenic mice. Biology of Reproduction 56, 284–289. 
Hubbert WT, Stalheim OH & Booth GD (1972). Changes in organ weights and fluid volumes 
during growth of the bovine fetus. Growth 36, 217–233. 
Hwa V, Oh Y & Rosenfeld RG (1999). The insulin-like growth factor-binding protein (IGFBP) 
superfamily. Endocrine Reviews 20, 761–787. 
Ihle JM (2000). The challenges of translating knockout phenotypes into gene function. Cell 102, 
131–134. 
Ikeda E, Achen MG, Breier G & Risau W (1995). Hypoxia-induced transcriptional activation 
and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. 
Journal of Biological Chemistry 270, 19761–19766. 
Irving JA & Lala PK (1995). Functional role of cell surface integrins on human trophoblast cell 
migration: regulation by TGF-beta, IGF-II, and IGFBP-1. Experimental Cell Research 217, 
419–427. 
Irwin JC & Giudice LC (1998). Insulin-like growth factor binding protein-1 binds to placental 
cytotrophoblast alpha5beta1 integrin and inhibits cytotrophoblast invasion into decidualized 
endometrial stromal cultures. Growth Hormone & Igf Research 8, 21–31. 
Iwashita M, Kudo Y, Yoshimura Y, Adachi T, Katayama E & Takda Y (1996). Physiological 
role of insulin-like-growth-factor-binding protein-4 in human folliculogenesis. Hormone 
Research 46, 31–36. 
Jaffe RB (2000). Importance of angiogenesis in reproductive physiology. Seminars in 
Perinatology 24, 79–81. 
167 
 
Jenkinson CM, Min SH, Mackenzie DD, McCutcheon SN, Breier BH & Gluckman PD (1999). 
Placental development and fetal growth in growth hormone-treated ewes. Growth hormone 
& IGF research : official journal of the Growth Hormone Research Society and the 
International IGF Research Society 9, 11–17. 
Johnson LW & Smith CH (1988). Neutral amino acid transport systems of microvillous 
membrane of human placenta. American Journal of Physiology 251, C773–C780. 
Jones CJP (1994). Lectin-histochemical analysis of glycans in ovine and bovine near-term 
placental binucleate cells. Cell Tissue Research 278, 601–610. 
Jones CT, Gu W, Harding JE, Price DA & Parer JT (1988). Studies on the growth of the fetal 
sheep. Effects of surgical reduction in placental size, or experimental manipulation of 
uterine blood flow on plasma sulphation promoting activity and on the concentration of 
insulin-like growth factors I and II. Journal of Developmental Physiology 10, 179–189. 
Jones JI & Clemmons DR (1995). Insulin-like growth factors and their binding proteins: 
biological actions. Endocrine Reviews 16, 3–34. 
Jones JI, D’Ercole AJ, Camacho HC & Clemmons DR (1991). Phosphorulation of insulin-like 
growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-
I. Proceedings of the National Academy of Sciences of the United States of America 88, 
7481–7485. 
Jones JI, Gockerman A, Busby WJ, Wright G & Clemmons DR (1993). Insulin-like growth 
factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 intergrin by 
means of ite ARg-Gly-Asp sequence. Proceedings of the National Academy of Sciences of 
the United States of America 90, 10553–10557. 
Kaneda H, Hayashi J, Takahama S, Taya C, Lindahl KF & Yonekawa H (1995). Elimination of 
paternal mitochondrial DNA in intraspecific crosses during early mouse embryogenesis. 
Proceedings of the National Academy of Sciences of the United States of America 92, 4542–
4546. 
Kato Y, Yabuuchi A, Motosugi N, Kato J-ya & Tsunoda Y (1999). Developmental Potential of 
Mouse Follicular Epithelial Cells and Cumulus Cells After Nuclear Transfer. Biology of 
Reproduction 61, 1110–1114. 
Kaufmann P (1982). Development and differentiation of the human placental villous tree. 
Bibliotheca Anatomica 22, 29–39. 
Kaufmann P (1990). Placentation und Placenta. In: Human embryologie  KV Hinrichsen, ed 
Springer-Verlag, Berlin159–204. 
Kaufmann P, Sen DK & Schweikhart G (1979). Classification of human placental villi. I. 
Histology. Cell & Tissue Research 200, 409–423. 
168 
 
Kaye PL, Bell KL, Beebe LF, Dunglison GF, Gardner HG & Harvey MB (1992). Insulin and the 
insulin-like growth factors (IGFs) in preimplantation development. Reproduction, Fertility, 
& Development 4, 373–386. 
Keller ML (1996). The insulin-like growth factor system in the bovine uterus and elongating 
embryo. PhD thesis, Colorado State University. 
Kendall RL & Thomas AL (1993). Inhibition of vascular endothelial growth factor activity by an 
endogenously encoded soluble receptor. Proceedings of the National Academy of Sciences 
of the United States of America 90, 10705–10709. 
Kendall RL, Wang G & Thomas KA (1996). Identification of a natural soluble form of the 
vascular endothelial growth factor receptor, Flt-1, and its heterodimerization with KDR. 
Biochemical & Biophysical Research Communications 226, 324–328. 
Kiess W, Blickenstaff GD, Sklar MM, Thomas CL, Nissley SP & Sahagian GG (1988). 
Biochemical evidence that the type II insulin-like growth factor receptor is identical to the 
cation-independent mannose 6-phosphate receptor. Journal of Biological Chemistry 263, 
9339–9344. 
Killian JK, Byrd JC, Jirtle JV, Munday BL, Stoskopf MK, MacDonald RG & Jirtle RL (2000). 
M6P/IGF2R imprinting evolution in mammals. Molecular Cell 5, 707–716. 
Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ & Park BC (1998). Insulin-like growth factor II  
induced by hypoxia may contribute to angiogenesis of hepatocellular carcinoma. Cancer 
Research 58, 348–351. 
King WA, Shepherd DL, Plante L, Lavoir MC, Looney CR & Barnes FL (1996). Nucleolar and 
mitochondrial morphology in bovine embryos reconstructed by nuclear transfer. Molecular 
Reproduction & Development 44, 499–506. 
Kitsukawa T, Shimuzu M, Sanbo M, Hirata T, Taniguchi M, Bekku Y, Yagi T & Fujisawa H 
(1997). Neuropilin-1-semaphorin III/D-mediated chemorepulsive signals play a crucial role 
in peripheral nerve projection in mice. Neuron 19, 995–1005. 
Klagsbrun M & D’Amato RJ (1991). Regulation of angiogenesis. Annual Review of Physiology 
53, 217–239. 
Kleemann DO, Walker SK, Hartwich KM, Fong L, Seamark RF, Robinson JS & Owens JA 
(2001). Fetoplacental growth in sheep administered progesterone during the first three days 
of pregnancy. Placenta 22, 14–23. 
Klisch K, Hecht W, Pfarrer C, Schuler G, Hoffmann B & Leiser R (1999). DNA content and 
ploidy level of bovine placentomal trophoblast giant cells. Placenta 20, 451–458. 
169 
 
Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U & Risau W (1998). Angiopoietin-1 induces 
sprouting angiogenesis in vitro. Current Biology 8, 529–532. 
Kono T (1998). Influence of epigenetic changes during oocyte growth on nuclear reprogramming 
after nuclear transfer. Reproduction, Fertility & Development 10, 593–598. 
Kornfeld S (1992). Structure and function of the mannose 6-phosphate/insulinlike growth factor 
II receptors. Annual Review Biochemistry 61, 307–330. 
Kruip TAM & den Daas JHG (1997). In vitro produced and cloned embryos: effects on 
pregnancy, parturition and offspring. Theriogenology 47, 43–52. 
Lackey BR, Gray SLL & Henricks DM (2000). Physiological basis for use of Insulin-like growth 
factors in reproductive applications: a review. Theriogenology 53, 1147–1156. 
Lacroix MC, Servely JL & Kann G (1995). IGF-I and IGF-II receptors in the sheep placenta: 
evolution during the course of pregnancy. Journal of Endocrinology 144, 179–191. 
Lane M & Gardner DK (1994). Increase in postimplantation development of cultured mouse 
embryos by amino acids and induction of fetal retardation and exencephaly by ammonium 
ions. Journal of Reproduction & Fertility 102, 305–312. 
Langford K (1994). The pathophysiology of the insulin-like growth factor axis in fetal growth 
failure: a basis for programming by undernutrition? European Journal of Clinical 
Investigation 24, 851–856. 
Langford KS, Nicolaides KH, Jones J, Abbas A, McGregor AM & Miell JP (1995). Serum 
insulin-like growth factor-binding protein-3 (IGFBP-3) levels and IGFBP-3 protease 
activity in normal, abnormal, and multiple human pregnancy. Journal of Clinical 
Endocrinology & Metabolism 140, 5587–5597. 
Lanza RP, Cibelli JB, Blackwell C, Cristofalo VJ, Francis MK, Baerlocher GM, Mak J, 
Schertzer M, Chavez EA, Sawyer N, Lansdorp PM & West MD (2000). Extension of cell 
life-span and telomere length in animals cloned from senescent somatic cells. Science 288, 
665–669. 
Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P & Stewart CL (1994). Loss of the imprinted 
IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and 
perinatal lethality. Genes & Development 8, 2953–2963. 
Lauwers (1991). Cursus embryologie, Universiteit Gent, Fakulteit Diergeneeskunde. 
Lavoir MC, Kelk D, Rumph N, Barnes F, Betteridge KJ & King WA (1997). Transcription and 
translation in bovine nuclear transfer embryos. Biology of Reproduction 57, 204–682. 
170 
 
Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR 3rd & 
Conover CA (1999). The insulin-like growth factor (IGF)-dependent IGF binding protein-4 
protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. 
Proceedings of the National Academy of Sciences of the United States of America 96, 3149–
3153. 
LeRoith D, Werner H, Beitner-Johnson D & Roberts  Jr. CT (1995). Molecular and cellular 
aspects of the insulin-like growth factor 1 receptor. Endocrine Reviews 16, 143–163. 
Leach L (2002). The phenotype of th human materno-fetal endothelial barrier: molecular 
occupancy of paracellular junctions dictate permeability and angiogenic plasticity. Journal 
of Anatomy 200, 599–606. 
Lee CS, Wooding FB & Brandon MR (1986). Ultrastructural immunogold investigation of the 
function and diversity of binucleate cells in the ovine placenta using a monoclonal antibody. 
Placenta 7, 495–504. 
Lee JT (2000). Disruption of imprinted X inactivation by parent - of origin effects at Tsix. Cell 
103, 17–27. 
Leiser R (1987). Mikrovaskularisation der Ziegenplazenta dargestellt mit rasterelektronish 
untersuchten Gefassausgussen. Schw Arch Tierheilk 129, 59–74. 
Leiser R, Krebs C, Klisch K, Ebert B, Dantzer V, Schuler G & Hoffmann B (1997). Fetal 
villosity and microvasculature of the bovine placentome in the second half of gestation. 
Journal of Anatomy 191, 517–527. 
Leutenegger CM, Higgins LC, Matthews DL, Tarantal AF, Luciw P, Pedersen NC & North TW 
(2001). Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-
chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Research 
Human Retroviruses 17, 243–251. 
Levy AP, Levy NS, Wegner S & Goldberg MA (1995). Transcriptional regulation of the rat 
vascular endothelial growth factor gene by hypoxia. Journal of Biological Chemistry 270, 
13333–13340. 
Levy NS, Chung S, Furneaux H & Levy AP (1998). Hypoxic stabilization of vascular 
endothelial growth facotr mRNA by the RNA-binding protein HuR. Journal of Biological 
Chemistry 273, 6417–6423. 
Lewis IM, Peura TT & Trounson AO (1998). Large-scale applications of cloning technologies 
for agriculture: an industry perspective. Reproduction, Fertility & Development 10, 677–
681. 
Li M, Squire JA & Weksberg R (1998a). Overgrowth syndromes and genomic imprinting: from 
mouse to man. Clinical Genetics 53, 165–170. 
171 
 
Li X, Gray SG, Flam F, Pietsch T & Ekstrom TJ (1998b). Developmental-dependent DNA 
methylation of the IGF2 and H19 promoters is correlated to the promoter activities in 
human liver development. International Journal of Developmental Biology 42, 687–693. 
Lighten AD, Hardy K, Winston RM & Moore GE (1997). Expression of mRNA for the insulin-
like growth factors and their receptors in human preimplantation embryos. Molecular 
Reproduction & Development 47, 134–139. 
Louvi A, Accili D & Efstratiadis A (1997). Growth-promoting interaction of IGF-II with the 
insulin receptor during mouse embryonic development. Developmental Biology 189, 33–48. 
Ludwig T, Eggenschwiler J, Fisher P, D’Ercole AJ, Davenport ML & Efstratiadis A (1996). 
Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality 
in Igf2 and Igf1r null backgrounds. Developmental Biology (Orlando) 177, 517–535. 
Maglione D, Guerriero V, Viglietto G, Delli-Bovi P & Persico MG (1991). Isolation of a human 
placenta cDNA encoding for a protein related to the vascular permeability factor. 
Proceedings of the National Academy of Sciences of the United States of America 88, 9267–
9271. 
Maharajan P & Maharajan V (1993). Growth hormone signal transduction. Experientia 49, 980–
987. 
Makinen T, Olofsson B, Karpanen T, Hellman U, Soker S, Klagsbrun M, Eriksson U & Alitalo 
K (1999). Differential binding of vascular endothelial growth factor B splice and preteolytic 
isoforms to neuropilin-1. Journal of Biological Chemistry 274, 21217–21222. 
Massagué J (1990). The transforming growth factor-beta family. Annual review of cell biology 6, 
597–641. 
Matsuzaki M & Shiga K (2002). Endocrine characteristics of cloned calves. Cloning and stem 
cells 4, 261–267. 
Maxfield EK, Sinclair KD, Dolman DF, Staines ME & Maltin CA (1997). In vitro culture of 
sheep embryos increases weight, primary fiber size and secondary to primary fiber ratio in 
fetal muscle at day 61 of gestation. Theriogenology 47, 376. 
McClintock AE (1998). Impact of cloning on cattle breeding systems. Reproduction, Fertility & 
Development 10, 667–669. 
McCusker RH (1998). Controlling insulin-like growth factor activity and the modulation of 
insulin-like growth factor binding protein and receptor binding. Journal of dairy science 81, 
1790–1800. 
McKinnon T, Chakraborty C, Gleeson LM, Chidiac P & Lala PK (2001). Stimulation of human 
extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving 
172 
 
inhibitory G protein(s) and phosphorylation of MAPK. Journal of Clinical Endocrinology 
& Metabolism 86, 3665–3674. 
McKinnon T, Gleeson LM, Chakraborty C LP (1999). ) Insulin like growth factor (IGF)-II 
stimulates extravillous trophoblast (EVT) migration and invasion by signalling through type 
2 IGF receptor. Placenta 20, 47. 
McLaren RJ & Montgomery GW (1999). Genomic imprinting of the insulin-like growth factor 2 
gene in sheep. Mammalian Genome 10, 588–591. 
McLellan KC, Hooper SB, Bocking AD, Delhanty PJ, Phillips ID, Hill DJ & Han VK (1992). 
Prolonged hypoxia induced by the reduction of maternal uterine blood flow alters insulin-
like growth factor-binding protein-1 (IGFBP-1) and IGFBP-2 gene expression in the ovine 
fetus. Endocrinology 131, 1619–1628. 
Meeker AK & Coffey DS (1997). Telomerase: a promising marker of biological immortality of 
germ, stem, and cancer cells. Biochemistry (Moscow) 62, 1323–1331. 
De Mellow JS & Baxter RC (1988). Growth hormone-dependent insulin-like growth factor (IGF) 
binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin 
fibroblasts. Biochemical & Biophysical Research Communications 156, 199–204. 
Melton AA, Berry RO & Butler OD (1951). The interval between the time of ovulation and 
attachment of the bovine embryo. Journal of Animal Science 10, 993–1005. 
Memili E & First NL (2000). Zygotic and embryonic gene expression in cow: a review of timing 
and mechanisms of early gene expression as compared with other species. Zygote 8, 87–96. 
Mereilles F & Smith LC (1998). Mitochondrial genotype segregation during preimplantation 
development in mouse heteroplasmic embryos. Genetics 148, 877–883. 
Merimee RJ, Zaph J & Froesch ER (1981). Dwarfism in the pygmy: An isolated deficiency of 
insulin-like growth factor I. New England Journal of Medicine 305, 965–968. 
Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, 
Buttner M, Rziha HJ & Dehio C (1999). A novel vascular endothelial growth factor 
encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 
(KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO Journal 18, 363–374. 
Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, Baumann H & Neufeld G 
(1998). Neuropilin-1 is a placenta growth factor-2 receptor. Journal of Biological Chemistry 
273, 22272–22278. 
Moffat J, F.W. B, P.J. H, P.W. C & R.M. R (1987). Purification, secretion and 
immunocytochemical localization of the uterine milk proteins, major progesterone-induced 
proteins in secretions of the sheep. Biology of Reproduction419–430. 
173 
 
Moore T & Reik W (1996). Genetic conflict in early development: parental imprinting in normal 
and abnormal growth. Reviews of Reproduction 1, 73–77. 
Mostaghini K & Ivoghli B (1977). Diabetes mellitus in the bovine. Cornell Vet 1977, 24–28. 
Munson L, Kao JJ & Schlafer DH (1989). Characetrization of glycoconjugates in the bovine 
endometrium and chorion by lectin histochemistry. Journal of Reproduction & Fertility 87, 
509–517. 
Munson L, Wilhite A, Boltz VF & Wilkinson JE (1996). Transforming growth factor beta in 
bovine placentas. Biology of Reproduction 55, 748–755. 
Murphy LJ & Ghahary A (1990). Uterine insulin-like growth factor-1: regulation of expression 
and its role in estrogen-induced uterine proliferation. Endocrine Reviews 11, 443–453. 
Murphy LJ, Molnar P, Lu X & Huang H (1995). Expression of human insulin-like growth factor-
binding protein-3 in transgenic mice. Journal of Molecular Endocrinology 15, 293–303. 
Murphy SK & Jirtle RL (2000). Imprinted genes as potential genetic and epigenetic toxicologic 
targets. Enviormental Health Perspectives 108, 5–11. 
Nagao Y, Totsuka Y, Atomi Y, Kaneda H, Lindahl KF, Imai H & Yonekawa H (1998). 
Decreased physical performance of congenic mice with mismatch between the nuclear and 
the mitochondrial genome. Genes and Genetic Systems 73, 21–27. 
Nathanielsz PW (1996). The timing of birth. American Scientist 84, 562–569. 
Neuenschwander S, Schwartz A, Wood TL, Roberts CTJ & Henninghausen L (1996). Involution 
of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse 
model. Journal of Clinical Investigation. 
Neufeld G, Kessler O & Herzog Y (2002). The interaction of Neuropilin-1 and Neuropilin-2 with 
tyrosine kinase receptors for VEGF. Advances in Experimental Medicine & Biology 515, 
81–90. 
Neufeld G, Tessler S, Gitay-Goren H, Cohen T & Levi BZ (1994). Vascular endothilial growth 
factor and its receptors. Progressive Growth Factor Research 5, 89–97. 
Obata Y, Kaneko-Ishino T, Koide T, Takai Y, Ueda T, Domeki I, Shiroishi T, Ishino F & Kono 
T (1998). Disruption of primary imprinting during oocyte growth leads to the modified 
expression of imprinted genes during embryogenesis. Development 125, 1553–1560. 
Oh H, Takagi H, Suzuma K, Otani A, Matsumura M & Hoonda Y (1999). Hypoxia and vascular 
endothelial growth factor selectively up-regulated angiopoietin-2 in bovine microvascular 
endothelial cells. Journal of Biological Chemistry 274, 15732–15739. 
174 
 
Oh Y, Nagalla SR, Yamanaka Y, Kim H-S, Wilson E & Rosenfeld RG (1996). Synthesis and 
Characterization of Insulin-like Growth Factor-binding Protein (IGFBP)-7. 
RECOMBINANT HUMAN mac25 PROTEIN SPECIFICALLY BINDS IGF-I AND -II. 
Journal of Biological Chemistry 271, 30322–30325. 
Olofsson B, Jeltch M, Eriksson U & Alitalo K (1999). Current biology of VEGF-B and VEGF-
C. Current Opinion in Biotechnology 10, 528–535. 
Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, 
Shibuya M, Alitalo K & Eriksson U (1998). Vascular endothelial growth facotr B (VEGF-
B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial 
cells. Proceedings of the National Academy of Sciences of the United States of America 95, 
11709–11714. 
Olofsson B, Pajusola K, Kaipainen A, von Euler G, Juokov V, Saksela O, Orpana A, Pettersson 
RF, Alitalo K & Eriksson U (1996). Vascular endothelial growth factor B, a novel growth 
factor for endothelial cells. Proceedings of the National Academy of Sciences of the United 
States of America 93, 2576–2581. 
Ono Y, Shimozawa N, Ito M & Kono T (2001). Cloned Mice from Fetal Fibroblast Cells 
Arrested at Metaphase by a Serial Nuclear Transfer. Biology of Reproduction 64, 44–50. 
Orbus R (1999). Placental function in placental insufficiency-intrauterine growth restricted 
pregnancies. Master thesis, Colorado State University. 
Osborn BH, Fowlkes J, Han VK & Freemark M (1992). Nutritional regulation of insulin-like 
growth factor-binding protein gene expression in the ovine fetus and pregnant ewe. 
Endocrinology 131, 1743–1750. 
Osipo C, Dorman S & Frankfater A (2001). Loss of insulin-like growth factor II receptor 
expression promotes growth in cancer by increasing intracellular signaling from both IGF-I 
and insulin receptors. Experimental Cell Research 264, 388–396. 
Osorio M, Torres J, Moya F, Pezzullo J, Salafia C, Baxter R, Schwander J & Fant M (1996). 
Insulin-like growth factors (IGFs) and IGF binding proteins-1, -2, and -3 in newborn serum: 
relationships to fetoplacental growth at term. Early Human Development 46, 15–26. 
Ostlund E, Bang P, Hagenas L & Fried G (1997). Insulin-like growth factor I in fetal serum 
obtained by cordocentesis is correlated with intrauterine growth retardation. Human 
Reproduction 12, 840–844. 
Owens JA (1991). Endocrine and substrate control of fetal growth: placental and maternal 




Owens JA, Kind KL, Carbone F, Robinson JS & Owens PC (1994). Circulating insulin-like 
growth factors-I and -II and substrates in fetal sheep following restriction of placental 
growth. Journal of Endocrinology 140, 5–13. 
O’Dell SD & Day IN (1998). Insulin-like growth factor II (IGF-II). International Journal of 
Biochemistry & Cell Biology 30, 767–771. 
de Pagter-Holthuizen P, Jansen M, van Schaik FM, van der Kammen R, Oosterwijk C, Van den 
Brande JL & Sussenbach JS (1987). The human insulin-like growth factor II gene contains 
two development-specific promoters. FEBS Letters 214, 259–264. 
Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R & Belfiore A (2002). Insulin/insulin-like 
growth factor I hybrid receptors have different biological characteristics depending on the 
insulin receptor isoform involved. Journal of Biological Chemistry 277, 39684–39695. 
Park JE, Chen HH, Winer J, Houck KA & Ferrara N (1994a). Placental growth factor.  
Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high 
affinity binding to Flt-1 but not Flk-1/KDR. Journal of Biological Chemistry 269, 25646–
25654. 
Park JH, McCusker RH, Mohammadpour H, Blackwood DJ, Hrbek M & Vanderhoof JA 
(1994b). Dexamethasone inhibits mucosal adaptation after small bowel resection. American 
Journal of Physiology 266, G497–G503. 
Penninga L & Longo LD (1998). Ovine placentome morphology: effect of high altitude, long-
term hypoxia. Placenta 19, 187–193. 
Perry VEA, Norman ST, Owens JA, Daniel RCW & Phillips N (1999). Low dietary protein 
during early pregnancy alters bovine placental development. Animal Reproduction Science 
55, 13–21. 
Persico MG, Vinenti V & DiPalma T (1999). Structure, expression and receptor-binding 
properties of placental growth factor (PlGF). Current Topics of Microbiology & 
Immunology 237, 31–40. 
Peterson AJ & McMillan WH (1998). Variation in the rate of emergence of the bovine allantois. 
In: Proceedings of the 29th annual Conference of the Australian Society for Reproductive 
Biology Abstract 23. 
Petrik J, Pell JM, Arany E, McDonald TJ, Dean WL, Reik W & Hill DJ (1999). Overexpression 
of insulin-like growth factor-II in transgenic mice is associated with pancreatic islet cell 
hyperplasia. Endocrinology 140, 2353–2363. 
Pfuender M, Sauerwein H, Funk B, Kessler U, Barenton B, Schwarz HP, Hoeflich A & Kiess W 
(1995). The insulin-like growth factor-II/Mannose-6-phosphate receptor is present in fetal 
bovine tissues throughout gestation. Domestic Animal Endocrinology 12, 317–324. 
176 
 
Poole TJ & Coffin D (1989). Vasculogenesis and angiogenesis: two distinct morphogenetic 
mechanisms establish embryonic vascular pattern. Journal of Experimental Zoology 251, 
224–231. 
Popovici RM, Lu M, Bhatia S, Faessen GH, Giaccia AJ & Giudice LC (2001). Hypoxia regulates 
insulin-like growth factor-binding protein 1 in human fetal hepatocytes in primary culture: 
suggestive molecular mechanisms for in utero fetal growth restriction caused by 
uteroplacental insufficiency. The Journal of clinical endocrinology and metabolism 86, 
2653–2659. 
Price WA, Rong L, Stiles AD & D’Ercole AJ (1992). Changes in IGF-I and -II, IGF binding 
protein, and IGF receptor transcript abundance after uterine artery ligation. Pediatric 
Research 32, 291–295. 
Prior RL & Laster DB (1979). Development of the bovine fetus. Journal of Animal Science 48, 
1546–1553. 
Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg 
MA, D’Amato RJ & Adamis AP (1997). Regulation of vascular endothelial growth factor 
expression by insulin-like growth factor I. Diabetes 46, 1619–1626. 
Puri MC, Rossant J, Alitalo K, Bernstein J & Partanen (1995). The receptor tyrosine kinase TIE 
is required for integrity and survival of vascular endothelial cells. EMBO Journal 14, 5884. 
Putney DJ, Pepe GJ & Albrecht ED (1990). Influence of the fetus and estrogen on serum 
concentrations and placental formation of insulin-like growth factor I during baboon 
pregnancy. Endocrinology 127, 2400–2407. 
Quinn TP, Peters KG, de Vries C, Ferrara N & Williams LT (1993). Fetal liver kinase 1 is a 
receptor for vascular endothelial growth factor and is selectively expressed in embryyonic 
vascular endothelium. Proceedings of the National Academy of Sciences of the United 
States of America 90, 7533–7537. 
Rajaram S, Baylink DJ & Mohan S (1997). Insulin-like growth factor-binding proteins in serum 
and other biological fluids: regulation and functions. Endocrine Reviews 18, 801–831. 
Ranier S, Johnson LA & Dobry CJ (1993). Relaxation of imprinted genes in human cancer. 
Nature 362, 747–749. 
Redman CW (1991). Current Topic: pre-eclampsia and the placenta. Placenta 12, 304–310. 
Redmer DA, Dai Y, Li J, Charnock-Jones DS, Smith SK, Reynolds LP & Moor RM (1996). 
Characterization and expression of vascular endothelial growth factor (VEGF) in the ovine 
corpus luteum. Journal of reproduction and fertility 108, 157–165. 
177 
 
Regnault TR, Orbus RJ, de Vrijer B, Davidsen ML, Galan HL, Wilkening RB & Anthony RV 
(2002a). Placental expression of VEGF, PlGF and their receptors in a model of placental 
insufficiency-intrauterine growth restriction (PI-IUGR). Placenta 23, 132–144. 
Regnault TR, de Vrijer B & Anthony RV (2002b). The IGF-II-deficient placenta: aspects of its 
function. Trends in Endocrinology & Metabolism 13, 410–412. 
Regnault TRH, Galan HL, Parker TA & Anthony RV (2002c). Placental development in normal 
and compromised pregnancies - A Review. Placenta 23, S119–S129. 
Regnault TRH, de Vrijer B, Galan HL, Davidsen ML, Trembler KA, Battaglia FC, Wilkening 
RB & Anthony RV (2003). The relationship between transplacental O2 diffusion and 
placental expression of PlGF, VEGF and their receptors in a placental insufficiency model 
of fetal growth restriction. The Journal of physiology 550, 641–656. 
Reik W & Walter J (2001). Genomic imprinting: Parental influence on the genome. Nature 
Reviews Genetics 2, 21–32. 
Reik W, Constancia M, Dean W, Davies K, Bowden L, Murrell A, Feil R, Walter J & Kelsey G 
(2000). Igf2 imprinting in development and disease. International Journal of 
Developmental Biology 44, 145–150. 
Reik W, Davies K, Dean W, Kelsey G & Constancia M (2001). Imprinted genes and the 
coordination of fetal and postnatal growth in mammals. In: The cell cylce and development 
Wiley, Chichester (Novartis Foundation Symposium 237)19–35. 
Reimers TJ, Ullman MB & Hansel W (1985). Progesterone and prostanoid production by bovine 
binucleate trophoblast cells. Biology of Reproduction 33, 1227–1236. 
Renard JP (1998). Chromatin remodelling and nuclear reprogramming at the onset of embryonic 
development in mammals. Reproduction, Fertility, & Development 10, 573–580. 
Renard JP, Chastant S, Chesne P, Richard C, Marchal J, Cordonnier N, Chavatte P & Vignon X 
(1999). Lymphoid hypoplasia and somatic cloning. Lancet 353, 1489–1491. 
Reynolds LP (1986). Utero-ovarian interactions during early pregnancy: Role of conceptus-
induced vasodilation. Journal of Animal Science 62, 47–61. 
Reynolds LP & Redmer DA (1988). Secretion of angiogenic activity by placental tissues of cows 
at several stages of gestation. Reproduction and Fertility 83, 497–502. 
Reynolds LP, Millaway DS, Kirsch JD, Infeld JE & Redmer DA (1987). Angiogenic activity of 
placental tissues of cows. Journal of Reproduction & Fertility 81, 233–240. 
178 
 
Reynolds TS, Stevenson KR & Wathes DC (1997). Pregnancy-specific alternations in the 
expression of the insulin-like growth factor system during early placental development in 
the ewe. Endocrinology 138, 886–897. 
Richard DE, Berra E & Pouyssegur J (1999). Angiogenesis: how a tumor adapts to hypoxia. 
Biochemical & Biophysical Research Communications 266, 718–722. 
Rieger D (1998). Effects of the in vitro chemical environment during early embryogenesis on 
subsequent development. Archives of toxicology (Suppl. 20, 121–129. 
Roberts RM & Bazer FW (1988). The functions of uterine secrections. Journal of Reproduction 
and Fertility 82, 875–892. 
Roberts RM, Xie S, Nagel RJ, Low B, Green J & Beckers JF (1995). Glycoproteins of the 
aspartyl proteinase gene family secreted by the developing placenta. Advanced 
Experimental Medical Biology 362, 231–240. 
Robinson JN & Abuhamad AZ (2000). Abdominal wall and umbilical cord anomalies. Clinics in 
Perinatology 27, 947–978. 
Rodriguez-Arnao J, Miell JP & Ross RJM (1993). Influence of thyroid hormones on the GH-
IGF-1 axis. Trends Endocrinological Metabolism 4, 169–173. 
Rosenfeld CR, Morriss FH, Makowski EL, Meschia G & Battaglia FC (1974). Circulatory 
changes in teh reproductive tissues of ewes during pregnancy. Gynecologic Investigation 5, 
252–268. 
Russe I & Sinowatz F (1991). Embryologie der Haustiereed. Imogen Russe PP. Berlin. 
Russe I, Sinowatz F, Richter L, Lehmann M & Schallenberger E (1992). The development of the 
yolk sac in ruminants (sheep and cattle). Anatomia, Histologia, Embryologia: Veterinary 
Medicine Series C 21, 324–347. 
Rutanen EM, Koistinen R, Wahlstrom T, Bohn H & Seppala M (1984). The content of placental 
protein12 in decidua and fetal membranes is greater than placenta. British Journal of 
Obstetrics & Gynaecology1240–1244. 
Sahagian GG, Distler JJ & Jourdian GW (1987). Characterization of a membrane-associated 
receptor from bovine liver that binds phosphomannosyl residues of bovine testicular beta-
galactosidase. Proceedings of the National Academy of Sciences of the United States of 
America 78, 4289–4293. 
Santos F, Zakhartchenko V, Stojkovic M, Peters A, Jenuwein T, Wolf E, Reik W & Dean W 
(2003). Epigenetic marking correlates with developmetal potential in cloned bovine 
preimplantation embryos. Current Biology 13, 1116–1121. 
179 
 
Sara VR, Carrlsson-Skwirut C, Andersson C, Hall E, Sjorgen B, Homgren A & Jornvall H 
(1986). Characeterization of somatomedins from human fetal brain: identification of a 
variant from insulin-like growth factor I. Proceedings of the National Academy of Sciences 
of the United States of America 83, 4904–4907. 
Sato T, Tozawa Y, Deutsch U, Wolburg-Bucholz K, Fujiwara Y, Gendron-Maguire M, Gridley 
T, Wolburg H, Risau W & Qin Y (1995). Distinct roles of the receptor tyrosine kinases Tie-
1 and Tie-2 in blood vessel formation. Nature 376, 70–74. 
Scalia P, Heart E, Comai L, Vigneri R & Sung CK (2001). Regulation of the Akt/Glycogen 
synthase kinase-3 axis by insulin-like growth factor-II via activation of the human insulin 
receptor isoform-A. Journal of cellular biochemistry 82, 610–618. 
Schlafer DH, Fisher PJ & Davies CJ (2000). The bovine placenta before and after birth: placental 
development and function in health and disease. Animal Reproduction Science 60-61, 145–
160. 
Schmidt M, Greve T, Avery B, Beckers JF, Sulon J & Hansen HB (1996). Pregnancies, calves 
and calf viability after transfer of in vitro produced bovine embryos. Theriogenology 46, 
527–539. 
Schneider MR, Lahm H, Wu M, Hoeflich A & Wolf E (2000). Transgenic mouse models for 
studying the functions of insulin-like growth factor-binding proteins. FASEB Journal 14, 
629–640. 
Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M, Wilmut I, Colman A & 
Campbell KH (1997). Human factor IX transgenic sheep produced by transfer of nuclei 
from transfected fetal fibroblasts. Science 278, 2130–2133. 
Schrader AD, Iqbal MJ & Jones KL (2003). Gene expression in cloned bovine fetal liver. 
Cloning & Stem Cells 5, 2003. 
Schultz GA, Harvey MB, Watson AJ, Arcellana-Panlilio MJ, Jones K & Westhusin ME (1996). 
Regulation of early embryonic development by growth factors: Growth factor gene 
expression in cloned bovine embryos. Journal of Animal Science 74, 50–57. 
Schutz M, Freeman A, Lindberg G & Beitz D (1993). Effects of maternal lineages grouped by 
mitochondrial genotypes on milk yield and composition. Journal of Dairy Science 76, 621–
629. 
Sciacca L, Constantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, 
Vigneri R & Belfiore A (1999). Insulin receptor activation by IGF-II in breast cancers: 
evidence for a new autocrine/paracrine mechanism. Oncogene 18, 2471–2479. 
180 
 
Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R & Belfiore A (2002). In IGF-I receptor-
deificient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from 
apoptosis via the insulin receptor isoform A. Oncogene 21, 8240–8250. 
Seidel GE, Brink Z, Holland MD & Wilson JM (1997). Pregnancy attrition from frozen bovine 
embryos cloned by nuclear transplantation. Theriogenology 47, 236 (abstr.). 
Semenza GL, Agani F, Iyer N, Kotch L, Laughner E, Leung S & Yu A (1999). Regulation of 
cardiovascular development and physiology by hypoxia-inducible factor 1. Annual New 
York Academy of Science 874, 262–268. 
Senger DR, Galli SJ & Dvorak AM (1983). Tumor cells secrete a vascular permeability factor 
that promotes accumulation of ascites fluid. Science 219, 983–985. 
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML & Schuh AC 
(1995). Failure of blood island formation and vasculogenesis in Flk-1 deficient mice. 
Nature 376, 62–66. 
Shen BQ, Lee DY & Zioncheck TF (1999). Vascular endothelial growth factor governs 
endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase 
C signaling pathway. Journal of Biological Chemistry 274, 33057–33063. 
Shen SJ, Wang CY, Nelson KK, Jansen M & Ilan J (1986). Expression of insulin-like growth 
factor II in human placentas from normal and diabetic pregnancies. Proceedings of the 
National Academy of Sciences of the United States of America 83, 9179–9182. 
Sherer DM & Abulafia O (2001). Angiogenesis during implantation, and placental and early 
embryonic development. Placenta 22, 1–13. 
Shiels PG, Kind AJ, Campbell KH, Waddington D, Wilmut I, Colman A & Schnieke AE (1999). 
Analysis of telomere lengths in cloned sheep. Nature 399, 316–317. 
Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR & Torry DS (1997). Vascular endothelial 
growth factor, placental growth factor and their receptors in isolated human trophoblast. 
Placenta 18, 657–665. 
Sinclair KD (1998). Workshop on Embryo Development In Vitro: Current Challenges and 
Future Concepts. Proceedings IETS Satelite Symposium28–29. 
Sinclair KD, Maxfield EK, Robinson JJ, Maltin CA, McEvoy TG, Dunne LD, Young LE & 
Broadbent PJ (1997). Culture of sheep zygotes can alter fetal growth and development. 
Theriogenology 47, 380 (Abstr.). 
Sinclair KD, McEvoy TG, Carolan C, Maxfield EK, Maltin CA, Young LE, Wilmut I, Robinson 
JJ & Broadbent PJ (1998). Conceptus growth and development following in vitro culture of 
ovine embryos in media supplemented with bovine sera. Theriogenology 49, 218 (Abstr.). 
181 
 
Sinclair KD, Young LE, Wilmut I & McEvoy TG (2000). In-utero overgrowth in ruminants 
following embryo culture: lessons from mice and a warning to men. Human reproduction 
(Oxford, England) 15 Suppl 5, 68–86. 
Soker S, Takashima S, Miao G, Neufeld G & Klagsbrun M (1998). Neuropilin-1 is expressed by 
endothelial and tumor cells as an isoform-specific receptor for vascualr endothelial growth 
factor. Cell 92, 735–745. 
De Sousa PA, King T, Harkness L, Young LE, Walker SK & Wilmut I (2001). Evaluation of 
gestational deficiencies in cloned sheep fetuses and placentae. Biology of reproduction 65, 
23–30. 
Spagnoli A & Rosenfeld RG (1996). The mechanisms by which growth hormone brings about 
growth. The relative contributions of growth hormone and insulin-like growth factors. 
Endocronology & MetabolismClinics of North America 25, 615–631. 
Spemann H (1938). Embryonic development and induction. Yale University Press, New Haven, 
CT. 
Stegeman JHJ (1974). Placental development in sheep and its relation to fetal development. 
Bijdragen tot de Dierkunde 44, 3–72. 
Steven DH (1968). Placental vessels of the foetal lamb. Journal of Anatomy 103, 539–551. 
Stevenson KR & Wathes DC (1996). Insulin-like growth factors and their binding proteins in the 
ovine oviduct during the oestrous cycle. Journal of Reproduction & Fertility 108, 31–40. 
Stewart CEH & Rotwein P (1996). Growth, differentiation and survival: multiple physiological 
functions for insulin-like growth factors. Physiology Review 76, 1005–1026. 
Stice SL, Robl JM, Ponce de Leon FA, Golueke PJ, Cibelli JB & Kane JJ (1998). Cloning: new 
breakthroughs leading to commercial opportunities. Theriogenology 49, 129–138. 
Stice SL, Strelchenko NS, Keefer CL & Matthews L (1996). Pluripotent bovine embryonic cell 
lines direct embryonic development following nuclear transfer. Biology of Reproduction 54, 
100–465. 
Surani MA (1998). Imprinting and the initiation of gene silencing in the germ line. Cell 93, 309–
312. 
Szuba Z, Kalisinska E & Babula Z (1988). Growth of body weight and length of bovine fetuses. 
Anatomia, Histologia, Embryologia: Veterinary Medicine Series C 17, 53–59. 
Tani T, Kato Y & Tsunoda Y (2001). Direct exposure of chromosomes to nonactivated ovum 
cytoplasm is effective for bovine somatic cell nucleus reprogramming. Biology of 
Reproduction 64, 324–330. 
182 
 
Tarantino S, Verhage HG & Fazleabas AT (1992). Regulation of insulin-like growth factor-
binding proteins in the baboon (Papio anubis) uterus during early pregnancy. Endocrinology 
130, 2354–2362. 
Tazuke SI, Mazure NM, Sugawara J, Garland G, Faessen GH, Suen LF, Irwin JC, Powell DR, 
Giacca AJ & Giudice LC (1998). Hypoxia stimulates insulin-like grwoth factor binding 
protein-I (IGFBP-I) gene expression in HepG2 cells: a possible model for IGFBP-1 
expression in fetal hypoxia. Proceedings of the National Academy of Sciences of the United 
States of America 95, 10188–10193. 
Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D 
& Bohlen P (1992). Identification of the KDR tyrosine kinase as a receptor for vascular 
endothelial cell growth factor. Biochemical & Biophysical Research Communications 187, 
1579–1586. 
Thissen JP, Ketelslegers JM & Underwood LE (1994). Nutritional regulation of the insulin-like 
growth factors. Endocrine Reviews 15, 80–101. 
Thompson JG & Peterson AJ (2000). Bovine embryo culture in vitro: new developments and 
post-transfer consequences. Human Reproduction 15, 59–67. 
Thrailkill K, Quattrin T, Baker L, Litton J, Dwigun K, Rearson M, Poppenheimer M, Kotlovker 
D, Giltinan D, Gesundheit N & Martha P (1997). Dual hormonal replacement therapy with 
insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent 
diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system. The 
Journal of clinical endocrinology and metabolism 82, 1181–1187. 
Tilghman SM (1999). The sins of the fathers and mothers: Genomic imprinting in mammalian 
development. Cell 96, 185–193. 
Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC & Abraham JA (1991). 
The human gene for vascular endothelial growth factor. Journal of Biological Chemistry 
266, 11947–11954. 
Torry DS & Torry RJ (1997). Angiogenesis and the expression of vascular endothelial growth 
factor in endometrium and placenta. American Journal of Reproductive Immunology 
(Copenhagen) 37, 21–29. 
Torry DS, Wang HS, Wang TH, Caudle MR & Torry RJ (1998). Preeclampsia in associated with 
reduced serum levels of placental growth factor. American Journal of Obstetrical 
Gynecology 179, 1539–1544. 
Trounson AO (1997). Cloning: potential benefits for human medicine. Medical Journal of 
Australia 167, 568–569. 
183 
 
Tsutsumi Y (1962). The vascular pattern of the placenta in farm animals. Journal of Faculty 
Agriculture Hokkaido University Sapporo 52, 408–420. 
Tsutsumi Y & Hafez ESE (1966). Vascular architecture of the placentome in the cow and rabbit. 
Cornell Veterinarian 56, 527–543. 
Tucker KL, Beard C, Dausmann J, Jackson-Grusby L, Laird PW, Lei H, Li E & Jaenisch R 
(1996). Germ-line passage is required for establishment of methylation and expression 
patterns of imprinted but not of nonimprinted genes. Genes & Development 10, 1008–1020. 
Unterman T, Lascon R, Gotway MB, Oehler D, Gounis LC, Simmons RA & Ogata ES (1990). 
Circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) snf heptic 
mRNA are increased in the small for gestational age (SGA) fetal rat. Endocrinology 127, 
2035–2037. 
Veikkola T & Alitalo K (1999). VEGFs, receptors and angiogenesis. Seminars in Cancer 
Biology 9, 211–220. 
Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V & Belfiore A (2002). A novel 
autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of 
thyroid cancer. The Journal of clinical endocrinology and metabolism 87, 245–254. 
Verhaeghe J, Coopmans W, van Herck E, van schoubroeck D, Deprest JA & Witters I (1999). 
IGF-I, IGF-II, IGF binding protein 1, and C-peptide in second trimester amniotic fluid are 
dependent on gestational age but do not predict weight at birth. Pediatric Research 46, 101–
108. 
Viuff D, Hendriksen PJ, Vos PL, Dieleman SJ, Bibby BM, Greve T, Hyttel P & Thomsen PD 
(2001). Chromosomal abnormalities and developmental kinetics in in vivo-developed cattle 
embryos at days 2 to 5 after ovulation. Biology of Reproduction 65, 204–208. 
Voelkel SA & Hu YX (1992). Direct transfer of frozen-thawed bovine embryos. Theriogenology 
37, 23–37. 
Volpert O, Jackson D, Bouck N & Linzer DI (1996). The insulin-like growth factor II/mannose 
6-phosphate receptor is required for proliferin-induced angiogenesis. Endocrinology 137, 
3871–3876. 
Vrana PB, Guan XJ, Ingram RS & Tilghman SM (1998). Genomic imprinting is disrupted in 
interspecific Peromyscus hybrids. Nature Genetics 20, 362–365. 
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N & Williams LT (1992). The fms-like 
tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989–991. 
de Vrijer B, Anthony RV & Regnault TR (2002). Placental development in normal and 
compromised pregnancies-- a review. Trends in Endocrinology & Metabolism 13, 410–412. 
184 
 
Vuorela P, Hatva E, Lymboussaki A, Kaipainen A, Joukov V, Persico MG, Alitalo K & 
Halmesmaki E (1997). Expression of vascular endothelial growth factor and placenta 
growth factor in human placenta. Biology of Reproduction 56, 489–494. 
Van Wagtendonck-de Leeuw AM, Mullaart E, de Roos APW, Merton JS, den Daas JHG, Kemp 
B & de Ruigh L (2000). Effect of different reproduction techniques: AI, MOET or IVP, on 
health and welfare of bovine offspring. Theriogenology 53, 575–599. 
van Wagtendonk-de Leeuw AM, Aerts BJ & den Daas JH (1998). Abnormal offspring following 
in vitro production of bovine preimplantation embryos: a field study. Theriogenology 49, 
883–894. 
Wakayama T, Perry AC, Zuccotti M, Johnson KR & Yanagimachi R (1998). Full-term 
development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature 
394, 369–374. 
Wakayama T, Rodriguez I, Perry AC, Yanagimachi R & Mombaerts P (1999). Mice cloned from 
embryonic stem cells. PNAS 96, 14984–14989. 
Walker SK, Hartwich KM & Seamark RF (1996). The production of unusually large offspring 
following embryo manipulation: concepts and challenges. Theriogenology 45, 111–120. 
Wallace JM, Bourke DA, Aitken RP & Cruickshank MA (1999). Switching maternal dietary 
intake at the end of the first trimester has profound effects on placental develpment and fetal 
growth in adolescent ewes carrying singleton fetuses. Biology of Reproduction 61, 101–110. 
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M & Heldin CH (1994). Different 
signal transduction properties of KDR and Flt1, two receptors for vascular endothelial 
growth factor. Journal of Biological Chemistry 269, 26988–26995. 
Wathes DC, Reynolds TS, Robinson RS & Stevenson KR (1998). Role of the insulin-like growth 
factor system in uterine function and placental development in ruminants. Journal of Dairy 
Science 81, 1778–1789. 
Watson AJ, Hogan A, Hahnel A, Wiemer KE & Schultz GA (1992). Expression of growth factor 
ligand and receptor genes in the preimplantation bovine embryo. Molecular Reproduction & 
Development 31, 87–95. 
Watson AJ, Watson PH, Arcellana-Panlilio M, Warnes D, Walker SK, Schultz GA, Armstrong 
DT & Seamark RF (1994). A growth factor phenotype map for ovine preimplantation 
development. Biology of Reproduction 50, 725–733. 
Wells DN, Misica PM & Tervit HR (1999). Production of Cloned Calves Following Nuclear 




Westhusin ME, Levanduski MJ, Scarborough R, Looney CR & Bondioli KR (1992). Viable 
embryos and normal calves after nuclear transfer into Hoechst stained enucleated demi-
oocytes of cows. Journal of Reproduction and Fertility 95, 475–480. 
Westwood M, Gibson JM, Williams AC, Clayton PE, Hamberg O, Flyvbjerg A & White A 
(1995). Hormonal regulation of circulating insulin-like growth factor-binding protein-1 
phosphorylation status. Journal Clinical Endocrinalolgy Metabolism 80, 3520–3527. 
White KL & Yue C (1996). Intracellular receptors and agents that induce activation inbovine 
oocytes. Theriogenology 45, 91–100. 
Willadsen SM (1979). A method for culture of micromanipulated sheep embryos and its use to 
produce monozygotic twins. Nature 277, 298–300. 
Willadsen SM (1986). Nuclear transplantation in sheep embryos. Nature 320, 63–65. 
Willadsen SM, Janzen RE, McAlister RJ, Shea BF, Hamilton G & McDermand D (1991). The 
viability of late morulae and blastocysts produced by nuclear transplantation in cattle. 
Theriogenology 35, 161–170. 
Wilmut I (1998). Embryonic and somatic cell cloning. Reproduction, Fertility, & Development 
10, 639–643. 
Wilmut I, Schnieke AE, McWhir J, Kind AJ & Campbell KH (1997). Viable offspring derived 
from fetal and adult mammalian cells. Nature 385, 810–813. 
Wilson JM, Williams JD, Bondioli KR, Looney CR, Westhusin MR & McCalla DF (1995). 
Comparison of birth weight and growth characteristics of bovine calves produced by 
nuclear transfer (cloning), embryo transfer and natural mating. Animal Reproduction 
Science 38, 73–84. 
Winnick M & Noble A (1965). Quantitative changes in DNA, RNA, and protein during prenatal 
and postnatal growth in the rat. Developmental Biology 12, 451. 
Wooding FB (1992). Current topic: the synepitheliochorial placenta of ruminants: binucleate cell 
fusions and hormone production. Placenta 13, 101–113. 
Wooding FB & Wathes DC (1980). Binucleate cell migration in the bovine placentome. Journal 
of Reproduction & Fertility 59, 425–430. 
Wooding FB, Morgan G & Adam CL (1997). Structure and function in the ruminant 
synepitheliochorial placenta: central role of the trophoblast binucleate cell in deer. 
Microscopy Research & Technique 38, 88–99. 
186 
 
Yang HC & Pardee AB (1986). Insulin-like growth factor I regulation of transcription and 
replicating enzyme induction necessary for DNA synthesis. Journal of Cellular Physiology 
127, 410–416. 
Yazawa S, Aoyagi Y, Konishi M & Takedomi T (1997). Characterization and cytogenetic 
analysis of Japanese black calves produced by nuclear transfer. Theriogenology 48, 641–
650. 
Yonekura H, Sakurai S, Liu X, Migita H, Wang H, Yamagishi S, Nomura M, Abedin MJ, Unoki 
H, Yamamoto Y & Yamamoto H (1999). Placental growth factor and vascular endothelial 
growth factor B and C expression in microvascualr endothelial cells and pericytes.  
Implication in autocrine and paracrine regulation of angiogenesis. Journal of Biological 
Chemistry 49, 35172–35178. 
Young LE (2001). Imprinting of genes and the Barker hypothesis. Twin Research 4, 307–317. 
Young LE & Fairburn HR (2000). Improving the safety of embryo technologies: Possible role of 
genomic imprinting. Theriogenology 53, 627–648. 
Young LE, Fernandes K, McEvoy TG, Butterwith SC, Gutierrez CG, Carolan C, Broadbent PJ, 
Robinson JJ, Wilmut I & Sinclair KD (2001). Epigenetic change in IGF2R is associated 
with fetal overgrowth after sheep embryo culture. Nature Genetics 27, 153–154. 
Young LE, Sinclair KD & Wilmut I (1998). Large offspring syndrome in cattle and sheep. 
Reviews of Reproduction 3, 155–163. 
Yu J, Iwashita M, Kudo Y & Takeda K (1998). Phosphorylated insulin growth factor (IGF)-
binding protein -1 (IGFBP-1) inhibits while non-phosphorylated IGFBP-1 stimulates IGF-
1-induced amino acid uptake by cultured trophoblast cells. Growth Hormone & Igf 
Research 8, 65–70. 
Yun K, Jinno Y, Sohda T, Niikawa N & Ikeda T (1998). Promoter-specific insulin-like growth 
factor 2 gene imprinting in human fetal liver and hepatoblastoma. Journal of Pathology 
185, 91–98. 
Zaina S & Squire S (1998). The soluble type 2 insulin-like growth factor (IGF-II) receptor 
reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms. Journal of 
Biological Chemistry 273, 28610–28616. 
Zakhartchenko V, Alberio R, Stojkovic M, Prelle K, Schernthaner W, Stojkovic P, Wenigerkind 
H, Wanke R, Düchler M, Steinborn R, Mueller M, Brem G & Wolf E (1999). Adult cloning 
in cattle: potential of nuclei from a permanent cell line and from primary cultures. 
Molecular reproduction and development 54, 264–272. 
187 
 
Zhou J, Damsky CH & Fisher SJ (1997). Preeclampsia is associated with failure of human 
cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective 
endovascular invasion in this syndrome? Journal of Clinical Investigation 99, 2152–2164. 
Zhou Y, Damsky CH, Chui K, Roberts JM & Fisher SJ (1993). Preeclampsia is associated with 
abnormal expression of adhesion molecules by invasive trophblasts. Journal of Clinical 
Investigation 91, 950–960. 
Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battaglia FC, Paoletti I, Bana A, Tucci 
M, Parise G, Vincenti V, Granger HJ, Viglietto G & Persico MG (1997). Placental growth 
factor-1 is chemotactic, mitogenic, and angiogenic. Laboratory Investigation 76, 517–531. 
Zumkeller W (2000). Current topic: the role of growth hormone and insulin-like growth factors 
for placental growth and development. Placenta 21, 451–467. 
 
